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Abstract 
 
Diabetes affects around 2.3 million people in the UK and can lead to both acute and 
chronic complications. One of the chronic effects of diabetes is the damage that occurs 
to the vascular endothelium, affecting multiple organ systems, collectively termed 
diabetic vascular disease. Many proteins have been identified as being altered in 
diabetes, one of which is annexin 2, a calcium dependent phospholipid binding protein 
involved in many cellular processes. In response to diabetes annexin 2 is enriched on 
the surface of the endothelium where it functions as a co-receptor for tissue 
plasminogen activator and plasminogen to form plasmin, creating a pro-fibrinolytic 
environment. This thesis aimed to further examine the role of annexin 2 in diabetes, 
utilising the annexin 2 knockout mouse in both in vitro and in vivo experiments. As part 
of our in vitro experiments, we identified a hyperglycaemic translocation of annexin 2 
to alternative cellular compartments, using sucrose density centrifugation, and an 
increased susceptibility of VE-cadherin to destabilisation upon the action of vascular 
endothelial growth factor in annexin 2 knockout endothelial cells. In the in vivo 
experiments we utilised streptozotocin to induce diabetes in the annexin 2 knockout 
mouse, and examined the progression of both diabetic retinopathy and diabetic 
nephropathy. Annexin 2 knockout mice developed more severe symptoms of diabetic 
nephropathy with increased microalbuminuria, mesenchymal matrix expansion and 
histological changes indicative of renal disease. In contrast to this, symptoms pertaining 
to diabetic retinopathy were mild in all mice. Non-diabetic annexin 2 knockout mice 
also exhibited mild hypoglycaemia, potentially implicating defects in the insulin 
signalling pathway, and suggesting a novel role for annexin 2 in glucose homeostasis.  
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Chapter 1 Introduction 
 
1.1 Diabetes 
 
Approximately 2.3 million people in the UK alone are diagnosed with diabetes, with 
around half a million unaware they have the disease (http://www.diabetes.org.uk/). The 
disease is characterised by the presence of hyperglycaemia, although it manifests 
clinically as increased urination, weight loss and lethargy (http://www.diabetes.org.uk). 
There are three main types of diabetes: Insulin-dependent diabetes (Type 1), Non-
insulin dependent diabetes (Type 2) and Gestational diabetes. Recently there have also 
been reports of a fourth type of diabetes linked to Alzheimer’s disease, where it is 
believed that the progression of the disease leads to a reduction in the ability of the 
brain to respond to insulin. For this reason, the term ‘type-3 diabetes’ has been used to 
describe Alzheimer’s disease, with the contribution of insulin signalling to the 
pathogenesis of Alzheimer’s the subject of other investigations
1. 
  Focusing on type 1 diabetes, unlike the other types it is induced by the actions of 
the immune system whereby the β-islet cells of the pancreas that produce insulin are 
lost. This is instigated both by antibodies directed against self antigens in the pancreas 
(auto-antibodies), and the progressive infiltration of a wide range of destructive auto-
reactive immune cells
2. Much work has been carried out on the progression of type 1 
diabetes, which has been shown to require the action of CD4+ (helper, effector) and 
CD8+ (cytotoxic) T-cells, and macrophages
3,4,5,6,7,8,9,10,11,12, that usually follows a 
distinct pathological progression. In the initial stages immune cells accumulate in the 
pancreas but are not destructive, a triggering event then occurs, the exact cause of which 
is still unknown, leading to the destruction of the β-islet cells
13,14,15. Due to the critical 
role of the immune system in the progression of type-1 diabetes, the immunological 
response has been well characterised. In brief, since so many immune cells are present 
in the pancreas at the initiation of destruction the response is often fast and very intense, 
with T cells, B-cells and macrophages communicating via antigen presentation, 
cytokines and cell-cell interactions
16. Macrophages are ultimately responsible for the 
activation of the other two major cell types, CD8+ cytotoxic T-cells and autoreactive 
CD4+ effector cells
14, but also contribute directly to the destruction of the β-islet cells 
by the production of toxic substances such as nitrogen and oxygen derived free 
radicals
17. The critical requirement of macrophages for the progression of diabetes has   15
been demonstrated in a mouse model of diabetes, since if they are removed the 
generation of the CD8+ T-cell response is inhibited
18,19,20. The autoreactive CD8+ T-
cells destroy the β-islet cells of the pancreas directly through release of toxic substances 
such as perforin, leading to membrane disruption. However, CD4+ T-cells initiate the 
activation of B-cells, leading to the production of auto-antibodies that are one of the 
hallmarks of the disease
14. CD4+ T-cells also contribute directly to damage of the β-
islet cells through the generation of cytokines including IL-1 (Interleukin-1), INF-γ 
(Interferon gamma) and TNF-α (Tumor necrosis factor alpha) that are secreted into the 
local environment, leading to membrane disruption, nitric oxide (NO) production and 
free radicals 
15,21,22,23. Other cytokines such as IL-2 (Interleukin 2), IL-12 (Interleukin 
12), IL-17 (Interleukin 17) and IL-18 (Interleukin 18) are also secreted by CD4+ T-cells 
contributing to the inflammatory state by initiating a T-helper cell type 1 response
22,23. 
Even with this vast array of immunological insults, the clinical manifestations of the 
disease do not occur immediately following activation of the autoimmune response, and 
usually require approximately 90% of the β-islet cells to have been destroyed
13, hence 
allowing treatment options to be directed against multiple stages of the disease. 
Currently the treatments for type 1 diabetes have three main aims, firstly 
replacement of the insulin lost as a result of the β-islet cell destruction, protection of the 
pancreas, and finally regeneration of β-islet function. The most common method of 
insulin replacement is through subcutaneous injections, which are given to patients with 
type-1 diabetes on a regular basis. There are also studies ongoing which aim to produce 
alternative methods of insulin replacement, such as an artificial pancreas
24, however 
their viability are still under investigation
25. In terms of restoring β-islet function there 
are two current approaches, prevention of β-islet cell loss, and regeneration or 
restoration of β-islet cell mass
26. Therapies aimed at the prevention of β-islet cell loss 
are directed at the immunological level either through specific or non-specific 
immunosuppression whilst therapies aimed at regenerating or restoring β-islet function 
are focused on transplantation, pharmacological agents and stem cell therapies, however 
the latter are still in a pre-clinical phase. Apart from the administration of exogenous 
insulin it is unfortunately the case that no single treatment regimen has shown enough 
progress to give long-term benefits, and a restorative treatment will potentially have to 
encompass a number of different therapies to provide any lasting effect.   
Type 2 diabetes is the more common form of diabetes
2, and is more prevalent in 
older people since β-islet function declines over a number of years. It has strong links to 
obesity and hypertension and is thought to be due to a long term increase in the levels of   16
insulin in the blood as a result of long term exposure to higher levels of glucose. This 
then leads to a down-regulation of the insulin receptor and hence ineffective insulin 
signalling. This ‘insulin resistance’ then goes on to cause many of the complications 
found in type-1 diabetes, but often with a less aggressive nature; characterised by a 
longer duration of the initial symptoms or stages of the condition. There are a number of 
treatments for type-2 diabetes, many of which are focused on generating more insulin 
from the pancreas, with control of blood glucose through proper diet and exercise.   
Irrespective of the type of diabetes, there are a number of acute and chronic 
complications that arise. Acute complications include diabetic keto acidoses and non-
ketotic hyperosmolar state; the latter more commonly seen in elderly individuals with 
type 2 diabetes. Chronic conditions of diabetes effect many organ systems and are 
mostly responsible for the morbidity of the disease. They can be classified into vascular 
and non-vascular complications, with the latter consisting of skin changes, gastroporesis 
and sexual dysfunction. The vascular complications can additionally be split into 
microvascular and macrovascular complications, with peripheral vascular disease, 
cerebrovascular disease and coronary artery disease examples of macrovascular 
complications, whilst microvascular diabetic complications comprise diabetic 
retinopathy, nephropathy and neuropathy.  
This thesis focuses on diabetic microvascular complications with particular 
reference to diabetic retinopathy and diabetic nephropathy. With the diabetic 
vasculopathies in general, the main force of the hyperglycaemic insult is taken by the 
endothelial cell, leading to endothelial dysfunction. Since the endothelium is a diverse 
subject area some of its main functions will be summarised below before describing the 
dysfunctions that occur as a consequence of diabetes. 
 
1.2 The Endothelium 
 
The endothelium comprises the inner biologically active layer of blood vessels, 
with direct responsibility for encapsulating the circulating blood. It is also involved in 
many homeostatic processes. Once believed to be an inert layer of cells, the 
endothelium in humans has a surface area ranging from 1-7m
2 27, and is capable of a 
wide range of responses, with the ability to adapt to widely variable environments. A 
suitable illustration of this variability is that in the brain, endothelial cells form a tight 
barrier between one another, using tight junction proteins such as occludin and ZO-1 
(zonula occludens-1) to form the blood brain barrier (BBB)
28. In contrast, endothelial   17
cells of the liver and spleen take on a discontinuous form to allow the passage of 
cellular traffic, with the endothelium of the kidney and intestinal villi forming 
fenestrations, to allow for selective permeability
29. In accordance with their adaptable 
nature, endothelial cells in different organs express proteins specific to their function. 
Signals for endothelial cell differentiation come from the surrounding environment in 
the form of mechanical forces, paracrine actions of growth factors and interactions with 
supporting cells such as pericytes and smooth muscle cells. The effect of the 
microenvironment upon the endothelial cell to define its function has been shown in 
both in vitro and in vivo experiments through utilisation of chick/quail transplantation 
models
30 and culture of endothelial cells on extracellular matrix derived from various 
organs
31.  
Although originally described as a inert layer of cells, the endothelium is not 
only present to form a structural barrier between the blood and various tissues, but 
actively participates in maintaining vascular haemodynamics. The main way this is 
achieved is through the secretion of factors such as NO, prostacyclin (PGI2), 
endothelins (ET) and platelet activating factor (PAF). Apart from NO, these factors are 
not constitutively stored by the endothelium and so their manufacture must be regulated. 
To briefly summarise their actions; NO is a potent vasodilator
32 and as previously 
mentioned is constitutively produced, however, the rate at which the endothelium does 
so can be influenced by various chemical and physical stimuli. NO has many different 
effects on the vasculature, with one of the most well characterised being it’s ability to 
relax smooth muscle cells
32 leading to changes in blood pressure. A further action of 
NO is its contribution to wound healing, inhibiting platelet and leucocyte adhesion
33, as 
well as the binding of fibrinogen
34. Further to this, NO also has local effects on 
endothelial cells by enhancing their migration and proliferation
35, whilst inhibiting 
smooth muscle cell migration
36 and proliferation
37.  
In sharp contrast to NO, endothelin-1 (ET-1) has an antagonistic effect on NO 
production, and is a potent vasoconstrictor
38, with its production stimulated by hypoxia, 
shear stress and ischemia
39. ET-1 acts through binding to the endothelin-A (ET-A) 
receptor present on vascular smooth muscle cells which triggers a rise in intracellular 
calcium, increasing smooth muscle cell tone
40 and hence blood pressure. The actions of 
ET-1 on the endothelium can have long lasting effects through the longevity of elevated 
intracellular calcium, an effect that can be inhibited by the action of NO
41 to restore 
basal calcium levels. A balance between these two signalling molecules is therefore key 
to maintenance of vascular tone, and in experimental cases where NO is absent and ET-  18
1 is allowed to function without antagonism, vasoconstriction and smooth muscle cell 
proliferation ensue unchecked
42.  
Another key action of the endothelium is to maintain the fluidity of the vascular 
network, such that all the organ systems are constantly perfused. In essence, this is 
accomplished by inhibiting the adhesion and clotting of platelets on the endothelial cell 
surface, although there are different ways in which this is achieved. In brief, the control 
of thrombin generation is crucial, since through its activities as a serine protease it has 
wide ranging roles in the activation of coagulation factors
43. Due to this, the 
endothelium controls thrombin levels by various pathways
44, and very little of the 
protein is found under healthy circumstances
45. The extracellular matrix that is secreted 
by the endothelium, composed of heparan sulphate and other glycosaminoglycans, 
promotes the activity of thrombin inhibitors such as anti-thrombin III
46, and heparin 
cofactor II
47. As well as this mechanism of thrombin control, the endothelium secretes 
other soluble inhibitors of thrombin, such as thrombomodulin
48 that can bind thrombin, 
inactivate it, and causes its endocytosis and degradation
49. In addition to direct binding 
of thrombin, thrombomodulin can promote anticoagulant pathways such as the actions 
of anticoagulant protein C
50. 
Despite these interventions by the endothelial cell to suppress the generation of 
thrombi some invariably form, and must be dealt with swiftly if the flow of the vascular 
network is to be maintained. One of the key proteins involved in this process is plasmin, 
which is produced from plasminogen through the activities of plasminogen activators. 
Tissue-plasminogen activator (t-PA) is a commonly found plasminogen activator and 
when cultured in vitro all endothelial cells produce and secrete it into the local 
environment. However, this is not reflective of the in vivo situation as t-PA has been 
localised to particular subsets of endothelial cells and is more commonly found in the 
microvasculature, with those negative for t-PA remaining so even upon stimulation to 
produce it
51,52,53. Due to its critical role in maintenance of vascular flow t-PA can be 
activated by various stimuli, but is regulated both at the level of transcription and 
cellular release to ensure aberrant activity does not occur
54,55. Another plasminogen 
activator commonly found is urokinase type plasminogen activator (u-PA), however this 
derivative is usually found in the context of wound repair and angiogenesis
56. Although 
it is not expressed by quiescent endothelial cells
57 u-PA has been shown to be involved 
in homeostasis since its deletion in mice leads to inflammation-induced thrombi
58.  
In situations where the action of plasmin is required at a specific location, 
endothelial cells can utilise the action of plasminogen receptors that bind both   19
plasminogen and plasminogen activators, to enhance the formation of plasmin
59,60, with 
their presence in various contexts reported by several groups
59,61,56,62,60,63. Other proteins 
have also been described as plasminogen receptors, one of which is annexin 2
64, which 
is covered in more detail later. 
Although the maintenance of vascular flow and thereby perfusion of the organs 
of the body is a critical function of the endothelium, in times of injury or damage to the 
vascular network clots must be formed to limit damage, aid repair and prevent infection. 
Hence the endothelium is in a dynamic equilibrium between thrombotic and anti-
thrombotic states that are balanced by a vast array of extracellular signals
65. In situations 
where clotting of the blood, and hence the formation of fibrin is required, a pivotal step 
is the induction of tissue factor, which occurs rapidly after injury
66, and can be found in 
atherosclerotic plaques
67,68. Tissue factor is not normally expressed by quiescent 
endothelium
69, however, once active it accelerates clotting factor activation, leading to 
increased mediators of the clotting cascade such as factors X and IX
69. Tissue factor 
expression is induced by various stimuli ranging from cytokines to hypoxia
70,71, and is 
also enhanced by the products of apoptosis such as anionic phospholipids
72. When 
expressed, tissue factor is usually localised to the basolateral surfaces between 
endothelial cells
73 such that disruption of the endothelial layer is required for it to be 
mobilised, although some evidence has more recently emerged that it can also be 
expressed on the surface of endothelial cells
74. Endothelial cells expressing tissue factor 
accumulate fibrin on their surface
75, suggesting that they must have binding sites for 
pro-coagulative proteins, however many of these are as of yet unknown
76. The best 
characterised receptor on an endothelial cell for binding of a coagulation protein is 
protease-activated receptor-1 (PAR-1). PAR-1 is activated by thrombin, whereby an 
amino terminal fragment of the PAR-1 receptor is released and subsequently binds the 
remaining portion of the receptor. Once active it leads to the stimulation of both 
thrombotic and anti-thrombotic pathways, and can disrupt cell-cell contacts
77. Other 
PAR receptors PAR-2 and PAR-3, have also been characterised, and in conjunction 
with PAR-1 they have wide ranging patterns of expression in various tissues of the 
body
78,79. Other binding sites involved in coagulation, such as receptors for fibrin and 
fibrin degradation products, can also be found on endothelial cells
80. Examples include 
the 130-kDa protein
81, tissue transglutaminase
82 and αVβ3 integrin, although the in vivo 
contexts of these interactions are only now emerging
83,84.  
In addition to the maintenance of blood flow, or stagnation in the appropriate 
context, a more obvious role of the endothelium is the delivery of micro and macro   20
molecules to the tissues, and regulation of permeability. The endothelium utilises two 
main routes to transport solutes into the tissue, namely transcellular and paracellular. 
Transcellular transport utilises intracellular vesicles to move macromolecules from one 
side of the endothelium to the other through the endothelial cell itself, and is dependent 
upon proteins such as caveolin
85. In contrast, the paracellular pathway relies on the 
regulation of the space between adjacent endothelial cells, allowing solutes and 
macromolecules to pass between endothelial cells, and is therefore moderated by the 
proteins that connect endothelial cells to one another, or the endothelial cell junction. 
Junctions between endothelial cells are comprised of two main compartments: the tight 
junction, consisting of proteins such as occludin and claudin, and the adherens junctions 
containing VE-cadherin (vascular endothelial cadherin)
86. VE-cadherin, as the name 
suggests, is specific to the endothelium and is a member of the superfamily of calcium 
dependent adhesive receptors that bind cells together by homotypic interactions, and is 
crucial for the maintenance of vascular integrity
87. This is highlighted by the fact that 
mice deficient in VE-cadherin are embryonically lethal due to aberrant formation of the 
vascular networks
88,89. The canomical cadherin structure comprises 5 modular 
extracellular domains of approximately 110 amino acids each, a transmembrane domain 
and a conserved cytoplasmic tail
90,91. The intracellular C-terminal tail is responsible for 
the interaction between VE-cadherin and the actin cytoskeleton through proteins such as 
the α, β and γ catenins and p120
92. The extracellular domain of VE-cadherin has also 
been investigated and been shown to contain seven-stranded-barrels with structural 
similarity to the immunoglobulin fold domain
93,94,95,96. Tight junctions, in contrast to 
VE-cadherin based adherens junctions, are less common in endothelial cells, but are still 
important for maintaining the integrity of the endothelium, especially in the blood-brain 
and blood-retina barriers. A particularly important protein in the tight junction is 
occludin
97, with various claudins also present, of which claudin-5 appears to be the most 
abundant
98,99. 
 
As well as mediating transport via the paracellular route, the endothelial junction 
is crucial in directing and regulating the permeability of the endothelium, and since VE-
cadherin is found at all endothelial cell junctions it can be considered key to the 
maintenance of endothelial paracellular permeability. When the dynamics of VE-
cadherin are examined it can be seen that there are a wide range of other proteins are 
involved in its function. Of particular interest is p120, which functions as a scaffold 
protein regulating interactions between cadherins, various kinases, phosphatases and   21
Fig 1.1 Proteins that comprise the junctions in endothelial 
cells.
The junctions between endothelial cells consist of various 
protein interactions with tight, adherens and pericyte
interactions displayed. Image adapted from Dejana, E. (2004). 
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RhoGTPases, which in turn then interact with one another and the catenins to alter the 
stability of VE-cadherin, and hence endothelial junctions
100. The importance of p120 in 
VE-cadherin stabilisation is further highlighted by reports that an increase or decrease in 
p120 leads to a greater or lesser amount of VE-cadherin found at the surface of the 
endothelial cell
101,102 with the interplay between proteins subsequently recruited by 
p120 also important in the stabilisation of endothelial adherens junctions
103. Various 
proteins can destabilise VE-cadherin, and hence increase the permeability of the 
endothelium. For example thrombin reduces VE-cadherin surface content, and causes 
phosphorylation of the protein through the actions of PKC-α (Protein kinase C alpha), to 
a form that is less stable than its native form
103. In addition to phosphorylation, 
destabilisation can also be mediated by agonists such as VEGF, which induces 
internalisation of the protein
104. In sharp contrast, stabilisation of VE-cadherin is centred 
around p120, especially since the internalisation of VE-cadherin gives rise to an 
increase in p120, subsequently reducing destabilising proteins such as RhoA (Ras 
homolog gene family, member A), whilst increasing Rac1 (Ras-related C3 botulinum 
toxin substrate 1) and cdc42 (cell division cycle 42) that function to stabilise VE-
cadherin
105. These stabilisation events are then further supported by the de-
phosphorylation of VE-cadherin and the subsequent re-association of p120
106.   
With the wide diversity of roles, and multiple actions required to maintain 
stability, the endothelium is very biologically active with a high rate of protein 
synthesis. Endothelial cells utilise both fatty acids and glucose as energy sources, and   22
whilst most tissues of the body selectively transport glucose in response to demand 
using the insulin regulated GLUT-4 transporter, the main transporter of glucose in 
endothelial cells is GLUT-1. GLUT-1 is functionally different to GLUT-4 in that it is a 
constitutively open channel for glucose once inserted into the membrane, essentially 
ensuring that the glucose concentration of the cytosol is equivalent to that of the blood. 
Regardless of this, the majority of the glucose that reaches the endothelium is not 
utilised by the cell itself but delivered to the underlying tissue. Endothelial cells achieve 
this in two ways as outlined above, either by permitting glucose flow between cell-cell 
junctions, or by transcellular transport. In the brain the blood brain barrier (BBB) 
created by the endothelium, is sufficiently tight that the brain must rely on transcellular 
transport alone to ensure the brain is supplied with glucose. This is achieved through 
distribution of GLUT-1 transporters on the basal surface of the endothelium, however 
the true contribution of the GLUT-1 receptor to glucose homeostasis of the underlying 
tissues has not been fully investigated. 
 
1.3 Endothelial dysfunction 
 
The correctly functioning endothelium is adaptable to many different 
physiological conditions and stimuli, however in diabetes the endothelium becomes 
compromised by hyperglycaemia. This process is termed “Endothelial dysfunction” and 
is characterised when the response of the endothelium is inadequate to the demands 
requested of it. As mentioned previously, endothelial intracellular glucose is 
equilibrated to the blood glucose concentration through the actions of the GLUT-1 
transporter. Therefore, the increase in intracellular glucose concentration in endothelial 
cells, along with the plethora of growth factors and other vasoactive compounds 
influenced by diabetes, produces the endothelial dysfunction seen in diabetic 
microvascular and macrovascular complications.  
The molecular mechanisms of hyperglycaemia in endothelial cells comprise four 
main pathological processes
107. These are increased flux of glucose through the polyol 
pathway, an increase in advanced glycation end products (AGEs), increased activation 
of protein kinase C isoforms and increased hexosamine pathway activity. 
  Considering first the polyol pathway, when intracellular glucose becomes too 
high one of the enzymes affected is aldose reductase. This enzyme is usually 
responsible for removing toxic aldehydes from the cell, by reducing them into inactive 
alcohols. This process requires the co-factor NADPH for the reduction reaction, but   23
when intracellular glucose concentrations become too high aldose reductase instead uses 
NADPH to reduce glucose to sorbitol. The consequence of this is the reduced 
availability of NADPH, which is involved in many different biological processes. One 
such process important in the progression of diabetes, is the requirement of NADPH for 
the regeneration of reduced glutathione; an anti-oxidant. Hence with reduced levels of 
NADPH, the cell is more vulnerable to toxic free radicals that can accumulate in 
hyperglycaemic conditions. In vivo evidence for this was shown in a study by Engerman 
et al (1994), where pharmacological inhibition of aldose reductase in diabetic dogs 
improved the neurological conduction velocity in comparison to their control cohorts
108. 
  Advanced glycation end products are formed either through the Maillard 
reaction (non-enzymatic glycation) or via other compounds such as methylglyoxal. In 
the presence of hyperglycaemia both the availability of glucose for the Maillard reaction 
and the concentration of methylglyoxal are increased, leading to a concurrent increase 
in AGEs. These products can have three main effects, if formed in the cytosol they can 
go on to damage intracellular proteins, disrupting their function
109. Secondly, if formed 
or secreted into the extracellular environment they can go on to activate the AGE 
receptor
110, or thirdly crosslink extracellular proteins such as those that form the 
basement membrane of the endothelium, causing it to thicken or harden
111.  
  As well as interfering with enzyme action and the formation of AGEs, 
hyperglycaemia increases the amount of diacylglycerol in the cell. Diacylglycerol is the 
critical activation co-factor for many protein kinase C isoforms and its increase leads to 
an up-regulation of the activity of these proteins, and their various downstream 
signalling pathways. Not all these pathways have been implicated in the progression of 
diabetes, but some of those that have are outlined here. eNOS and endothelin-1 are two 
proteins, negatively and positively regulated respectively by PKC, that are involved in 
management of vascular tone, and hence blood flow. In hyperglycaemic conditions the 
activation of these proteins by PKC is increased, leading to vasoconstriction. Increased 
PKC can also up regulate the activity of other proteins such as VEGF (vascular 
endothelial growth factor), TGF-β (Transforming growth factor beta), NF-κB and 
NADPH oxidases, leading to other complications such as vessel occlusion, leucocyte 
attraction, oedema and increased reactive oxygen species (ROS). 
  The fourth and final process that has been shown to be affected by 
hyperglycaemia is the hexosamine pathway. This pathway describes the initial 
metabolism of glucose, where it is converted first to glucose-6-phosphate and then 
fructose-6-phosphate. Under normal circumstances the fructose-6-phosphate would then   24
be used in the glycolytic pathway to produce ATP. However, when hyperglycaemia is 
present the concentrations of these metabolites increase and some of the fructose-6-
phosphate gets diverted via the enzyme glucosamine:fructose-6-phosphate 
amidotransferase to produce glucosamine-6-phosphate, and then finally uridine 
diphosphate N-acetylglucosamine (UDP-GLcNAc). This compound then targets serine 
or threonine residues of transcription factors leading to changes in their activity and 
subsequently their genetic targets, causing disruption throughout the cell.  
  A recent publication proposed a linking mechanism for these four pathways 
whereby hyperglycaemia leads to an increase in superoxide production potentiating the 
activity of the enzyme poly ADP-ribose polymerase (PARP)
107. This in turn down-
regulates a key glycolytic enzyme glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH), leading to an increase in glyceraldehyde-3 phosphate and other metabolites 
further upstream. This then creates substrates for the four previously mentioned 
pathways since glyceraldehyde-3 phosphate is one of the major compounds responsible 
for the formation of AGEs, and also is used to produce diacylglycerol, hence increasing 
the activity of PKC. Further upstream increased fructose-6-phosphate participates in the 
hexosamine pathway and abberant glucose metabolism in the polyol pathway. 
In addition to the direct actions of hyperglycaemia on the endothelial cell, 
hyperglycaemia can also induce changes in the activity or abundance of molecules in 
the local environment that can affect endothelial cell function. TGF-β, TNF-α, CRP (C 
reactive protein) and VEGF all fall into this category and shall be explored briefly here. 
The actions of TGF-β are well defined in a number of vascular pathologies 
112, however 
in diabetes it becomes activated by the actions of hyperglycaemia induced PKC 
activation, AGEs and other cytokine derived activation of endothelial cells
113. Upon 
contact with endothelial cells TGF-β has a number of functions ranging from changes in 
the rate of cell growth, to cellular differentiation and apoptosis. TGF-β is also a potent 
inducer of the proteins that make up the basement membrane of endothelial cells such as 
collagens I and IV, fibronectin, laminin and proteoglycans, and as such is thought to 
play a significant role in fibrosis phenotypes, seen in conditions such as diabetic 
nephropathy
114. 
TNF-α is a pro-inflammatory cytokine produced by many cell types which can 
have various effects on the endothelium. These include an increase in vascular 
permeability, altered vasoregulatory responses, activation of NF-κB and an increase in 
coagulation through inhibition of anti-coagulant proteins and activation of pro-
coagulant activity
115. Induction of NF-κB activity by TNF-α has various effects on   25
endothelial cells including the up regulation of ICAM-1 and other cellular adhesion 
factors such as VCAM and E-selectin that lead to the recruitment of immune cells, and 
subsequent inflammation. NF-κB also induces the expression and activity of pro-
inflammatory cytokines such as IL-1, IL-6 and IL-8, leading to further non-specific 
inflammation that is characteristic of some diabetic microvasculopathies such as 
diabetic retinopathy.  
In addition to the actions of NF-κB mediated through TNF-α, levels of CRP, an 
important pro-inflammatory, pro-atherogenic protein, are increased in both type-1 and 
type-2 diabetes
116,117. Its effects on endothelial cells include decreased NO and 
prostacyclin production, an increase in cell adhesion molecules and increase in ET-1, 
MCP-1 (monocyte chemotactic protein-1), IL-8 and PAI-1 (Plasminogen activator 
inhibitor-1) production, leading to changes in vascular tone, inflammation and fibrin 
production. It can also exert its effects on endothelial cells by acting on the supporting 
smooth muscle cells of the vasculature, further increasing NO and NF-κB as well as 
increasing angiotensin II (Ang II) signalling, resulting in the increased production of 
reactive oxygen species (ROS). Lastly VEGF signalling in the context of diabetes in the 
endothelial cell is of particular importance, and is thought to play a significant role in 
many diabetic vasculopathies. As such the contribution of VEGF to diabetic 
vasculopathies will be discussed in detail later. 
Once affected by the actions of diabetes, the endothelium is said to become 
dysfunctional, however, the term “Endothelial dysfunction” is not indicative of a single 
condition, but instead describes the situation where one or more of the constituent 
functions of the endothelial cell are altered to the detriment of the overall functioning of 
the vasculature. One of the more classical types of endothelial dysfunction in the 
context of diabetes is thickening of the basement membrane, through the actions of 
TGF-β and other contributory factors
118,119. In this situation dermatan sulphate 
proteoglycans and chondroitin sulphate proteoglycans are increased, whilst heparan 
sulphate proteoglycans are drastically reduced
120. Since the extracellular matrix requires 
a large quantity of heparan sulphate proteoglycans for correct functioning, a reduction 
in these leads to dysfunction of the endothelium evident in reduced NO availability, 
increased adhesion of mononuclear cells and platelets, and leakage of macromolecules 
across the endothelial layer. These in turn lead to changes in vascular tone, 
inflammation and aberrant fibrin formation.  
Microalbuminurea is also a common consequence of endothelial dysfunction, 
however it’s exact mechanisms are not clearly defined. Changes in hydrostatic pressure,   26
the selectivity of the glomeruli, disruption of the supporting cells (podocytes) in the 
glomeruli interactions with the endothelium and decreased protein reabsorption in the 
kidney are all thought to contribute; concepts that will be explored in more detail later 
upon examination of diabetic nephropathy since microalbuminuria is a defined 
constituent of the disease progression
121,122.  
As mentioned previously, a major function of the endothelium is to maintain the 
fluidity of the blood and to prevent clot formation unless required to promote wound 
healing or protection from infection. The presence of diabetes can influence the 
sensitive dynamics in this process leading to an increase in thrombus formation. Such 
events are mediated by an increase in soluble thrombomodulin and inhibitors of t-PA, 
with a concurrent decrease in tPA itself, leading to an inability to promote anticoagulant 
pathways, and hence create and maintain fibinolytic environments 
123,124. Increased von 
Willebrand factor (vWF) levels have also been correlated with increased risk of 
cardiovascular complications in diabetes patients
125,124, and is of particular interest 
regarding thrombus formation since it is involved in the adhesion of platelets and 
complexes with clotting factor VIII.  
Endothelial repair is usually carried out via angiogenesis, but in the 
hyperglycaemic environment this is yet another process that becomes dysfunctional. In 
the case of wound healing the angiogenesis response is inadequate resulting in reduced 
wound healing, aberrant responses to vascular occlusion and an increased risk of 
myocardial infarction
126. However, the opposite can also be seen in other diabetic 
pathologies such as diabetic retinopathy where angiogenesis is allowed to progress 
unchecked, although in both conditions it is a reduced blood supply that stimulates the 
response.  
Through the actions of numerous processes diabetic endothelial dysfunction can 
give rise to multiple organ system complications particularly affecting the kidney, heart 
and eye. In these organs it is the microvascular networks that bear most of the insult, 
two such examples of diabetic microvasculopathy commonly found in diabetic patients 
being diabetic retinopathy and diabetic nephropathy.  
 
1.4 Diabetic retinopathy 
 
In the eye the damage to the vascular network of the retina is characterised by a 
condition called diabetic retinopathy. Diabetic retinopathy is the leading cause of legal   27
blindness in the working population in the US, and a significant proportion of diabetics 
will present some signs of the disease within 15 years of diagnosis.  
The eye consists of multiple layers of cells, which collectively ensure light is 
focused onto the light-sensing part of the eye, namely the retina. In essence the retina is 
comprised of four major cell types, neurons (photoreceptors, ganglion, bipolar, 
horizontal and amacrine cells), microglia (resident macrophages) macroglia (Müller 
cells and astrocytes), and finally the microvascular cells, comprising the endothelium 
and pericytes. In brief, the neurons detect light both in intensity and spectrum and 
deliver that information to the optic nerve which is subsequently directed to the visual 
cortex of the brain. The glial cells (macro- and micro-) are positioned between the blood 
vessels and neurons such that they can provide nutritional and regulatory support and 
span the entirety of the retina, detecting and responding to any immunological cue that 
may arise, and clearing necrotic and dead cells. This leaves the retinal vasculature, 
consisting of the primary, inner deeper and outer deeper plexuses. The former of these 
originates from the optic nerve head in development giving rise to the deeper plexuses 
later in development. During vasculogenesis of the retina, supporting cells such as 
pericytes are recruited which strengthen the barrier between the blood and retina. The 
ratio of pericytes to endothelial cells can often approach values of 1:1, highlighting the 
importance of vascular integrity, a subject that will be commented upon later. Further 
information regarding the development and constituents of the retinal vasculature can be 
found in a recently published review
127.  
A large part of the detectable changes associated with the progression of diabetic 
retinopathy involve the vasculature, but the other cells that make up the retina are also 
affected by hyperglycaemia. Macroglia, for example, release inflammatory mediators 
and change their levels of certain proteins. In astrocytes this is seen in the down 
regulation of an intermediate filament protein GFAP (Glial fibrillary acidic 
protein)
128,129. Since the function of the astrocyte is closely linked to it’s levels of 
GFAP, down-regulation of this protein is indicative of reduced astrocytic function. 
Conversely, in Müller cells GFAP is up-regulated in response to hyperglycaemia
130, 
even before the clinical signs of diabetic retinopathy are evident, in addition to 
expressing less glutamine synthetase
131,132. Microglia also become activated through the 
actions of hyperglycaemia
129,133, undergoing proliferation and becoming more active, 
expressing proteins such as OX-42. Both types of glial cell can also express VEGF 
(vascular endothelial growth factor), a cytokine that shall be commented upon in detail 
later.   28
One of the initial symptoms of diabetic retinopathy is the presence of 
microaneurysms, usually located in the inner nuclear layer of the retina. These are a 
hallmark of diabetic retinopathy
134,135,136, and usually appear as dark red or white spots 
upon examination of the eye using ophthalmoscopy. The steps required to form a 
microaneurysm have yet to be fully described but are thought to involve damage to the 
basement membrane
137 and require changes in endothelial proliferation
138, vascular 
flow
139,140, and increased pericyte cell death
141,142. Indeed, pericyte cell death appears to 
be critical for the formation of microaneurysms, since several studies have shown that 
microaneurysms consistently lack pericytes upon histological analysis
143,144. In addition 
to this, ‘pericyte ghosts’, or the residual basement membrane left by an apoptosed 
pericyte, can often been seen close to the site of a microaneurysm, further suggesting 
that pericyte death contributes to their formation
136,145,146. The apoptosis of these 
supporting cells is, however, not the only factor in the formation of microaneurysms, 
and localised increases in capillary lumen pressure are also thought to play a role
147. 
This concept is further supported by the observations of microaneurysms in 
microvascular diseases that are not characterised by the loss of pericytes, such as 
hypertension, branch retinal vein occlusion, Coats’ disease and sickle cell anaemia. 
Once formed, various cell types have been reported to populate microaneurysms, which 
change as it matures. In early microaneurysms immune cells and resident endothelial 
cells can be found, whilst in later stages the endothelium dies leaving only erythrocytes 
visible by histology.  
Fig 1.2 Manifestations of diabetic retinopathy.
Various abnormalities can be detected at the back of the retina that 
indicate progression of diabetic retinopathy, ranging from 
microaneurisms through to haemorrhages. Image adapted from 
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The loss of pericytes is hard to detect at a diagnostic level, however, animal 
models have given us insight into the mechanisms of pericyte loss. The vasculature is 
particularly resistant to enzymatic digestion, whereas the remainder of the cells that 
make up the retina are not. For this reason the retina can be treated with high levels of 
trypsin to digest away the neurons and other supporting cells, leaving the vasculature 
behind. When this is done the loss of pericytes can be detected as pockets in basement 
membranes that do not colour with nuclear stains and which are then classified as 
‘pericyte ghosts’
136,142. The microaneurysms themselves can also be visualised using 
this technique, and can be seen as discrete regions where the vasculature has ‘ballooned 
out’ and the blood is allowed to pool.  
The exact cause of pericyte loss in diabetic retinopathy is unclear. Previous 
studies have noted that pericytes have a particularly high expression of the enzyme 
aldose reductase, which converts glucose to sorbitol and, in the presence of 
hyperglycaemia, can cause the accumulation of sugar alcohols
148. It was also suggested 
by these authors that this would be a feasible mechanism for specific pericyte loss since 
other retinal cells, such as endothelial cells, did not express aldose reductase at such 
high levels
149. However, the opposite has now also been shown in other studies, 
suggesting that the actions of aldose reductase in hyperglycaemia may not be the only 
mechanism of pericyte loss. The accumulation of AGEs in pericytes is another proposed 
mechanism for pericyte loss through the actions of the receptor for advanced glycation 
end products (RAGE)
150. In spite of this, the timing of AGE accumulation is 
inconsistent with the timing of pericyte loss
151, suggesting that this also is not the only 
mechanism. In essence, pericyte loss in diabetic retinopathy is more likely to be due to 
the contribution of multiple factors including aldose reductase and AGEs and also 
cytokines such as TNF-α
152,153 and the actions of NF-κB
154.  
Other physical manifestations of diabetic retinopathy that usually present after 
pericyte loss include venous beading, looping or segmentation. Haemorrhages can also 
be found, often in the middle retinal layers, and are classified as dot or blot 
haemorrhages. As mentioned previously, capillaries can become occluded either by the 
action of thrombi, or static leukocytes. When this occurs ophthalmologists can often 
detect what are described as cotton wool spots, resulting from occlusion of capillaries in 
the nerve fibre layer. Intraretinal microvascular abnormalities (IRMA), are then often 
detected close to areas of capillary occlusion, and are observed as dilated capillaries 
functioning as collateral channels for the flow of blood.    30
   As mentioned previously, ophthalmologists use the physical manifestations of 
diabetic retinopathy to screen for the disease, hence a scale of severity of the condition 
has been created to give some indication of its progression. There are four 
classifications of non-proliferative diabetic retinopathy: mild, moderate, severe and very 
severe
155. The presence of one or more microaneurysms without any further symptoms 
is sufficient to classify the disease as mild
156, and an increase in number, in addition to 
hemorrhages, cotton wool spots, venous beading and IRMA within set frequencies and 
distributions then mark the disease as ‘moderate’. Further progression to the ‘severe’ 
and ‘very severe’ categories are met by the increase in frequency of these symptoms and 
their increasing distribution throughout the retina, in accordance with standard 
photographs
155 and measurements of the retina.   
In terms of the visual changes associated with these stages of diabetic 
retinopathy, it is not the previous changes that cause the majority of symptoms, but the 
associated macular oedema. This occurs when fluids and exudates from the blood 
vessels affected by the hyperglycaemia leak into the macula, between the outer 
plexiform layer and inner nuclear layer, causing it to swell, distorting vision and making 
it appear ‘out of focus’ through the loss of ‘fine’ vision. Macular oedema is thought to 
occur through either breakdown of the junctions between endothelial cells and/or the 
loss of pericytes
157,158,159, or alterations in paracellular transport. Upon initial 
examination of the eye ophthalmologists often use the formation of hard exudates 
(lipoprotein deposits between the inner plexiform and inner nuclear layers of the retina), 
to indicate signs of macular oedema, although it can also be detected by the use of 
optical coherence tomography (OCT). Towards the later stages of the disease the fluid 
can spread to all the layers of the retina, exacerbating the alterations in vision. 
Clinically, macular oedema is classified as retinal thickening within 1 disk diameter 
from the centre of the macula
160,161, but can progress to ‘clinically significant macular 
oedema’ (CSME) if one of the following criteria are satisfied: “retinal thickening or 
hard exudates within 500µm of the centre of the macula and/or zone(s) of retinal 
thickening 1 disk area in size at least in part of which is within 1 disk diameter of the 
macula centre”
160. In addition to the CSME classification, macular oedema can be 
characterised as focal or diffuse. Focal macular oedema is usually the result of leakage 
from microaneurysms, or discrete areas of the vasculature
162, usually surrounded by 
hard exudates, whereas diffuse macular oedema is indicative of generalised leakage 
from the capillaries, IRMAs or in severe cases the macrovasculature
163,
164. Although 
spontaneous recovery from macular oedema is not uncommon, treatment is important   31
since in approximately a quarter of cases the absence of treatment will result in 
moderate vision loss within three years 
165,166. 
Vascular leakage can be detected by a method called fluorescein angiography. 
This utilises a fluorescent dye which is injected intravenously in humans, or into the 
peritoneal cavity in animal models of diabetes, and subsequently detected in the retinal 
vasculature by scanning laser ophthalmoscopy (SLO) as it perfuses systemically. If the 
retinal vasculature is intact the dye will remain in the vessels and will be safely 
excreted, however, if the vasculature of the retina is damaged and vascular leakage is 
occurring the fluorescent dye will leak out into the surrounding tissue, detectable as a 
widening area of florescence at the point of leakage. It is important to note, however, 
that the presence of vascular leakage is not always indicative of retinal swelling, since 
leakage is required to exceed the capacity for removal by the retinal pigment epithelium 
(RPE) pump before swelling will occur.  
Up until this point all the described effects fall into the category of ‘non-
proliferative diabetic retinopathy’, the disease then has two further characterisation 
points that are set as early or high-risk proliferative diabetic retinopathy, the former 
defined as the presence of newly formed blood vessels and the latter as the haemorrhage 
of those vessels, where the patient is then at a high risk of irreversible vision loss either 
through obscured vision or retinal detachment
167. Although there are many cellular 
changes attributable to the pathogenesis of diabetic retinopathy and these are 
accountable to hyperglycaemia and other factors, one signalling molecule seems 
consistently involved with the majority of the changes, namely vascular endothelial 
growth factor (VEGF). 
VEGF is a dimeric glycoprotein of approximately 40kDa that, as suggested by 
it’s name, stimulates endothelial growth through enhancement of proliferation, 
migration and tube formation, leading to the formation of new vessels. It consists of 
seven family members with VEGF-A commonly referred to as ‘VEGF’, and VEGF-B to 
VEGF-F with placental growth factor (PlGF) constituting the six remaining members. 
In addition to these family variations, the VEGF gene can be alternatively spliced 
producing proteins of different solubility, linked to their ability to bind heparin, with 
VEGF206 and VEGF189 binding strongly to heparin, and hence the extracellular matrix, 
keeping them effectively insoluble. VEGF121 however, is unable to bind heparin and is 
hence freely soluble, with VEGF165 moderately able to bind heparin and hence 
moderately soluble. As well as these angiogenic forms of VEGF there have recently 
been discovered dominant negative forms of VEGF, called VEGFxxxb, that whilst   32
largely homologous have subtle changes at their C-terminal ends that only partly 
activate their receptor
115 leading to a dominant negative type effect. The functional 
significance of these dominant negative forms of VEGF has also recently come to light 
with evidence suggesting they are down-regulated in both physiological angiogenesis
168 
and pathological angiogenesis
169, highlighting their central role in vascular homeostasis.  
The actions of VEGF are mediated through VEGF receptors, of which there are 
4 members: VEGFR1 (VEGF receptor 1), VEGFR2 (VEGF receptor 2), Flt-3 (fms-like 
tyrosine kinase-3) and Flt-4 (fms-like tyrosine kinase-4). Each has its own specificity 
for the different VEGF family members, but broadly speaking VEGFR1 and VEGFR2 
are involved in angiogenesis
170, whereas Flt-3 and Flt-4 are involved in haematopoiesis 
and lymphangiogenesis
171. Regardless of this, they all have a 750aa extracellular 
domain constituting seven immunoglobulin like domains, a single transmembrane 
domain, followed by a split tyrosine kinase domain and a C-terminal tail. Activation of 
VEGF receptors requires their dimerisation and they form either hetero- and homo- 
dimmers to achieve this
172. Once dimerised and activated, auto-phosphorylation of key 
residues occurs on the intracellular tail, which leads to the binding and activation of 
SH2 domain containing proteins, and subsequent signalling cascades. VEGFs also bind 
to a further type of receptor called the neuropilins that function as co-receptors for 
VEGF. The neuropilins have various functions with neuropilin-1 contributing to 
endothelial migration and adhesion, whilst other forms contribute to bone-marrow 
derived cell differentiation into vascular precursors
173 and synthesis and release of 
prostacyclin
174. Due to the complexities of the different isoforms and splice variants of 
VEGF proteins, with the additional complexities of the VEGF receptors, the 
downstream signalling pathways of activation are wide ranging. Focusing on VEGFR2, 
one of the main receptors activated by VEGF, surprisingly few proteins have been 
shown to directly interact with the receptor. These that do include phospholipase-C-γ 
(PLCγ), Shb, Sck, VRAP (VEGF receptor associated protein) and annexin 5
175. Briefly, 
activation of PLCγ in the context of VEGF signalling activates MAP Kinase signalling, 
stimulating proliferation
176, and also activates protein kinase-C via DAG and elevation 
of intracellular calcium. Shb, however, stimulates endothelial cells to migrate and can 
activate PI3 Kinase that subsequently influences actin dynamics through Rac and p38 
MAP kinase signalling, or serves to activate Akt and enhance cell survival
177, in 
addition to increasing NO production through eNOS activation. Sck binding to the 
VEGFR2 results in its association with Grb2 that in turn activates MAP kinase, with 
VRAP activation by VEGFR2 binding important in migration, and regulation of Src   33
signalling through direct interactions. There are also pathways downstream of VEGF 
receptor activation that have not been completely elucidated, such as signalling through 
FAK (focal adhesion kinase) to paxillin that regulates focal adhesions.  
In the context of diabetic retinopathy it is often the lack of oxygen (hypoxia) that 
induces VEGF levels to rise. Hypoxia upregulates VEGF levels by many different 
mechanisms
178 including increased transcription, increased stability of mRNA, 
differential protein translation using IRES sequences, and increased chaperone protein 
expression. Increased transcription of VEGF in hypoxic conditions is mostly 
attributable to HIF1 (hypoxia inducible factor-1), a heterodimer consisting of HIF1-α 
and HIF1-β. The latter, HIF1-β is constitutively expressed whilst levels of the former, 
HIF1-α, are responsive to oxygen levels in the cell
179. Under normoxia HIF1-α is 
targeted for degradation, however under hypoxia these mechanisms are inhibited and 
HIF1-α levels increase
180, HIF1-α then binds HIF1-β where it is translocated to the 
nucleus and binds the hypoxia responsive element of the VEGF gene, initiating 
transcription
181,182,183,184,185.  
The second method through which VEGF levels are up regulated is mRNA 
stabilisation. The mRNA of VEGF is unusually unstable in comparison to that of most 
other eukaryotic genes, with a half-life of only 1-2 hours instead of the more normal 10-
12 hours. However, hypoxia has been shown to increase the half-life of VEGF mRNA 
2-3 fold
186, due to the stabilising effect of HuR, a 36kDa RNA binding protein, which 
binds to the 3’-UTR of VEGF mRNA preventing its degradation
187,188. Thirdly, IRES 
sequences, specific sites of attachment for the ribosomal machinery that override the 
normal methods of translation have been found in the 5’-UTR of VEGF mRNA
189. 
Lastly, up-regulation of a chaperone protein, ORP150 that shuttles VEGF from the 
endoplasmic reticulum to the Golgi apparatus has been shown in the context of hypoxia 
to facilitate VEGF transport and secretion
190. 
VEGF is not only regulated by oxygen levels, it has also been shown to be 
regulated by other proteins such as IGF-1. IGF-1 is critical for vessel development in 
vitro
191,
192, with pre-term infants with reduced serum levels of IGF-1 showing a higher 
incidence of retinopathy
193. Despite this, IGF-1 does not directly influence the levels of 
VEGF protein, as demonstrated in mouse knockout models
194, but does so by 
decreasing Akt activation in the context of VEGF signalling, which has been shown to 
be important for endothelial cell survival
195.  
In terms of the effects of VEGF on diabetic retinopathy, it has been described as 
the primary mediator of vascular alterations in disease progression
196,197,198. Indeed   34
many of the changes associated with diabetes such as hyperglycaemia and production of 
AGE have been noted to increase VEGF expression, and the levels of VEGFR2
199,200. 
There is also a strong correlation between VEGF levels in the eye and development of 
proliferative diabetic retinopathy
196, with therapies designed to block the actions of 
VEGF shown to decrease the associated permeability defects of diabetic retinopathy 
both in patients
201,202,203,204 and animal models
205,206,207.  
Many factors thus contribute to the increased expression of VEGF including 
hypoxia, growth factors, inflammatory cytokines and ROS. Each of these has been 
shown to up-regulate VEGF in disease models but not all have yet been characterised in 
the context of diabetic retinopathy. Hypoxia is by far the most studied regulator of 
VEGF expression in diabetic retinopathy, with increases in capillary density linked to 
hypoxic regions of the retina
208. However, up-regulation of VEGF occurs as early as 1 
week post diabetes, when hypoxic regions of the retina would not have yet formed, 
suggesting that other factors may play a role its up-regulation. Such examples include 
TGF-β, TNF-α, IGF-1 (discussed earlier), AGEs and oxidative stress
209,210,211,212,213. 
Whilst their mechanisms of action are unclear, all have been shown to up-regulate 
VEGF in the context of diabetic retinopathy. 
ROS, also up-regulated in diabetes, have a clearer mechanism of VEGF up-
regulation via the activation of STAT3
214,215. Interestingly, STAT3 is heavily involved 
in the actions of VEGF in diabetic retinopathy, especially since the actions of VEGF on 
endothelial cells are sufficient to cause STAT3 activation, promoting autocrine VEGF 
expression
216,217. STAT3 has also been demonstrated as being critical for HIF1-α 
activation, and hence VEGF expression in multiple signalling pathways
218. When one 
further considers that the actions of hyperglycaemia are sufficient to activate STAT3, 
via NADPH oxidase activity
219,215, it is clear that STAT3 is a transcription factor of 
extreme interest in the context of diabetic retinopathy. 
As mentioned previously VEGF activates a wide range of signalling cascades in 
the progression of diabetic retinopathy, of which some of the most important are 
outlined below. VEGF strongly stimulates vascular inflammation, up-regulating ICAM-
1 and MCP-1
220,221,222, and hence VEGF levels are closely linked to the prevalence of 
leukostasis in diabetic retinopathy, local changes in inflammation, and potentially blood 
flow if sufficient leukocytes are recruited to block the vessel. VEGF levels in the eye 
are closely correlated with the permeability of the retinal vasculature and hence the 
degree of vascular leakage
223,224,214,207. This is highlighted by observations that anti-
VEGF treatments both in animal models and patients can reduce vascular leakage   35
205,206,207,201,203,204. VEGF induces endothelial permeability through an increase in 
transcellular transport and the formation of fenestrae
225 or caveolin-coated vesicles 
226,227, whilst other actions of VEGF are mediated through an increase in paracellular 
permeability
228,227. One such example of this is the action of VEGF on plasmin 
activation via up-regulation of receptors for plasminogen activators
229. This up-
regulation in plasminogen activator receptor leads to increased plasmin and therefore 
degradation of the subcellular matrix disrupting cell-cell and cell-substrate attachments, 
hence increasing vascular leakage. This process can also lead to the degredation of the 
basement membrane, through the actions of plasmin and matrix metalloproteinases, 
setting the stage for neovascularisation to occur. A further mechanism of VEGF induced 
permeability centres around the adherens junction protein VE-cadherin. In work by 
Gavard & Gutkind (2006), immortalised mouse endothelial cells were shown to 
endocytose VE-cadherin from the surface of the endothelium into early endosomes in 
response to VEGF
104. This internalisation was shown to be transmitted via the VEGFR2 
receptor in a Src, Vav2, Rac and PAK dependent signalling cascade, occurring as early 
as 2 minutes post VEGF stimulation. The actions of VEGF in this system were shown 
to enhance the permeability of the endothelial layer to FITC conjugated dextran, and 
could be modulated by the specific knockdown of Src or over-expression of 
constitutively active Src, decreasing and increasing respectively the permeability 
response to VEGF
104. 
Although it is known that hyperglycaemia is key to the development of diabetic 
retinopathy, a central mechanism for the instigation of the condition has yet to be 
elucidated. Regardless of this there are known risk factors for the development of the 
disease, some of which are outlined below.  
Inadequate control of blood glucose is one of the major risk factors in the 
development and progression of diabetic retinopathy
230. In accordance with this there is 
also a strong direct link between the development and severity of diabetic retinopathy, 
and time post-diagnosis of diabetes
231. In one study the presence of significant levels of 
protein in the urine (proteinuria), a symptom of diabetic nephropathy, was associated 
with a 95% increased risk of developing diabetic retinopathy amongst individuals with 
type 1 diabetes
231,  232. Hypertension has also been linked to the progression of both 
diabetic retinopathy and diabetic macular oedema, since it has been shown that tight 
blood pressure control can reduce the progression of diabetic retinopathy with a 47% 
reduced risk of deterioration of visual acuity
233. Other factors that influence the 
incidence and progression of diabetic retinopathy include serum lipid content, anaemia,   36
age, increased body mass index (BMI)
234 and pregnancy; in that pregnant women with 
type 1 diabetes are twice as likely to develop diabetic retinopathy than diabetic women 
who are not pregnant. 
Current data also suggest that diabetic retinopathy may have a genetic 
component, but studies into the genetic risk factors of diabetic retinopathy are limited 
by differences in approach that makes comparability between investigations 
problematic. These data should not however be disregarded, as there are genes that 
consistently emerge and which are probably significant despite these limitations. 
Examples of these include aldose reductase, b3 adrenoreceptor, endothelial constitutive 
eNOS, α-2 integrin, PON-1 (paraoxonase 1), GLUT-1, PAI-1, human leu-cociteantigen-
DR and DQ and ACE (angiotensin converting enzyme)
235,236.  
There are many treatments in various stages of testing for diabetic retinopathy, 
such as protein kinase C inhibitors
237, triamcinolone acetonide, inhibitors of the 
angiotensin pathway
238, growth hormone inhibitors
239,240, antioxidants
241 and 
cyclooxygenase-2 inhibitors. The best treatment currently available, as with most 
diabetic complications, is the strict control of glycaemia. This does however cause 
issues for sufferers as the potential for hypoglycaemia can increase if too much control 
is imposed, and some weight gain can be expected, increasing BMI and hence another 
risk factor. Interestingly, it has been shown that tight control of glycaemia was 
associated with an early worsening of diabetic retinopathy in a third of patients, often 
going from a mild to moderate stage
242. Mechanisms for this effect were not clearly 
defined but hypotheses include changes in blood flow with subsequent hypoxia
243 or 
increase in shear stress
244, and the actions of exogenous insulin on IGF-1 (insulin like 
growth factor 1) production potentially facilitating angiogenesis directly
245 or via VEGF 
246. Regardless of these observations, good metabolic control is central to the successful 
management of diabetic retinopathy, since uncontrolled diabetes will invariably lead to 
the disease. Another current therapy is tight control of blood pressure, which in itself is 
a risk factor for diabetes. High blood pressure is thought to increase the levels of shear 
stress on the endothelial cells, leading to stretching of the vasculature and subsequent 
VEGF release. Unlike glycaemic control, tight regulation of blood pressure has not been 
shown to have adverse effects on the progression of diabetic retinopathy and current 
targets for blood pressure in diabetic patients are below 130/85 mm Hg.  
Subsequent to these treatments, photo-coagulation (also called photodynamic 
therapy) is the remaining therapeutic option for diabetic retinopathy. The treatment 
involves the use of a laser to coagulate damaged vessels, but this can also lead to local   37
collateral destruction of neurons. The frequency of the light used seems irrelevant as 
lasers at 514nm, 532nm, 647nm, 810nm and 560nm-640nm are all effective
247. 
Candidates for focal or grid laser photo-coagulation include those with clinically 
significant focal macular oedema, with the aim being to destroy leaking aneurysms, 
whereas treatment of clinically significant diffuse macular oedema with laser photo-
coagulation is not advised since it is usually unresponsive
248,249,250. Patients with 
proliferative diabetic retinopathy are usually indicated for panretinal treatment, with the 
aim being to ablate the ischemic areas of the peripheral retina, such that the angiogenic 
factors that cause further progression of the disease are reduced. In recorded trials, pan 
retinal photo-coagulation reduced the chance of severe vision loss by 50% with focal or 
grid treatments reducing the risk of vision loss by at least 50% 
251. In some cases 
patients with severe or very severe non-proliferative diabetic retinopathy are suggested 
for pan-retinal laser photo-coagulation. These are cases where there is evidence of rapid 
advancement of the condition, history of poor patient follow up, close relations with 
diabetes or in patients who have had diabetes for an extended period of time. When 
photo-coagulation is not successful or there is a non-clearing vitreous haemorrhage or 
risk of retinal detachment, a further surgical intervention, vitrectomy, may be employed. 
The main aims of vitrectomy are to remove any opacities obscuring vision, relieve 
tractional adhesions and manage any complications of previous vitrectomy. However, 
the procedure is drastic in nature and can cause numerous complications such as retinal 
detachment, and involves the radical insertion of surgical instruments into the eye. It is 
however beneficial in patients with severe vision loss due to proliferative diabetic 
retinopathy, with studies demonstrating that in 25% of cases vision can remain 
improved at two years post surgery, in comparision to only 15% of those patients who 
only received careful monitoring
252,253,254,255,256. Vitrectomy can also be employed to 
treat macular oedema in cases where focal laser treatment is repeatedly unsuccessful, 
and has shown promise in restoring vision
257,258,259, 259, 260. 
It is often the case in diabetic patients, especially those without good glycaemic 
control, that they will be affected by more than one consequence of diabetic 
microangiopathy. As with diabetic retinopathy, diabetic nephropathy describes the 
damage that can occur to the kidneys as a result of diabetes, caused by dysfunction of 
the endothelium and the supporting milieu of cells. 
   38
1.5 Diabetic nephropathy 
 
In the USA diabetic nephropathy is the most common cause of end-stage renal 
disease where dialysis is required
261, and is the leading cause of end-stage renal disease 
worldwide
262. Between 20-40% of people with diabetes develop nephropathy, with 80% 
of untreated type-1 diabetics and 20-40% type-2 diabetics progressing to the overt 
stages of the disease within 15 years
263. Progression of the disease involves many 
different cell types, and has distinct phases of development. Changes to the function of 
the nephron at the level of the glomerulus, such as hyperperfusion and hyperfiltration 
occur before any clinical changes can be detected. Subsequently the basement 
membrane of the glomeruli thickens and mesangial cells proliferate, with increased 
production of extracellular matrix. Microalbuminuria, or the increased presence of 
albumin in the urine, usually presents early in the disease and is defined as the excretion 
of greater than 30mg but less than 300mg albumin in the urine per day. Further 
progression to later stages of the disease is variable
264, indicating that more factors than 
hyperglycaemia alone influence kidney deterioration.   
  Many of the biochemical pathways responsible for the diabetic insult are similar 
to those outlined earlier in endothelial cells with increased flux through the polyol 
pathway along with increased AGE, active PKC isoforms and hexosamine pathway 
activity. Interestingly, unlike diabetic retinopathy the influence of genetics in the 
progression of diabetic nephropathy is thought to play a major role since, as stated 
previously 20-40% of diabetics progress to the later stages of disease
254, irrespective of 
glycaemic control. To illustrate how genetics play a role in this disease one study in 
Pima Indians demonstrated that in individuals who had a history of two successive 
generations of type 2 diabetes, the incidence of nephropathy was 14% if neither parent 
had proteinuria, an advanced symptom of diabetes. However if one parent had 
proteinuria the rate increased to 23%, and to 46% if both parents had proteinuria
265. So 
far there have been two methods of collecting genetic data, namely case-control 
association studies and family studies. Association studies have been the most common 
approach to date, with genes such as the angiotensin II receptor, extracellular matrix 
components, various cytokines and proteins involved in glucose or lipid metabolism 
identified. The approach is not without limitations since some contradictory evidence 
has been highlighted
266. However problems also exist in family studies, since there is no 
simple Mendelian inheritance model available as most affected parents of the patients 
are dead due to increased morbidity. Investigators have instead used sibling pairs, and   39
have identified regions on chromosomes 3, 7, 9, 10, 12 and 20
267,268,269 that are of 
potential interest.  
  As mentioned previously the early signs of diabetic nephropathy often escape 
clinical observation and are due to hyperperfusion and hyperfiltration of the glomerulus. 
These are mediated by constrictions of the afferent and efferent arterioles of the 
glomerulus, with the afferent more affected, thereby increasing intraglomerular 
pressure. Many different factors have been identified in the progression of this 
dysfunction including NO, VEGF, TGF-β, prostanoids and angiotensin II. These early 
changes in the hemodynamic of the glomerulus facilitate albumin leakage, thickening of 
the basement membrane and mesangial matrix expansion that provide the early 
indicators of disease
270,271. 
Interestingly all three of the above indicators of the disease can be linked to 
damage to a specific cell in the kidney glomerulus, namely the podocyte. These are 
unique, terminally differentiated cells that are located between the glomerular capillary 
basement membrane and Bowman’s space. One of their key features is the podocytic 
foot process that connects the cell body of the podocyte to the glomerular basement 
membrane. Combined with the fenestrated endothelium and glomerular basement 
membrane, podocytes form the filtration barrier that allows water and solutes to pass, 
but retains proteins inside the capillary. The podocyte foot process is known to be 
enriched in actin and it’s associated proteins, providing the interaction between the foot 
process and the basement membrane
272. Another unique characteristic of podocytes is 
the junction between foot processes, known as the slit diaphragm, which contains 
proteins such as nephron and podocin. The correct functioning of the podocyte is known 
Fig 1.3 Glomerular changes indicative of diabetic nephropathy.
Various changes occur in the glomerulus in response to diabetes including podocyte death, basement 
membrane thickening and mesangial matrix expansion. Image adapted from Jefferson, J.A. et al
(2008) Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney international. 74
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to be important for the functionality of the glomerular filtration barrier, but is also 
important for counteracting increases in glomerular pressure, as well as the synthesis 
and maintenance of the glomerular basement membrane and production of VEGF. It is 
hypothesised by many groups that changes in both the unique structures present in the 
podocyte and their interactions with other cells can link many of the symptoms of 
diabetic nephropathy.  
  In terms of the microalbuminuria that eventually progresses to proteinuria, both 
the haemodynamic changes and structural changes to the basement membrane and 
podocytic foot processes are thought to play a role. Changes to podocytic foot processes 
usually constitute effacement to the basement membrane, a well described finding in 
diabetic nephropathy, and can be the result of disruption to the slit diaphragm, 
alterations in the glomerular basement membrane or the interaction between the 
podocyte and the basement membrane. There are a number of investigations that have 
proposed mechanisms for podocyte foot effacement
273, ZO-1 has been shown to mis-
localise in the presence of hyperglycaemia, from the membrane to the cytoplasm, 
potentially causing disruption of tight junctions. Signalling pathways such as the MAP 
kinase pathway have also been suggested to play a role, since activation of the pathway 
can subsequently activate a small heat shock protein HSP25
274, that is important in the 
maintenance of the actin cytoskeleton in response to metabolic stress. In fact, 
investigators have shown that early in chemically-induced diabetes early activation of 
the MAP kinase pathway is associated with increased activation of HSP25 and 
preservation of the podocytic foot process structure and maintenance of 
normoalbuminuria. The actin cytoskeleton of the foot process itself can also become 
altered since hyperglycaemia has been shown to alter the subcellular localisation and 
levels of one of the proteins important in active cytosketeton crosslinking, namely α-
actinin-4
275.    
  A further way in which podocytes are involved in the pathogenesis of diabetic 
nephropathy is through apoptosis. Due to their terminally differentiated nature 
podocytes cannot regenerate, and as such their loss through apoptosis is thought to 
permanently alter the characteristics of the filtration barrier. Studies have revealed that 
the number of podocytes are reduced in both type 1 and type 2 diabetes
276,277, and that 
apoptosis of podocytes can have a direct effect on the glomerular capillary
278. Two 
mechanisms of podocyte apoptosis include the action of ROS directly on podocytes, 
supported by in vitro and  in vivo experiments, and the observation that antioxidant 
therapy prevents podocyte apoptosis
279. Second is the action of angiotensin II through   41
the renin-angiotensin system, supported by observations in ex vivo experiments, an 
effect that may be mediated through TGF-β activity. Although the podocyte plays a key 
role in the development of diabetic nephropathy, there are further factors involved 
including angiotensin II (Ang II), VEGF and TGF-β. 
  The role of Ang II and the renin-angiotensin system is well known in diabetic 
nephropathy and its pathological activation is thought to be induced by the 
hyperglycaemic induction of increased intraglomerular pressure resulting in the 
production of stretch-stress responses. Ang II is produced initially from the actions of 
renin on angiotensinogen to produce Ang I (Angiotensin I), then through the actions of 
angiotensin converting enzyme (ACE) it is converted to Ang II. The majority of the 
effects of Ang II are mediated through the angiotensin II receptor – type 1 (AT1) 
receptor
280,281,282,  283, though a second receptor AT2 has also been described, and is 
thought to be important in development. Ang II binding to the AT1 receptor can have 
various effects, including vasoconstriction through modulation of NO and intracellular 
calcium, inflammation via up regulation of NF-κB activity, cell growth, cell 
proliferation and a decrease in renal blood flow. Due to this, various inhibitors of the 
angiotensin system have been used in the treatment of diabetic nephropathy, with one 
such example being synthetic antagonists. Their use in diabetic nephropathy has been 
reported to decrease proteinuria, TGF-β levels, oxidative stress, pore size of the 
glomerular membrane, and preserve the structure of the glomerulus and tubules, hence 
making such drugs important in the prevention of kidney failure in diabetic 
nephropathy. Untreated however, Ang II activation can up-regulate various cytokines, 
including VEGF and TGF-β, that have additional effects on the progression of diabetic 
nephropathy.  
VEGF secreted from the podocyte is known to be required for the correct 
functioning of the endothelium in the glomerulus
284. In addition, diabetes is known to 
affect the levels of VEGF in many of its associated disorders, and diabetic nephropathy 
is no exception, there is however some controversy over whether VEGF levels increase 
or decrease in response to diabetic nephropathy. The majority of the evidence indicates 
that VEGF levels and activity increase during disease
285-287, however investigators have 
also found that the levels of VEGF mRNA in glomeruli of diabetic patients are 
reduced
288. One potential explanation for this is the apoptosis and loss of podocytes
289, 
and as such the true setting of the data is of yet unknown. In terms of the up-regulation 
of VEGF activity, the stretch response as well as the actions of Ang II
290 are known to 
up-regulate the levels of VEGF in the context of diabetes with Ang II also capable of   42
VEGF up-regulation in normoglycaemia
290, potentially through the induction of another 
inducer of VEGF, HIF-1α
119. Once VEGF is present it has multiple effects such as an 
increase in permeability of the endothelium
119, most likely through the actions of NO, 
down-regulation of the slit diaphragm protein nephron
119, and increased basement 
membrane thickening by increasing levels of α3 collagen. Investigations into the 
neutralisation of VEGF in animal models have demonstrated that microalbuminuria can 
be attenuated
291, with elements of the mesenchymal matrix expansion also 
impeded
291,292.  
TGF-β has been shown in various studies to play an important role in the 
pathogenesis of diabetic nephropathy. Investigations both in animal models of 
diabetes
293 and human patients
294 over the past 15 years have demonstrated that TGF-β 
levels and activity are increased during disease. Evidence of the close link between 
TGF-β and the progression of diabetic nephropathy comes from a number of 
observations, including that increased levels of TGF-β in the urine are closely linked 
with the levels of microalbuminuria. TGF-β signalling, in the context of diabetic 
nephropathy, has been demonstrated in both in vitro and in vivo models and is thought 
to occur through the actions of Smad 3 binding to the promoter regions of TGF-β target 
genes such as collagen α1 and fibronectin. TGF-β activity can also be communicated 
through the actions of the MAP kinase pathway
295, which in turn induces the activity of 
AP-1 (activating protein 1) which is capable of binding and activating Smad proteins 
involved in the TGF-β pathway. The actions of TGF-β in the context of diabetic 
nephropathy have earned its status as the major cytokine involved in the mesenchymal 
matrix expansion
296,297,298,299. However TGF-β also signals via other molecules to 
produce various effects such as the induction of connective tissue growth factor 
(CTGF)
300 and NO production; seemingly through the up-regulation of eNOS
301. 
Central to the activation of TGF-β in the context of diabetic nephropathy is the 
observation that hyperglycaemia increases the level of GLUT-1 in mesangial cells
302 
thereby leading to an increase in the transcription rate of TGF-β mainly through the 
upstream transcription factor (USF) family
303. However TGF-β has also been shown to 
be activated through RAGE signalling
119 and by hyperglycaemia or increased levels of 
albumin in vitro. Therapies aimed at reducing the action of TGF-β have been explored 
and neutralising antibodies have been shown to prevent renal hypertrophy, 
mesenchymal matrix expansion, increases in mRNA of collagen and fibronectin, 
GLUT-1 overexpression in mesangial cells and the deterioration of renal function in 
diabetic mice
304, some of which can also be achieved by the inhibition or down   43
regulation of Smad3
305. In addition, it has also been observed that inhibition of the 
actions of Ang II can lead to lower TGF-β activity
306, postulating a potential link 
between TGF-β and hypertension.   
 
1.6 The annexins and annexin 2 
 
Since diabetic nephropathy and diabetic retinopathy are diseases of the 
microvasculature and their associated cells it is important to identify key proteins that 
contribute to and mediate the deleterious effects of hyperglycemia. One such family of 
proteins that could fulfil this requirement are the annexins, a group of calcium 
dependent phospholipid binding proteins found in almost all cells of the body. As a 
family they share a common C-terminal core domain that contains the calcium-binding 
sites and which forms a conserved curved disk shape consisting of 4 homologous 
‘annexin’ repeats of around 70 amino acids each. The convex surface contains the 
calcium binding sites, and it is thought to be the calcium ion bound to the annexin core 
that is responsible for organising the interaction between the carbonyl and carboxyl 
groups of the annexin protein and phospholipid membrane respectively
307. Since the 
core domain of the annexin family is highly conserved it is the N-terminal domain that 
largely distinguishes one annexin from another. The N-terminal domain forms a 
functionally independent subunit and is located adjacent to the convex phospholipid 
binding face of the C-terminal core. These data came from the elucidation of the crystal 
structure of annexin 1, where this model of the N-terminal domain was confirmed. 
Interestingly, it was also shown that in the absence of calcium the N-terminal domain 
was buried into the C-terminal core
308 hence demonstrating a further reliance of the 
annexins on calcium for their activation.  
  Although there are 12 annexins in the vertebrate gene family, in terms of 
endothelial cell function, annexin 2 has been the most studied. As with all annexins it 
comprises a C-terminal core domain and N-terminal domain, which is the target of 
many interactions and modifications that regulate annexin 2 function. One of the most 
pivotal interactions is the formation of the annexin 2 heterotetramer through binding of 
two annexin 2 monomers to a dimer of S100A10, a member of the S100 family of EF-
Hand proteins
309, also known as the ‘annexin 2 light chain’. S100A10
263, 310 was initially 
identified in a complex with annexin 2
311,312,313. Like annexin 2, it is found in many 
different cells and tissues, with the highest expression in the intestine, lung and 
kidney
314,315. S100A10 is unique within its gene family in that its actions are   44
independent of calcium. In other S100 proteins binding of calcium causes 
conformational changes that expose their hydrophobic surfaces allowing interactions to 
occur with their various target proteins
310,316,317,318. However, S100A10 has changes to 
amino-acids in its EF-hand loops that cause the calcium binding sites to become 
inactive
312,319, and leave the protein in a permanently activated configuration
309.  
Annexin 2 has many intracellular functions, which include its long establised 
role as a phospholipid binding protein, and more recently its role in actin dynamics. It 
has been known since 1984 that annexin 2 interacts with actin
311 and since 1994 that 
annexin 2 can bundle actin monomers into filaments in vitro in a calcium dependent 
manner
320, with the actin binding site of annexin 2 localised to a specific site in the C-
terminus by Filipenko & Waisman in 2001
321. A role for the binding of annexin 2 to 
actin has been shown in many of its actions, including the secretory pathway and 
phagocytosis. A further role revealed in a study of live cells transfected with annexin 2-
GFP using evanescent field microscopy where it was observed to be enriched in the 
actin tails of macropinocytic vesicles, an interaction that could be abolished with the 
transfection of a dominant negative variant of annexin 2
322. A further recent 
development in the study of annexin 2 and actin has come from work by Hayes et al 
where it was shown that not only is annexin 2 localised to dynamic actin protrusions 
inside the cell, but depletion of annexin 2 by siRNA can abolish these structures and 
cause the cell to lose its protrusive and retractile activity
323. In addition, it was shown 
that in specific circumstances annexin 2 can inhibit actin polymerisation at the barbed 
ends of the actin filament
323. Links between annexin 2 and actin have been further 
substantiated with the role of annexin 2 in vesicle rocketing demonstrated in Lowe 
syndrome fibroblasts, where these structures originate without stimulation and which 
are decreased with depletion of annexin 2 by siRNA
324. The actin bundling function of 
annexin 2 has also been demonstrated physiologically in cells infected by 
enterohemorrhagic Escherichia coli (EHEC)
325, whilst its identification as a regulator 
and effector of v-Src induced transformation demonstrates further support for its role in 
the modulation of actin dynamics
326.  
In addition to these ‘pathological’ settings, annexin 2 function has also been 
highlighted in a more physiological process, namely wound healing. Epithelial cell 
migration to heal wounds is known to require actin dynamics, and in a study by Babbin 
et al annexin 2 siRNA treatment caused reduced cell spreading and wound closure, 
associated with decreased formation of filamentous actin along the base of the cells
327. 
Interestingly, the dynamics of Rho were also examined in this system, and upon   45
treatment with annexin 2 siRNA, Rho was found to be dissociated from the plasma 
membrane and less active. Further to this, transfection of constitutively active Rho 
restored the ability of epithelial cells to close wounds demonstrating the importance of 
actin dynamics and the role of annexin 2 in wound healing. 
As mentioned previously, annexins are phospholipid-binding proteins. In the 
case of annexin 2, binding to phosphatidylinositol (4,5)-bisphosphate (PIP2) has been 
described in various settings including infection by enteropathogenic Escherichia coli, 
where binding of annexin 2 to PIP2 causes actin accumulation
328. The translocation of 
annexin 2 to membranes has been shown to be responsive to both calcium
329, pH
330 and 
phosphorylation at the N-terminus
331. When taken together with its ability to interact 
with actin, the phospholipid binding properties of annexin 2 are central to its role in 
many different cellular processes, some of which will be outlined further below. 
During endocytosis the transport and fusion of endocytic vesicles is mediated by 
various proteins, one of which is annexin 2. Assays on the fusion efficiency of early 
endosomes revealed that normal endosomes could fuse with good efficiency, but that 
when endosomes were sonicated, and hence fractionated into smaller endosomes, only 
some of them could fuse
332. By examining which proteins were transferred to a donor 
endosome it was possible to identify proteins necessary for endosome fusion, one of 
which was found to be annexin 2. Many subsequent studies have highlighted the role of 
annexin 2 in the endocytic pathway. For example, it was shown that binding of annexin 
2 to cholesterol in endosomes can mediate their interaction with the cytoskeleton
333,
334. 
It was also shown that when cholesterol was depleted from endosomes, annexin 2 could 
no longer be isolated from them
333. In addition to this, more recent publications have 
demonstrated the role for annexin 2 in the generation of early endosomes where it has 
been shown as being important for nucleating actin on their surface in association with 
Spire1 and Arp2/3
335, with phosphorylation of annexin 2 shown to be essential for its 
proper endosomal association and facilitation of the endocytic pathways
336. 
Annexin 2 is also involved in the secretion of molecules by the cell, studies 
using adrenal chromaffin cells showed that annexin 2 is associated with secretory 
granule membranes and loss of secretory activity of permeabilised cells, due to leeching 
of intracellular proteins, can be rescued by the addition of annexin 2, a process that is 
then reversible by the addition of an antibody directed against annexin 2
337,338. In 
addition, annexin 2 has been shown to be critical for regulated secretion of molecules 
from endothelial cells when in complex with S100A10, since disruption of this 
interaction reduces secretion from these cells
339. Interestingly, annexin 2 has also been   46
shown to be selective in its secretory role, since upon its inactivation in endothelial 
cells, vWF secretion is inhibited whilst that of t-PA is not
340. Phagocytosis provides 
another example of a process that requires organised membrane dynamics, and which is 
therefore likely to involve annexins. Indeed, annexins 1-5 are associated with different 
stages of phagocytosis, with annexin 2 found on the plasma membrane co-localised with 
F-actin at membrane protrusions in macrophages
341. In addition, annexin 2 has been 
shown to regulate the kinetics of Src and FAK activation in retinal phagocytosis
342.  
Junction formation in endothelial and epithelial cells requires the participation of 
many different proteins. Annexin 2 has been identified in complex with Rac-1, a small 
GTPase involved in the regulation of cell migration and adhesion in epithelial cells. In a 
report by Hansen et al (2002) an annexin 2:Rac-1 complex was identified at epithelial 
cell junctions in response to cell-cell contact, a process dependent upon production of 
specific anionic phospholipids by PI3-Kinase
343. It is thought that in this context 
annexin 2 stabilises Rac-1 at the plasma membrane to facilitate junction formation, 
hence giving annexin 2 a role in epithelial junction formation. Further evidence for a 
role for annexin 2 in epithelial adherens junction formation has been shown by two 
separate studies that demonstrated failure of E-cadherin localisation to the periphery 
upon annexin 2 siRNA treatment
344,345. In terms of endothelial junction formation it is 
known that when endothelial cells reach confluence the cholesterol and annexin 2 
content of the plasma membrane increases
346. It is also known that in endothelial cells 
an annexin 2-SHP-2 complex is recruited to the plasma membrane in response to rising 
cholesterol levels and cell-cell contacts, leading to de-phosphorylation and stabilisation 
of adherens junction proteins
347. More recently, this complex with SHP-2 has been 
shown to be sensitive to calcium, the actions of growth factors, and heat shock protein 
70 (HSP70)
348. Indeed, a direct link has also been found between annexin 2 and VE-
cadherin, the main adherens junction protein in endothelial cells. In a study by Heyraud 
et al annexin 2 was found to bind VE-cadherin in confluent human umbilical vascular 
endothelial cells (HUVEC), translocating from the cytosol to the plasma membrane. It 
was also shown that annexin 2 in lipid rafts bound both actin and VE-cadherin, 
preventing the lateral diffusion of the VE-cadherin complex. Further to this, treatment 
with siRNA directed against annexin 2 caused mislocalisation of VE-cadherin away 
from adherens junctions, with VEGF decoupling annexin 2 from VE-cadherin 
potentially facilitating the switch from a quiescent to an immature state
349. Taken 
together, these observations highlight annexin 2 as a potentially important protein in the 
formation of cell-cell junctions.   47
As well as having intracellular actions, various extracellular roles have also been 
identified for annexin 2, despite the fact it lacks a typical signal peptide for secretion. 
One such interaction of annexin 2 on the surface of cells was described with tenascin-C. 
In a recent review tenascin-C was reported as having roles in the body’s response to 
stress and trauma, such that the tenascin-C knock-out mouse appears normal until it 
encounters a pathological challange
350. The binding of tenascin-C to annexin 2 on the 
surface of endothelial cells has been shown to cause three responses: loss of focal 
adhesions, growth of confluent cells exposed to growth factors, and increased cell 
migration
351. All these effects were blocked by an antibody specific for annexin 2 prior 
to the addition of tenascin-C, indicating that the processes are annexin 2 dependent and 
that the complex formed can signal to the inside of the cell. The physiological 
significance of the interaction of tenascin-C with annexin 2 has been linked to tumour 
formation, where endothelial annexin 2 binds to tenascin-C on lymphoma cells
352. 
  Tenascin-C is not the only protein that has been described to bind extracellular 
annexin 2, in the development of the foetus ‘immunoglobulin G’ (IgG) molecules are 
transferred across the placental membrane by Fc receptors on the membrane surface. 
Annexin 2 has been shown to have Fc-like properties, such that it can bind IgG and is 
found in placental tissue. Whether annexin 2 functions as a transport molecule for IgG 
was the subject of a study conducted by Kistoffersen & Matre, and although tetrameric 
annexin 2 was found on the surface of the syncytiotrophoblast microvillous plasma 
membrane it was unclear as to whether annexin 2 functioned to transport the IgG across 
into the foetal tissue
353. Another surface annexin 2 interaction has been described in a 
study conducted by Wright et al. In this investigation the human cytomegalovirus was 
found bound to the surface annexin 2 of endothelial cells, and that antibodies directed 
against annexin 2 could reduce the infectivity of the virus
354. 
  The ability of annexin 2 to bind membranes in an intracellular environment is 
well characterised. In contrast, the ability of annexin 2 to bind membranes when on the 
surface of endothelial cells was shown in a study by Lee et al, where annexin 2 was 
found to co-localise with other tight junction proteins such as occludin. In this instance 
it was proposed that it was the tetrameric form of annexin 2 that mediated the formation 
of the junction by bringing the two membranes close together. To this end it was also 
shown that a synthetic peptide targeted to disrupt the interaction between S100A10 and 
annexin 2, therefore inhibiting the tetrameric from of the protein, significantly reduced 
tight junction formation in these cells
355.    48
In addition to having roles in homeostatic and normal physiological processes, 
extracellular annexin 2 has also been implicated in the infectivity of HIV-1. In this 
instance it is the phosphatidyl serine binding capacity of annexin 2 that is exploited by 
HIV-1 virus particles to infect macrophages, an effect which can be inhibited using 
specific inhibitors of annexin 2
356,357. More recently annexin 2 has been shown to be 
coerced intracellularly post-infection by HIV-1, where binding of PIP2 facilitates the 
HIV-1 gag gene to mediate viral assembly
358.  
The most extensively studied extracellular interaction of annexin 2 is its binding 
to plasminogen and tPA on the surface of endothelial cells to mediate the formation of 
plasmin
64. Annexin 2 has been implicated as an important regulator of the fibrinolytic 
system
359 with evidence for this originating from various studies, including an 
examination of acute promyelocytic leukaemia (APL), in which patients suffer from 
haemorrhagic diathesis. In a study by Menell et al it was noted that patients with APL 
had increased amounts of annexin 2 on the surface of their leukemic cells, and an 
increased formation of plasmin
360. It was also shown that modulation of annexin 2 
levels could influence the rate of plasmin production and hence alter the fibrinolytic 
potential of the cells
360. Further evidence for the role of annexin 2 in fibrin generation 
emerged from studies utilising the annexin 2 knockout mouse, that displays not only 
reduced tPA-dependent plasmin generation, but also increased fibrin clots and 
decreased migration of endothelial cells both in in vitro and in vivo
361. Regulation of the 
effect of annexin 2 on plasmin generation is thought to come in part from the actions of 
its binding partner S100A10, since protein levels of the latter have been linked to the 
invasiveness of metastatic cancer cells
362, and it regulates the translocation of annexin 2 
to the surface of endothelial cells
363. Roles for the annexin 2 dependent generation of 
plasmin have also been linked to influenza infection, where annexin 2 incorporated into 
the viral envelope generates plasmin that degrades haemagglutinin and permits further 
infection
364.  
The study of annexin 2 has most often concentrated on its function inside or on 
the surface of cells, there are however a few studies on a soluble circulating form of 
annexin 2. Most of these have implicated soluble annexin 2 as a modulator of the 
immune system, with the ability to inhibit lymphocyte proliferation in the retroplacental 
serum
365, possibly to aid protection of the foetus from the maternal host defences. It has 
subsequently been shown by the same group that IgG and IgM secretion from 
mononuclear cells can be inhibited by soluble annexin 2
366. The second setting for the 
function of soluble annexin 2 originates from studies of osteoclast formation, the cells   49
responsible for bone resorption. It was observed that increased levels of soluble annexin 
2 enhance the differentiation of osteoclasts in an autocrine manner
367. Another 
interesting development has arisen more recently where a putative receptor for the 
annexin 2 protein has been found on osteoblasts and inhibition of this receptor has been 
shown to inhibit osteoclast formation
368. This result in itself may prove relevant to other 
fields of annexin 2 research and may provide more potential roles for soluble annexin 2.
  
 
1.7 Annexin 2 and Diabetes 
 
Given the diverse roles of annexin 2, it is unsurprising that it is implicated in 
many different physiological and pathological pathways. As mentioned earlier, two 
main pathological consequences of diabetes are diabetic retinopathy and nephropathy, 
multifactorial complications centred around the persistence of hyperglycaemia. 
Although annexin 2 has not been directly implicated in the progression of either of these 
complications of diabetes there are a number of observations regarding its function that 
indicate that it plays a role. 
Firstly, annexin 2 is responsive to hypoxia, translocating to membranes of cells 
independently of calcium
369. Since hypoxia is a key element in diabetic retinopathy 
leading to VEGF production, hyperpermeability and neovascularisation, it would be 
interesting to further elucidate whether the actions of annexin 2 in hypoxic 
hyperglycaemic conditions are protective or ultimately destructive. With regard to 
diabetic nephropathy, annexin 2 levels have been reported to increase in acute renal 
failure
370, and annexin 2 has been demonstrated to be important in the trafficking of 
aquaporin 2, a critical membrane protein of the kidney
371,372,373, that is important in the 
osmotic permeability of the collecting duct of the nephron. Of particular interest is the 
work carried out by Ishii et al where it was shown that addition of recombinant annexin 
2 to a murine model of type-2 diabetes was sufficient to protect against the development 
of albuminuria and histological changes
374. 
Although there have been a number of descriptions of annexins facilitating the 
functions of cell signalling pathways important in diabetes, some of the more complete 
and tangible data regarding a potential role for annexins in diabetes have emerged by 
examining the role of annexin 2 in the formation of plasmin. As stated previously, in 
normal conditions is it known that annexin 2 on the surface of endothelial cells can bind 
both plasminogen and tPA to facilitate plasmin formation and hence increase   50
fibrinolysis. Diabetes has long been known to induce a hypercoagulable state, and it is 
currently thought that a change in the ability of annexin 2 to perform it’s role in the 
formation of plasmin could play some part in this. Some of the initial data in this regard 
came from observations that annexin 2 is an early non-enzymatic glycation product
375, 
and that in cultured primary endothelial cells grown in high glucose, and high insulin, 
plasmin formation is reduced, an effect that can be reversed with the addition of 
recombinant annexin 2
376. These observations led to the hypothesis that glycation of 
annexin 2 is sufficient to disrupt its ability to function in the generation of plasmin
377, 
although this has not been shown experimentally. 
Further understanding of the effects of high glucose on annexin 2 came from a 
study by Lei et al who showed that stimulation of endothelial cells with high glucose 
was sufficient to enhance binding of annexin 2 to the heat shock protein HSP90α. These 
authors also demonstrated that this binding resulted in increased translocation of 
annexin 2 to the surface of endothelial cells, and that as a result an increase in plasmin 
production was observed
378, contrary to the findings of Ishii et al
376. The major 
distinction between the two studies was the addition of insulin, since in both studies 
high glucose was used, but only Ishii et al additionally exposed the endothelial cells to 
high insulin. The actions of insulin on annexin 2 have been investigated and it is known 
that insulin stimulation of cells leads to an increase in tyrosine phosphorylation of 
annexin 2
379,380, which in turn drives changes in the actin cytoskeleton
380. The question 
of whether this phosphorylation event is sufficient to perturb tPA or plasminogen 
binding to annexin 2 has yet to be answered. There is however evidence to suggest that 
other modifications of annexin 2 can alter its binding capacity for target proteins. One 
example of this is the action of hyperhomocysteinaemia on annexin 2, a condition 
known to influence diabetic retinopathy
381. The presence of elevated levels of 
homocysteine have been shown to reduce the cell surface binding of tPA by 60%, and 
this has been attributed to the change of the Cys8 residue on the N-terminus of annexin 
2 to a HomoCys8 which does not favor tPA binding
382,359,383. By examining the 
evidence so far one might therefore speculate that phosphorylation of annexin 2 could 
modify its ability to act as a plasminogen/tPA receptor, especially since the tyrosine 
phosphorylation site of annexin 2 is only 15 residues away on Tyr23
384. This presents 
the interesting question of whether these differences in annexin 2 function would arise 
in both type-1 and type-2 diabetics which differ with regard to the presence or absence 
of insulin.   51
Finally, because annexin 2 is implicated in the maintenance of endothelial 
junctions as outlined earlier, through interactions with SHP-2 and stabilisation of VE-
cadherin, the question arises as to whether phosphorylation, incorporation of 
homocysteine or glycation are sufficient to affect the function of annexin 2 in this 
context. It would be interesting to know whether inactivation of annexin 2 though the 
action of diabetes could lead to destabilisation of the endothelial cell junctions, resulting 
in the leakage of fluid seen in diabetic retinopathy, and macular oedema. 
Having outlined a number of potential roles for annexin 2 in the progression of 
diabetes, this thesis aims to examine whether annexin 2 function is altered by the action 
of diabetes, or whether loss of annexin 2 is sufficient to alter the progression of diabetic 
microvasculopathies. These questions will be addressed using both in vitro endothelial 
cell culture models, and by chemical induiction of diabetes in the annexin 2 knock-out 
mouse.    
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Chapter 2 Materials and Methods 
 
2.1 Materials 
 
  Mouse anti-annexin 2 was purchased from BD Biosciences and anti-mouse-
HRP, anti-rabbit-HRP, and rabbit-anti-GFAP purchased from DakoCytomation. Rabbit 
anti-GLUT-1 was purchased from Millipore, and mouse anti-transferrin receptor 
purchased from Invitrogen. Phalloidin-633, anti-mouse alexafluor-488, anti-rabbit 
alexafluor-568 and anti-goat alexafluor-488 were all purchased from Molecular Probes, 
with mouse anti-VE-cadherin antibody purchased from Santa Cruz. DAPI along with 
collagen I, collagen IV and fibronectin, in addition to Percoll™ and streptozotocin were 
purchased from Sigma. F-10, M199 and α-MEM basal media systems together with 
penicillin / stretptomycin and FCS (foetal calf serum) were purchased from Invitrogen 
whilst the EBM2-MV culture media was purchased from Lonza with all other additives 
from Sigma. 
 
All western blotting reagents were obtained from BioRad, and all histological 
reagents obtained from Agar Scientific ltd, with the exception of OCT (optimal cutting 
temperature) that was obtained from RA Lamb. Optium plus blood glucose testing strips 
were purchased from Abbott whilst all anaesthetics were obtained through the named 
veterinary surgeon with fluorescein obtained from Sigma. Collagenase and dispase were 
obtained from Worthington biochemical and recombinant mouse VEGF-164 purchased 
from R&D systems. Finally, mouse anti-tubulin (clone ID: 1A2) and Rabbit anti-ZO-1 
were kindly supplied by Prof Karl Matter (Inst of Ophth, UCL). Mouse anti-annexin 2 
(clone ID: HH7) was kindly supplied by Prof Volker Gerke (Inst Med Biochem, 
University of Münster) and mouse anti-annexin 2 (clone 444) kindly supplied by Jesus 
Ayala-Sanmartin (UPMC, Paris). HUVEC were supplied at passage one by Prof Daniel 
Cutler (LMCB, UCL), whilst GPNT and hCMEC/D3 were both supplied by Prof John 
Greenwood (Inst of Ophth, UCL). 
2.2 Primary cell and immortalised cell lines 
2.2.1 Cell culture 
 
For those cells in frozen stocks an aliquot was quickly defrosted at 37ºC, 
resuspended in 10 ml fresh media and centrifuged at 200 x g for 5 min at which point   54
the supernatant was discarded and the cells diluted to an appropriate concentration for 
culture. All cells were maintained in a humidified atmosphere at a constant temperature 
of 37ºC and 5% CO2, although each cell line required a different media composition and 
culture substratum (Table 1).  
Cell Line Media Substratum
GPNT 1:1 F-10 / α-MEM, 10% FCS, P/S* Collagen I
HUVEC M199, 20% FCS, 50µg/ml Gentamycin, 30µg/ml ECGS Gelatin
hCMEC/D3 EGM2-MV, 12.5% FCS, 25% supplied additives Collagen I
Primary murine EBM-2, 16% PDS, 50µg/ml puromycin^, P/S* Collagen IV +
endothelial cells Fibronectin
*P/S = Penicillin 100U/ml + Streptomycin 100µg/ml
^= Removed 48 hours post isolation  
 
The substratum was prepared prior to plating the cells by addition of sufficient volume 
of coating solution to cover the surface followed by removal and washing of the surface 
(Table 2). 
Incubation Incubation
Cell Line Substratum Concentration time temp Wash*
GPNT Collagen I 40 µg/ml o/n 37ºC HBSS
HUVEC Gelatin 1% w/v 10 min RT N/A
hCMEC/D3 Collagen I 40 µg/ml o/n 37ºC Water
Primary murine Collagen IV 100 µg/ml o/n 37ºC Water
endothelial cells Fibronectin 50 µg/ml
* = All washes repeated twice  
 
With the exception of the primary murine endothelial cells, once 70-90% confluence 
was achieved, cells were passaged by washing once in PBS, followed by incubation in 
0.2% trypsin until cells had loosened. Cells were then collected and mixed with at least 
2 volumes media, after which they were centrifuged at 200 x g for 10 min, diluted to the 
appropriate concentration and plated as required.  
 
2.2.2 Primary isolation of endothelial cells from murine brain 
 
Wild type or annexin 2 null mice were sacrificed by asphyxiation in CO2 
followed by cervical dislocation. Brains were then harvested, and the cerebellum, 
meninges and white matter removed. The remaining grey matter was homogenised 
using 10 passes of a Dounce homogeniser, centrifuged at 400 x g for 10 min and the 
supernatant discarded. The pellet was then fully resuspended in 22% bovine serum 
albumin solution in PBS and centrifuged at 1200 x g for 20 min. Once complete the 
myelin plug clearly visible at the top of the tube was removed without disturbing the 
Table 1: Media composition and culture substratum of cell lines used in this thesis. 
Table 2: Coating solution concentrations and coating protocols for the different cell lines 
used in this thesis.   55
pellet and transferred to a fresh centrifuge tube. The pellet was washed once in working 
buffer (HBSS -CaCl2, -MgCl2, -MgSO4, 0.5% w/v BSA, 10mM HEPES, 100u/ml 
penicillin, 100µm/ml streptomycin) and the pellet fully re-suspended and centrifuged at 
400 x g for 10 min; followed by storage at 4°C until required. Fresh 22% bovine serum 
albumin in PBS was added to the myelin plug from the previous step followed by 
centrifugation as previously described to yield three further pellets. The remaining 
myelin plug was then discarded and the four pellets pooled, centrifuged at 400 x g for 
10 min, supernatant discarded and pellet re-suspended in 1 ml working buffer. Each 
sample was then loaded onto a 70 µm nylon mesh (BD biosciences Cat# 352350), and 
washed thoroughly with working buffer, such that the vessel fragments adhered to the 
surface and the contaminating waste was allowed to wash through. The nylon mesh 
containing the vessel fragments was then inverted and washed through to allow the 
vessel fragments to collect in a fresh centrifuge tube. Vessel fragments were then 
centrifuged at 400 x g for 10 min and re-suspended in a solution containing 1 mg/ml 
collagenase and 1 mg/ml dispase. This solution was then incubated at 37°C whilst 
rotating at 250 rpm to allow efficient enzymatic activity. At the end of the incubation 
step, the solution was centrifuged at 400 x g for 10 min and the pellet resuspended in 
the primary cell culture medium. The vessel fragments were then plated onto the 
selected substratum at the appropriate density to ensure enough cells were present for 
the experiment required. 
 
2.3 Protein isolation and analysis 
2.3.1 Isolation of cell-surface annexin 2 
 
Cells were washed twice in HBSS (1.26mM CaCl2, 493µM MgCl2, 407µM 
MgSO4) and then incubated for 2 min in a 5 mM EGTA in PBS at 4°C. The EGTA 
solution was then collected and combined with an equal volume of acetone and left for a 
further 10 min at 4°C. Solutions were then centrifuged at 13,000 rpm in a tabletop 
microfuge, supernatants discarded and pellets re-suspended in a reducing sample 
loading buffer (250mM Tris, 10% glycerol, 2% SDS, 270 mg/ml DTT, 100 mg/ml 
bromophenol blue, pH 6.8). Samples were heated at 95°C for 5 min, followed by 
storage at -20ºC until required. 
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2.3.2 Preparation of whole cell lysates  
 
  Cells to be lysed were washed twice in HBSS, followed by lysis in 95°C 
reducing sample loading buffer. Lysed cells were scraped and transferred into 
Eppendorf tubes and heated at 95°C for 5 min followed by storage at -20°C until 
required. 
 
2.3.3 Protein isolation from whole tissue 
 
Tissue to be lysed was first isolated and washed in ice cold PBS, followed by 
homogenisation in lysis buffer (20 mM Tris, 150 mM NaCl2, 1 mM EDTA, 1 mM 
EGTA, 2.5 mM Na4P2O7, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1% Triton X-
100, pH 7.5) containing protease and phosphatase inhibitors (Sigma – Catalogue # 
P8340). Protein quantification was conducted using a Bradford assay (BioRad), as per 
the manufacturer’s instructions such that an equal amount of protein could be loaded in 
subsequent analyses.  
 
2.3.4 SDS-PAGE and western blotting 
 
Samples were resolved by 10% SDS-PAGE at 150 V for 90 min and transferred 
onto PVDF membranes at 400 mA at 4°C. Membranes were blocked with 10% 
skimmed milk in 0.05% Tween PBS solution for 1 h at room temperature, and then 
incubated with primary antibody loaded in fresh blocking solution overnight at 4°C. 
PVDF membranes were then washed several times in 0.05% Tween in PBS followed by 
the addition of the secondary antibody, conjugated to HRP, in fresh blocking solution at 
room temperature for 1 h. Bands were resolved using ECL reagents as per the 
manufacturer’s instructions. 
 
2.4 Biochemical and density gradient separation 
 
2.4.1 Detergent based surface / intracellular isolation of annexin 2 
 
  Surface annexin 2 was first isolated from cells as detailed earlier (2.3.1), after 
which cells were then washed once in HBSS and then lysed in 20 mM Tris, 150 mM 
NaCl2, 1 mM EDTA, 1 mM EGTA, 2.5 mM Na4P2O7, 1 mM β-glycerolphosphate, 1   57
mM Na3VO4, pH 7.5 containing 2% Triton-X100, with incubation at 4°C for 2 min. The 
cell lysates were then collected in Eppendorf tubes and centrifuged at 13,000 rpm for 10 
min, and once complete the supernatant was transferred to a fresh Eppendorf tube. An 
equal volume of acetone was added to the supernatant and the solution was allowed to 
incubate for 10 min at 4°C. Once the incubation was complete the solution was spun at 
13,000 rpm for 10 min. The supernatant was removed and discarded, after which both 
pellets from the two centrifugation steps were re-suspended in reducing sample buffer 
and heated to 95°C for 5 min. All samples were then stored at -20°C until required.  
 
2.4.2 Percoll sub-cellular fractionation 
 
  Cells were washed twice with PBS followed by incubation in just enough 1x 
trypsin solution at 37°C to cover the cells. Once the cells were loosened, media 
containing FCS was added to inactivate the trypsin with the cells collected and 
centrifuged in a 50 ml centrifuge tube at 200 x g to form a pellet. The supernatant was 
removed and the cells re-suspended in 1 ml of homogenisation buffer (10 mM HEPES, 
200 mM sucrose, 3 mM imidazole, pH7.2) at 4°C. The cells were then passed through a 
ball-bearing homogeniser with a 10 µm clearance 20 times at 4°C to gently break them 
open. The resulting cell homogenate was collected and spun at 4000 rpm in a tabletop 
microfuge at 4°C and the supernatant transferred to a fresh centrifuge tube containing 5 
ml of Percoll™ solution (Density: 1.08g/ml). The solution was well mixed, loaded into 
a 7 ml ultracentrifuge tube and centrifuged at 25,000 x g at 4°C for 45 min. Once 
complete, the cell lysate solution was fractionated into 1 ml fractions, and 20 µl Triton 
X-100 and 10 µl 0.5 M EGTA solution added to each fraction and mixed well. Each 
fraction was then centrifuged in the same rotor at 200,000 x g for 1 h. Once complete, 
the supernatants were removed from the fractions and an equal volume of acetone was 
added to each followed by incubation at 4°C for 10 min. Solutions were then 
centrifuged at 13,000 rpm and pellets re-suspended in reducing sample loading buffer, 
after which they were heated at 95°C for 5 min and stored at -20°C until required.  
 
2.4.3 Sucrose density gradient sub-cellular fractionation 
 
  Cells to be homogenised were trypsinised and centrifuged as for cell passaging, 
then re-suspended in a homogenisation buffer (10 mM HEPES, 200 mM sucrose, 3 mM 
imidazole, pH7.2). The cell suspension was then passed 20 times through a ball-bearing   58
homogeniser set with a 10 µm clearance. The cell homogenate was centrifuged at 4000 
rpm at 4°C to remove whole cells and nuclei. The supernatant was removed, adjusted to 
1 ml and loaded on top of a discontinuous gradient consisting of 5 x 1 ml fractions of 
60%, 50%, 40%, 30% and 20% sucrose respectively. Samples were then centrifuged at 
100,000 x g for 16 h with minimal acceleration and braking. Once complete the sucrose 
gradient was fractionated into 1 x 250 µl (fraction 1) and 11 x 500 µl (fractions 2-12), to 
which 800 µl of acetone at 4°C was added and incubated at 4°C for 10 min. Fractions 
were then centrifuged at 14,000 rpm for 10 min at 4°C, the pellets re-suspended in 1x 
reducing sample buffer and incubated at 95°C for 5 min prior to storage at -20°C until 
required. 
 
2.5 Streptozotocin induced diabetes  
 
2.5.1 Streptozotocin induced model of diabetes 
 
Wild type c57bl/6 and annexin 2 null mice (Ling et al., 2004) were maintained 
on a regular diet of food and water ad libitum, in accordance with UK Home Office 
regulations. When possible, prior to induction of diabetes, mice were fasted for 4 h and 
their weight and fasting blood glucose levels recorded as detailed below, with mice 
given 1 week to recover before continuation of the protocol. To induce diabetes mice 
were first fasted for 4 h followed by an intraperitoneal injection of 55mg/kg 
streptozotocin in 0.1M citrate buffer (pH 4.5), with sham animals receiving citrate 
buffer only. This was then repeated over five consecutive days, followed by glucose 
measurements at 14 days post the first injection, with treatment deemed successful if 
blood glucose ≥250 mg/dl. Weight and glucose testing were then continued every two 
weeks for the first two months, followed by measurements every four weeks, either with 
or without 4 h fasting prior to sampling depending upon the study. In some experiments 
mice had their weights and blood glucose levels recorded, followed by a 4 h fast, and 
then a subsequent glucose measurement recorded to assess the contribution of fasting to 
changes in blood glucose.   
 
2.5.2 Weight and glucose testing 
 
  Animals to be examined were placed in a fresh cage on scales suitable for 
weighing live animals and the weight recorded. Animals were then put back into their   59
own cage whilst littermates were weighed. Once complete, each mouse in turn was 
placed in a restraint to allow easy access to the tail, and a small cut made laterally to 
either of the tail veins. In the first set of experiments, a small drop of blood was 
collected and tested using 3 Optium plus glucose testing strips measured in an Optium 
glucose testing machine. As part of the second study, in situations where blood glucose 
concentrations were >500mg/dl and hence too high for the machine to record, 5 µl of 
blood was diluted with an equal volume of deionised water, blood glucose readings re-
measured and multiplied by two to give the final concentration. Pressure was then 
applied to the cut on the tail to aid healing, and the mouse returned to the cage to 
recover, followed by careful monitoring to spot any complications that may arise.  
 
2.5.3 Fluorescein angiography 
 
  Mice to be examined were weighed and given anaesthetic; 10 µl per gram body 
weight of 6.3 mg/ml Ketamine and 0.1 mg/ml Domitor, with signs of life checked 
regularly. Once sufficiently anaesthetised the mouse was placed in a nose bar, and it’s 
whiskers taped out of the way of the microscope objective.  Phenylephrine 
hydrochloride drops (2.5%) were given to dilate the pupils, and washed off with 0.3% 
hypromellose once sufficient dilatation had been achieved. The scanning laser 
ophthalmoscope (SLO) was then positioned and a reflective image of the retina taken. 
The mouse was then injected with 50 µl 10% fluorescein and fluorescent images taken 
with the SLO at 15 s intervals. Once 10 min of imaging was complete, additional 
images were taken as required, and the mouse removed from the nose bar. The mouse 
was then given an injection of 10 µl per gram 0.1 mg/ml antisedan to reverse the 
anaesthesia, and signs of life monitored carefully. Once all the sampling was complete, 
mice were taken to a recovery room where heat, via a heat mat, and soak diet was 
provided, for 24 h to aid recovery.   
 
2.5.4 Assessment of polydipsia 
 
Water consumption was assessed by measurement of the weight of the drinking 
water bottle before and after a given 24 h period. Samples were taken on days where the 
cages were not due to be cleaned to minimise vibration to the cage and hence artifactual 
loss of water.  
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2.5.5 Assessment of urinary albumin and creatinine 
 
  Urine samples were either taken from live animals at pre-determined time points 
or at death. For a pre-determined time point, mice were placed over a cage lid 
underlined with cling film and allowed to urinate. For urine collected at death, the 
bottom of the carbon dioxide chamber was carefully cleaned, and the mouse placed into 
the chamber, as per schedule 1 methods. Upon death the urinary sphincter would relax 
and the urine could be collected from the bottom of the chamber. In addition to this, any 
remaining urine could be extracted directly from the bladder, using a syringe and 
needle. Regardless of the collection point, samples were first centrifuged for 1 min to 
remove any contaminants and then subjected to ELISA for albumin (Exocell, Albuwell 
M Cat# 1011) and creatinine (Exocell, Creatinine companion Cat # 1012) as per the 
manufacturer’s instructions. 
 
2.6 Embedding, sectioning and digestion of tissue samples 
 
2.6.1 OCT embedding and sectioning  
 
  Tissue to be embedded was dissected from the mouse and washed briefly in 
PBS. Tissue samples were then washed twice in OCT compound, before transfer into a 
plastic mould of a suitable size for the sample containing fresh OCT. Samples were then 
cooled using dry ice until the OCT was set, at which point they could be transferred to a 
-80ºC freezer until required. Upon sectioning, samples were loaded into a Leica 
CM1850 cyrostat with equipment calibrated as per the manufacturer’s instructions, and 
the sample loaded onto the chuck using fresh OCT as an adhesive. Samples were first 
trimmed at 20 µm until the sample was visible, at which point serial sections were taken 
at 10 µm. Sections were transferred onto Superfrost® plus slides and dried for at least 1 
h under a fan. At this point slides were either stored at -80ºC or transferred to the 
staining protocol required. 
 
2.6.2 Wax embedding and sectioning 
 
  Samples to be mounted in wax were dissected from mice and immersed 
immediately in buffered 4% formaldehyde followed by incubation for 24 h at room 
temperature. Once this fixation step was complete, samples were further dissected as   61
required, loaded into histological cassettes and placed into a Leica TP 1020 tissue 
processor for overnight processing as per the manufacturer’s instructions. Once the 
samples were in histological wax they were embedded in fresh wax, using plastic 
moulds, loaded on top of the histological cassettes used for processing. At this point 
samples could be kept at room temperature or sectioned using a microtome. When 
sections were required, excess wax was trimmed from the outside of the histological 
cassette and the block loaded into the microtome. Samples were first trimmed until an 
even cutting surface was achieved, and then sections were cut at 6 µm. Sections were 
loaded onto standard glass slides using a 55ºC water bath to float the sections on, at 
which point they could be easily transferred onto glass slides, drained, and heated on a 
hot plate prior to use in the staining protocol required. 
 
2.6.3 EPON™ Resin embedding and sectioning  
 
  Eyes to be embedded were prepared with an incision along the ora serrata and 
removal of the lens. Kidney samples were taken by cutting a <1mm section of the 
cortex. In all cases samples were first fixed in a solution containing 2% 
paraformaldehyde (PFA) and 2% glutaraldehyde in 1x PBS for 24 h at room 
temperature. Samples were then washed 3 times in 0.1 M sodium cacodylate ensuring 
removal of any glutaraldehyde, and stained in a solution containing 1% osmium 
tetroxide, and 1.5% potassium ferricyanide for 1-2 h at 4ºC in the dark. When this was 
complete samples were washed 3 times in 0.1 M sodium cacodylate, again ensuring 
thorough disposal of any osmium tetroxide, and stained further in a solution containing 
1% tannic acid in 0.05 M sodium cacodylate for 40-60 min at room temperature with 
gentle end over end rotation. Once complete, samples were washed 3 times in 0.05M 
sodium cacodylate with a final wash in deionised water. Samples were then immersed 
in 70% ethanol for 10 min, followed by 90% ethanol for 10 min and two immersions in 
100% ethanol for 10 min each. At the end of these steps the samples were immersed 
twice in propylene oxide for 10 min each, after which they were placed in a solution 
containing 1:1 propylene oxide and EPON™ epoxy resin overnight with gentle end-
over-end rotation. Once complete, samples were given two separate immersions in fresh 
EPON™ for 4 h each, at which point they were transferred into a suitable mould, 
immersed in fresh EPON™ and incubated at 50ºC overnight or until the EPON™ had 
hardened. Samples could then be stored at room temperature until required or sectioned. 
Sectioning was conducted on a Leica ultracut S microtome and samples were first   62
trimmed with glass knives, followed by production of either semi-thin (0.7 µm) or 
ultrathin (60 nm) sections which were mounted on slides and transferred to the staining 
protocol required. 
 
2.6.4 Trypsin digest of retina  
 
Eyes were dissected and placed immediately into 2x PBS at 4ºC. When 
sampling was complete, eyes were fixed with 2% PFA in 2x PBS for 2 min, and then 
washed 3 times in 2x PBS. Eyes were then immersed in fresh 2x PBS and dissected 
under the microscope with a circular cut around the ora serrata removing the front of the 
eye and the lens. The remaining eye cup was then carefully turned inside out such that 
the retina could be removed from the eye cup. Once the retina had been isolated it was 
fixed for 48 h in 4% PFA in 1x PBS at 4ºC. Once complete, retinas were washed in a 
large volume of PBS for 24 h at room temperature, followed by incubation in 3% 
trypsin, 0.1 M Tris-HCL (pH 7.8) at 37ºC for one hour. Once this initial digest was 
complete the vitreous humor and some of the neural tissue was removed by gentle 
agitation, dissection and abrasion. The retinas were then returned to the 3% trypsin 
solution for a further 15 min or until the vascular network could be easily visualised. 
Tissue was then transferred to a slide where it was dried, and then stained with PAS and 
haematoxylin, and then coverslipped using DPX as a mountant.   
 
2.7 Immunostaining and histological staining 
 
2.7.1 Immunocytochemistry  
 
  Both isolated cells and tissue cryosections were stained using 
immunocytochemical techniques. If cells were to be used, they were first washed twice 
in full media, whereas tissue cryosections were washed twice in PBS, until all the OCT 
had been removed. For tissue sections fixation was conducted using 4% PFA in PBS for 
20 min at room temperature. Cells were also fixed using this method, but were 
alternatively fixed using 10% methanol for 5 min at -20ºC when stated. Regardless of 
the fixation procedure and sample type they were then washed in PBS followed by 
incubation in blocking solution for one hour at room temperature, consisting of 1% 
bovine serum albumin in PBS, with the addition of 0.2% Triton X-100 if fixed using 
PFA. Once the blocking step was complete samples were incubated with primary   63
antibody in blocking solution overnight at 4ºC. Samples were then washed twice with 
1x PBS after which secondary antibody was added in blocking solution for 1 h at 37°C, 
followed by a further two washes with PBS. Samples were then coverslipped using 
Vectorshield™ as a mountant, before imaging using either a Leica SP2 AOBS confocal 
microscope, or a Zeiss LSM510 meta confocal system, depending upon whether an 
inverted or upright objective was required.  
 
2.7.2 Haematoxylin and eosin staining 
 
  Sections cut from wax blocks were first heated to allow the wax to melt, 
followed by immersion in xylene for 10 min. Once complete sections were then 
immersed in 100% industrial methylated spirit (IMS) for 4 min, followed by a wash for 
2 min in water. For sections cut from OCT blocks, slides were washed thoroughly in 
water to remove all remnants of OCT before continuing with the protocol. Regardless of 
the type of section, slides were then placed in Shandon Haematoxylin solution for a 
period of time consistent with the embedding process used; 12 min for wax sections, 30 
s for OCT sections. Slides were then washed in water for 4 min and differentiated in 
0.5% hydrochloric acid in 70% IMS for 2 min. Slides were then washed once more in 
water for 2 min, followed by blueing in Shandon blueing agent for 2 min, and another 2 
min wash in water. Slides were then immersed in 95% IMS for 4 min before immersion 
in Eosin-Y for 2 min. After Eosin staining, slides were immersed in 95% IMS for 2 min, 
100% IMS for 6 min and xylene for 4 min before coverslipping using DPX as 
mountant. 
 
2.7.3 Periodic acid Schiff staining 
 
Wax sections were first deparaffinised to water by treatment in xylene for 10 
min, followed by 2 min incubations in decreasing concentrations of IMS: 100%, 90%, 
80%, 70%, 50%, 0%(Water). Cryosections were first fixed with 4% PFA at room 
temperature for 20 min, followed by two washes in water before continuation of the 
protocol. Regardless of embedding, media sections were then oxidised in 0.5% periodic 
acid solution for 5 min, after which they were rinsed in distilled water and placed in 
Schiff reagent for up to 15 min. Sections were then washed in tap water for up to 5 min 
followed by counterstaining with Shandon haematoxylin solution for approximately 1 
min and differentiation in 0.5% hydrochloric acid in 70% IMS for 4 min. At this point   64
sections were dehydrated using increasing concentrations of IMS (50%, 70%, 80%, 
90%, 100%) at 4 min intervals, followed by a 4 min incubation in xylene, before 
coverslipping using DPX as a mountant.  
 
2.7.4 Toluidine blue staining 
 
Thick sections cut from resin embedded tissue as detailed above, were allowed 
to dry on a hot plate. Once completely dry, sections were immersed in toluidine blue 
solution (1% toluidine blue, 2% sodium borate) for 1-2 min at which point the slides 
were rinsed in tap water and coverslipped using DPX as a mountant.  
 
2.7.5 Lead citrate staining for electron microscopy 
 
Ultra-thin sections cut from resin embedded tissue as detailed above were 
stained using lead citrate and imaged on a JEOL 1010 transmission electron 
microscope, with images recorded using a Gatan Orius B digital camera. 
 
2.8 Image analysis 
 
All image analysis was conducted using Image-J software with cell widths and 
basement membrane thicknesses calculated using the line tool, whilst areas of 
mesenchymal matrix expansion were calculated using the area tool. Densitometry of 
western blots was also conducted using Image-J, using the integrated density tool. 
 
   65
 
 
 
 
 
 
 
Chapter 3 Results   66
Chapter 3 Results 
 
Hyperglycaemia is known to affect many different proteins in endothelial cells, either 
by changing their levels, distribution or activity
385,287. These changes can be detected in 
many ways, either by observing the behaviour of the cell, or by observing effects on the 
specific proteins changed by the actions of hyperglycaemia. Annexin 2 has been shown 
to be altered by hyperglycaemia, becoming glycated
375, and increasing its presence upon 
the surface of the endothelial cell 
378, where it is thought to increase the production of 
plasmin. As well as this extracellular role, annexin 2 has many different functions inside 
the cell which are relevant to diabetes and hyperglycaemia, such as the maintenance of 
VE-cadherin junctions
349, and intracellular trafficking
335. To date, changes in the 
intracellular levels, or distribution of annexin 2 in response to hyperglycaemia have not 
been addressed, and therefore we set about examining the consequences of in vitro 
hyperglycaemia on annexin 2 in various endothelial cell lines. 
 
3.1 Hyperglycaemia and expression of annexin 2 
 
To assess the effect of hyperglycaemia on annexin 2 levels in the endothelium, 
hCMEC/D3 cells (human immortalised brain microvascular endothelial cells) were 
cultured for 1 week in various levels of glucose and mannitol. These consisted of 
euglycaemic 5mM glucose, 15mM glucose to represent an intermediate level of 
hyperglycaemia, 25mM glucose to represent a high level of hyperglycaemia, and 5mM 
glucose with 20mM mannitol ‘+20mM mannitol’ to act as an osmotic control for the 
increased sugar load. These conditions of culture will henceforth be referred to as ‘the 
hyperglycaemic culture conditions’ to minimise repetition.  
It has been reported previously that endothelial cells exposed to hyperglycaemia 
shuttle their annexin 2 to the surface of the cell, such that it is exposed to the lumen of 
the vessel
378. To determine whether this was true in our system we exploited the 
calcium dependent phospholipid binding properties of the annexins and collected 
annexin 2 from the surface of the endothelium using the calcium chelator EGTA 
(ethylene glycol tetraacetic acid) to release any annexins bound. Intracellular annexin 2 
was collected via cell lysis post elution of annexin 2 from the surface, and hence both 
‘surface’ and ‘intracellular’ fractions of annexin 2 were assessed for changes relative to 
one another.   67
   EGTA eluted fractions of annexin 2 from the surface of the endothelial cells 
cultured in the hyperglycaemic culture conditions were positive for both annexin 2 and 
tubulin when analysed via western blot (Figure 3.1). Since these samples are 
representative of the surface of endothelial cells they should be negative for tubulin, 
however, samples were consistently positive for tubulin, suggesting whole cell 
contamination of the sample. Although this experiment was repeated several times, 
eluates consistently contained tubulin, and hence this approach was abandoned.  
Whilst the surface fraction of endothelial cells was difficult to assess, annexin 2 
isolated from the intracellular compartment of hCMEC/D3 cells was still available for 
analysis. Both in the representative western blot, and the subsequent densitometry (n=3) 
the levels of annexin 2 did not vary significantly, suggesting that culture in varying 
levels of hyperglycaemia for 1 week is not sufficient to alter annexin 2 expression levels 
in these cells (Figure 3.2A). 
This experiment was also repeated for a macrovascular cell line, namely 
HUVEC (human umbilical vein endothelial cells). Similar data to those gained from the 
hCMEC/D3 cells are shown in a representative western blot, with annexin 2 and tubulin 
staining and a graphical representation of the data from three experiments shown on the 
right (Figure 3.2B). These data also show that annexin 2 is unchanged by culture in the 
varying glucose culture conditions for 1 week, demonstrating that neither microvascular 
nor macrovascular endothelial cells change their levels of intracellular annexin 2 in 
response to 1 week culture in hyperglycaemia. 
To assess the effect of longer term hyperglycaemia on intracellular annexin 2 in 
endothelial cells a third cell line, derived from immortalised rat brain endothelium 
(GPNT)
386 was cultured for 9 weeks in the varying glucose conditions. Due to 
differences in the culture medium, in this experiment the euglycaemic level was 6.1mM 
and the mannitol control 18.9mM, to bring the total sugar load to 25mM. Consistent 
with the previous two experiments no changes in annexin 2 levels were detectable once 
the annexin 2 protein bands were normalised to those of the tubulin loading controls 
(Figure 3.3). Whilst it might be possible at some time points to identify differences in 
the expression of annexin 2, no consistent discernable pattern was distinguished, hence 
the data suggest that there were no significant changes in annexin 2 expression in 
response to hyperglycaemia.   68
Figure 3.1: Annexin 2 isolated from the extracellular compartment is contaminated with 
tubulin.
Representative western blot of surface annexin 2 from hCMEC/D3 cells cultured for 7 days in the 
various conditions of glycaemia as shown, with a +20mM Mannitol control. Extracellular annexin 2 
was then obtained using EGTA, as detailed in the materials and methods. Samples were then western 
blotted for annexin 2 and tubulin, also as detailed in the materials and methods, using the following 
antibodies: Anti-annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 1A2, courtesy of Prof 
K.Matter), with the secondary in both cases Anti-mouse-HRP (1:5000; Dako). Protein bands were 
visualised using ECL
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Figure 3.1: Annexin 2 isolated from the extracellular compartment is contaminated with 
tubulin.
Representative western blot of surface annexin 2 from hCMEC/D3 cells cultured for 7 days in the 
various conditions of glycaemia as shown, with a +20mM Mannitol control. Extracellular annexin 2 
was then obtained using EGTA, as detailed in the materials and methods. Samples were then western 
blotted for annexin 2 and tubulin, also as detailed in the materials and methods, using the following 
antibodies: Anti-annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 1A2, courtesy of Prof 
K.Matter), with the secondary in both cases Anti-mouse-HRP (1:5000; Dako). Protein bands were 
visualised using ECL
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Figure 3.2: Intracellular annexin 2 protein levels do not change in response to hyperglycaemia 
in hCMEC/D3 or HUVEC cells. 
Representative western blots from three experiments showing intracellular annexin 2 and tubulin 
from both hCMEC/D3 cells (A) and HUVEC (B), cultured for 7 days in the various conditions of 
glycaemia as shown. Cell lysis, to collect intracellular annexin 2 only, was conducted via the 
reducing sample buffer based protocol as detailed in the materials and methods. Samples were then 
western blotted for annexin 2 and tubulin, also as detailed in the materials and methods, using the 
following antibodies: Anti-annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 1A2, courtesy 
of Prof K.Matter), with the secondary in both cases Anti-mouse-HRP (1:5000; Dako). Protein bands 
were visualised using ECL, and densitometry conducted using “Image-J” to produce graphs 
opposite, plotted as mean annexin 2 relative to tubulin ± s.d (n=3).
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Figure 3.2: Intracellular annexin 2 protein levels do not change in response to hyperglycaemia 
in hCMEC/D3 or HUVEC cells. 
Representative western blots from three experiments showing intracellular annexin 2 and tubulin 
from both hCMEC/D3 cells (A) and HUVEC (B), cultured for 7 days in the various conditions of 
glycaemia as shown. Cell lysis, to collect intracellular annexin 2 only, was conducted via the 
reducing sample buffer based protocol as detailed in the materials and methods. Samples were then 
western blotted for annexin 2 and tubulin, also as detailed in the materials and methods, using the 
following antibodies: Anti-annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 1A2, courtesy 
of Prof K.Matter), with the secondary in both cases Anti-mouse-HRP (1:5000; Dako). Protein bands 
were visualised using ECL, and densitometry conducted using “Image-J” to produce graphs 
opposite, plotted as mean annexin 2 relative to tubulin ± s.d (n=3).
Annexin 2
5mM Glucose
15mM Glucose
25mM Glucose
+20mM Mannitol
Tubulin
A
B
0
0.2
0.4
0.6
0.8
1
1.2
1.4
5mM Glucose 15mM Glucose 25mM Glucose +20mM Mannitol
R
e
l
a
t
i
v
e
 
a
n
n
e
x
i
n
 
2
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
5mM Glucose 15mM Glucose 25mM Glucose +20mM Mannitol
R
e
l
a
t
i
v
e
 
a
n
n
e
x
i
n
 
2
Annexin 2
Tubulin
5mM Glucose
15mM Glucose
25mM Glucose
+20mM Mannitol  70
Figure 3.3: Intracellular annexin 2 in GPNT cells in a model of chronic hyperglycaemia. 
Changes in annexin 2 and tubulin levels in GPNT cells cultured for up to 9 weeks in the various 
conditions of glycaemia as shown. Cell lysis, to collect intracellular annexin 2 only was conducted 
via the reducing sample buffer based protocol as detailed in the materials and methods. Samples 
were then western blotted for annexin 2 and tubulin, also as detailed in the materials and methods, 
using the following antibodies: Anti-annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 
1A2, courtesy of Prof K.Matter), with the secondary in both cases Anti-mouse-HRP (1:5000; 
Dako). Protein bands were visualised using ECL.
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Figure 3.3: Intracellular annexin 2 in GPNT cells in a model of chronic hyperglycaemia. 
Changes in annexin 2 and tubulin levels in GPNT cells cultured for up to 9 weeks in the various 
conditions of glycaemia as shown. Cell lysis, to collect intracellular annexin 2 only was conducted 
via the reducing sample buffer based protocol as detailed in the materials and methods. Samples 
were then western blotted for annexin 2 and tubulin, also as detailed in the materials and methods, 
using the following antibodies: Anti-annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 
1A2, courtesy of Prof K.Matter), with the secondary in both cases Anti-mouse-HRP (1:5000; 
Dako). Protein bands were visualised using ECL.
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3.2 Distributional changes of endothelial cell proteins in response to 
hyperglycaemia 
 
Since various proteins in endothelial cells are known to change their 
distribution, level or activity in response to hyperglycaemia, we next investigated the 
subcellular localisation of certain proteins known to be altered in response to 
hyperglycamia. 
GLUT-1 is one of the major glucose transporter of endothelial cells
387 and 
changes in its distribution/localisation as a consequence of diabetes are still under some 
debate
388,389. Examination of the distribution of GLUT-1 in HUVEC grown in the 
varying conditions of hyperglycaemia shows that minor changes were apparent after 1 
week in culture (Figure 3.4). Focusing on the staining in the perinuclear region, in 
comparison to those cultured in 5mM glucose, HUVEC cultured in 25mM glucose 
exhibited a very mild increase in the size of the region enriched for GLUT-1. In 
contrast, HUVEC cultured in 15mM glucose showed a reduction of signal, indicating 
possible differential responses to varying levels of hyperglycaemia. Since cells cultured 
in increased mannitol did not show any of these changes they presumably arise as a 
consequence of hyperglycaemia and not increased osmotic stress. 
Proteins involved in the maintenance of endothelial junctions are known to alter 
their distribution as a consequence of diabetes. ZO-1 is a marker of tight junctions, and 
in HUVECs grown in hyperglycaemic conditions it can be seen that after one week of 
culture the distribution of ZO-1 is unaffected (Figure 3.5), with the protein enriched at 
the cell junctions. VE-cadherin was also examined, as an adherens junction marker 
specific to endothelial cells (Figure 3.6). Similar to the results obtained for ZO-1, there 
was no significant change in VE-cadherin distribution in HUVECs exposed to 
hyperglycaemia for 1 week, with continuous staining seen at the cell junctions in all 
culture conditions.  
In these experiments cells were additionally stained for F-actin using 
fluorescently labelled phalloidin. In all the figures, the distribution or pattern of actin 
staining underwent minor changes when cells were exposed to hyperglycaemia. In 
comparison to cells cultured in 5mM glucose, cells cultured in hyperglycaemia 
displayed more stress fibers and diffuse staining around the cortex, with more 
distinctive changes detectable in cells cultured in 25mM glucose than 15mM glucose, 
suggesting a possible effect of hyperglycaemic dose. Some of these changes in F-actin Figure 3.4: Distribution of annexin 2 and GLUT-1 in HUVEC maintained in varying glucose 
/ mannitol concentrations for 1 week. 
HUVEC were plated onto glass coverslips and allowed to grow in the various conditions of 
glycaemia as shown. After 1 week cells were fixed and stained as described in the materials and 
methods using the following antibodies and reagents; Primary antibodies, Mouse-Anti-annexin 2 
‘HH7’ (1:100), Rabbit-Anti-GLUT-1 (1:100); Secondary Antibodies / Reagents, Anti-Mouse 
Alexafluor-488 (1:1000), Anti-Rabbit Alexafluor-568 (1:1000), DAPI (1:500) and Phalloidin-633 
(1:60). Scale bar 50µm
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Figure 3.5: Distribution of annexin 2 and ZO-1 in HUVEC maintained in varying glucose / 
mannitol concentrations for 1 week. 
HUVEC were plated onto glass coverslips and allowed to grow in the various conditions of 
glycaemia as shown. After 1 week cells were fixed and stained as described in the materials and 
methods using the following antibodies and reagents; Primary antibodies, Mouse-Anti-annexin 2 
‘HH7’ (1:100), Rabbit-Anti-ZO-1 (1:300); Secondary Antibodies / Reagents, Anti-Mouse 
Alexafluor-488 (1:1000), Anti-Rabbit Alexafluor-568 (1:1000), DAPI (1:500) and Phalloidin-633 
(1:60). Scale bar 50µm
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Figure 3.6: Distribution of VE-cadherin in HUVEC cells maintained in varying glucose / 
mannitol concentrations for 1 week. 
HUVEC were plated onto glass coverslips and allowed to grow in the various conditions of 
glycaemia as shown. After 1 week cells were fixed and stained as described in the materials and 
methods using the antibodies and reagents; Primary antibodies, Mouse-Anti-VE-cadherin (1:50); 
Secondary Antibodies / Reagents, Anti-Mouse Alexafluor-488 (1:1000), DAPI (1:500) and 
Phalloidin-633 (1:60). Scale bar 50µm
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distribution, can also however be detected in the cells exposed to additional mannitol, 
suggesting that changes may occur in response to osmotic stress.   
In both figures 3.4 and 3.5 cells were also stained for annexin 2 to examine 
possible changes in its distribution. In both cases the distribution of annexin 2 was 
observed to not change in response to hyperglycaemia when examined by confocal 
microscopy. There was no enrichment to membranes or cellular compartments that 
could be detected by this method and annexin 2 staining was absent from the nucleus 
with uniform diffuse staining across the cytoplasm. 
Annexin 2 staining was also examined in microvascular hCMEC/D3 cells to 
assess whether changes in localisation in response to hyperglycaemia could be observed 
that were not apparent in the macrovascular HUVECs (Figure 3.7A). Similar to the 
results obtained in HUVEC, the localisation of annexin 2 did not change in 
hyperglycaemic culture, with it being absent from the nuclei, and evenly distributed 
throughout the cell, with no localisation to any defined structures or organelles. To 
ensure no changes in annexin 2 staining were being masked by the selected fixation 
procedure, cells treated identically were subjected to methanol fixation and then stained 
for annexin 2 (Figure 3.7B). The staining obtained was simlar to that of PFA fixation 
with annexin 2 distributed throughout the cell, and no changes in localisation due to 
hyperglycaemia observed.  
 
3.3 Sucrose density gradient analysis of annexin 2 in endothelial cells cultured in 
hyperglycaemia 
 
Although the localisation of annexin 2 was apparently unaffected by culture in 
hyperglycaemia when examined by confocal microscopy, annexin 2 has been reported 
to move in response to hyperglycaemia, as mentioned previously, to the surface of the 
endothelial cell
378. Therefore some relocalisation may occur that cannot be detected by 
confocal microscopy. To address this point we employed a biochemical examination of 
annexin 2 via sub-cellular fractionation. Three different sub-cellular fractionation 
protocols were used to ascertain which would be best to optimise and conduct in 
triplicate. Initially cells were examined using a detergent solubility fractionation 
method. In these experiments GPNT cells were fractionated into ‘surface’, ‘detergent 
soluble’ and ‘detergent insoluble’ fractions, and then examined for annexin 2 via 
western blotting. Annexin 2 was identified in both the surface and detergent-soluble 
fractions of the cell, whilst none was detectable in the detergent-5mM Glucose 15mM Glucose
25mM Glucose +20mM Mannitol
5mM Glucose 15mM Glucose
25mM Glucose +20mM Mannitol
A
B
Figure 3.7: Effect of hyperglycaemia on annexin 2 in microvascular hCMEC/D3 cells.
hCMEC/D3 cells were cultured for 1 week in the varying glucose and mannitol conditions stated for 
1 week, followed by fixation in 4% PFA (A) or methanol (B) as stated in the materials and methods 
section. Cells were then stained for DNA (blue) and annexin 2 (green) using the following 
antibodies and reagents: DAPI (1:500), Annexin 2 (HH7: 1:100), secondary (Anti-Mouse 
Alexafluor-488 1:1000). Main panel is merged image with constituents in minor panels, DAPI 
(upper) and annexin 2 (lower). Scale bars 50µm
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insoluble fraction for all three replicates (Figure 3.8). Since no annexin 2 was detected 
in the detergent-insoluble fraction, and the protocol was complicated by technical 
issues, this method was abandoned. Using hCMEC/D3 cells Percoll™ fractionation was 
subsequently tested, separating annexin 2 into ‘surface’ and six intracellular fractions on 
the basis of density. Western blotting revealed annexin 2 in the surface compartment of 
the cell, and in four of the six intracellular fractions, peaking in fraction two (Figure 
3.9). Although this method produced good fractionation it was found that for the higher 
density fractions the Percoll™ could not be removed, even after centrifugation for 
extended periods of time at 200,000 x g. This resulted in Percoll™ contamination of the 
higher density fractions and subsequent dilution of the protein sample, distorting the 
results. Hence this protocol was also discarded and we tested sucrose density 
centrifugation. For this experiment hCMEC/D3 cells were cultured in the varying 
hyperglycaemic culture conditions for 1 week and subsequently subjected to the sucrose 
gradient fractionation protocol (Figure 3.10). Western blotting for annexin 2 from the 
12 fractions revealed staining for annexin 2 in fractions 2-8, with occasional localisation 
to fraction 12, forming a bell shaped curve upon quantification by densitometry. 
Transferrin receptor was used as a marker of early endosomes to indicate that the 
gradient was reproducible and that all four experiments produced a similar pattern of 
fractionation. Transferrin receptor was detected in fractions 5-7 regardless of glucose or 
mannitol load. Examining the results from the western blot for annexin 2 more 
thoroughly it can be seen that when hCMEC/D3 cells are cultured in 15mM and 25mM 
glucose there is a shift of the peak of annexin 2 to fractions of a higher density, such 
that in cells exposed to 15mM glucose the peak of annexin 2 shifted one fraction, whilst 
in cells cultured in 25mM glucose annexin 2 shifted two fractions. Furthermore, cells 
cultured in 5mM glucose +20mM mannitol did not exhibit this shift, indicating this to 
be a consequence of hyperglycaemic culture and not of osmotic stress. 
Since the sucrose gradient fractionation protocol produced the most interpretable 
results the experiment was repeated twice more with the results amalgamated (Figure 
3.10; Graph). After normalisation of the data a distinctive shift was evident for annexin 
2 isolated from cells cultured in 25mM glucose, with a ‘shoulder’ of annexin 2 moving 
to denser fractions. Analysis of this graphical representation reveals a dose sensitive 
shift in annexin 2 to higher density fractions when cells are cultured in 15mM and 
25mM glucose. This effect on annexin 2 was not a function of increased osmotic stress 
since cells cultured in ‘+20mM mannitol’ exhibited a similar distribution of annexin 2   78
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Figure 3.8: Sub-cellular fractionation of GPNT cells using the detergent based method. 
GPNT cells were grown in euglycemic 6.1mM glucose for 1 week in triplicate followed by 
detergent based sub-cellular fractionation as described in the materials and methods. Samples were 
then western blotted for annexin 2, also as detailed in the materials and methods, using primary 
antibody anti-annexin 2 (1:1000; BD Biosciences) and secondary antibody Anti-Mouse-HRP 
(1:5000; Dako). Bands were visualised using ECL. 
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Figure 3.8: Sub-cellular fractionation of GPNT cells using the detergent based method. 
GPNT cells were grown in euglycemic 6.1mM glucose for 1 week in triplicate followed by 
detergent based sub-cellular fractionation as described in the materials and methods. Samples were 
then western blotted for annexin 2, also as detailed in the materials and methods, using primary 
antibody anti-annexin 2 (1:1000; BD Biosciences) and secondary antibody Anti-Mouse-HRP 
(1:5000; Dako). Bands were visualised using ECL.   79
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Figure 3.9: Sub-cellular fractionation of hCMEC/D3 cells using the Percoll™ based method. 
hCMEC/D3 cells grown in 5mM glucose for one week were subjected to the Percoll™ based sub-
cellular fraction protocol as detailed in the materials and methods. Samples were then western blotted 
for annexin 2, also as detailed in the materials and methods, using primary antibody anti-annexin 2 
(1:1000; BD Biosciences) and secondary antibody Anti-Mouse-HRP (1:5000; Dako). Bands were 
resolved using ECL. Fraction numbers 1-6 are indicative of the fractions of the gradients with 1 
representing the lightest and 6 the heaviest, S represents annexin 2 taken from the surface of the cells 
prior to the fractionation.  
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Figure 3.9: Sub-cellular fractionation of hCMEC/D3 cells using the Percoll™ based method. 
hCMEC/D3 cells grown in 5mM glucose for one week were subjected to the Percoll™ based sub-
cellular fraction protocol as detailed in the materials and methods. Samples were then western blotted 
for annexin 2, also as detailed in the materials and methods, using primary antibody anti-annexin 2 
(1:1000; BD Biosciences) and secondary antibody Anti-Mouse-HRP (1:5000; Dako). Bands were 
resolved using ECL. Fraction numbers 1-6 are indicative of the fractions of the gradients with 1 
representing the lightest and 6 the heaviest, S represents annexin 2 taken from the surface of the cells 
prior to the fractionation.    80
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Figure 3.10: Hyperglycaemia affects the compartmentalisation of annexin 2 in hCEMC/D3 
endothelial cells.
hCMEC/D3 cultured for 7 days in the various conditions of glycaemia and subjected to the sucrose 
gradient based method as detailed in the materials and methods. Fraction 1 is the lightest fraction 
whilst fraction 12 the most dense; samples were western blotted for annexin 2 and transferrin
receptor, also as detailed in the materials and methods, using the following antibodies: Anti-annexin 
2 (1:1000; BD Biosciences), Anti-transferrin receptor  (1:1000; Invitrogen), with the secondary in 
both cases Anti-mouse-HRP (1:5000; Dako). Protein bands were visualised using ECL and 
densitometry conducted using “Image-J” to produce the graph,  plotted as mean percentage annexin 
2 ± sem (n=3). *=p<0.05 between ‘+20mM Mannitol’ and ’25mM Glucose’.
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Figure 3.10: Hyperglycaemia affects the compartmentalisation of annexin 2 in hCEMC/D3 
endothelial cells.
hCMEC/D3 cultured for 7 days in the various conditions of glycaemia and subjected to the sucrose 
gradient based method as detailed in the materials and methods. Fraction 1 is the lightest fraction 
whilst fraction 12 the most dense; samples were western blotted for annexin 2 and transferrin
receptor, also as detailed in the materials and methods, using the following antibodies: Anti-annexin 
2 (1:1000; BD Biosciences), Anti-transferrin receptor  (1:1000; Invitrogen), with the secondary in 
both cases Anti-mouse-HRP (1:5000; Dako). Protein bands were visualised using ECL and 
densitometry conducted using “Image-J” to produce the graph,  plotted as mean percentage annexin 
2 ± sem (n=3). *=p<0.05 between ‘+20mM Mannitol’ and ’25mM Glucose’.
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to those cultured in 5mM glucose. Statistical analysis of the normalised data using a 
Students t-test revealed that at fraction 6 there was a significant difference (p<0.05) 
between the levels of annexin 2 in the ‘+20mM mannitol’ and ‘25mM glucose’ samples, 
indicating a significant change in the distribution of annexin 2. These results suggest 
that the actions of hyperglycaemia are sufficient to move annexin 2 to a different 
compartment of the cell. This may occur in order for annexin 2 to fulfil a function in 
response to the hyperglycaemic conditions, or it could be that hyperglycaemia modifies 
annexin 2 in a manner that disrupts its normal cellular roles.  
 
3.4 The localisation of various endothelial cell markers is unaffected by the absence 
of annexin 2 
 
Having shown that the distribution of junctional cell markers is apparently 
unaffected by short term culture in hyperglycaemia, but that the subcellular 
compartmentalisation of annexin 2 appears to change, we next examined junctional 
proteins in endothelial cells lacking annexin 2. To do this brain microvascular 
endothelial cells from the annexin 2 knockout mouse (AnxA2
-/-) and wild-type control 
mice (AnxA2
+/+) were isolated and cultured. Initial examination of the endothelial cells 
by light microscopy revealed no obvious differences in morphology in the AnxA2
-/- 
cultured cells (Figure 3.11A). To ensure that the cells isolated were endothelial in 
origin, VE-cadherin staining was examined via confocal microscopy in AnxA2
+/+ 
endothelial cells from three different areas of the cultured monolayer, demonstrating 
that although the morphology of the cells can vary greatly, all are indeed endothelial in 
origin (Figure 3.11B). Examination of VE-cadherin distribution in AnxA2
-/- endothelial 
cells by this method showed continuous staining of the cell-cell junctions, equivalent to 
that of AnxA2
+/+ endothelial cells, demonstrating that the loss of annexin 2 does not 
influence the localisation of VE-cadherin in these cells (Figure 3.11C). Western blot 
analysis of cell lysates confirmed the absence of annexin 2 protein (Figure 3.11D). With 
this initial characterisation concluded we next examined of the effects of 
hyperglycaemia on AnxA2
-/- endothelial cells. To achieve this AnxA2
-/- and AnxA2
+/+ 
endothelial cells were cultured in the various hyperglycaemic culture conditions for one 
week and the localisations of VE-cadherin, ZO-1 and F-actin examined by confocal 
microscopy (Figure 3.12). VE-cadherin localisation was unaffected by culture in 
hyperglycaemia in both AnxA2
+/+ and AnxA2
-/- endothelial cells, maintaining its 
localisation at the periphery of the cell. ZO-1 localisation was also consistent in the Annexin 2
Tubulin
AnxA2+/+ AnxA2-/-
A B
C D
Figure 3.11: Microscopic examination of endothelial cells from AnxA2+/+ and AnxA2-/-mice.
AnxA2+/+ and AnxA2-/-endothelial cells were isolated and cultured to confluence as detailed in the 
materials and methods section. Cells were imaged by light (A) and confocal (B) microscopy, to 
demonstrate they were endothelial in origin, with further confocal analysis demonstrating that 
AnxA2-/- endothelial cells maintain normal VE-cadherin localisation (C). Cells were then lysed
using the reducing sample buffer based method, and western blotted for annexin 2 and tubulin to 
confirm the genotype of AnxA2-/- samples (D). Confocal microscopy reagents: anti-VE-cadherin
(1:50) Anti-Goat-Alexafluor-488 (1:1000) and DAPI (1:500). Antibodies for western blot, Anti-
annexin 2 (1:1000; BD Biosciences), Anti-Tubulin (Clone 1A2, courtesy of Prof K.Matter), with 
the secondary in both cases Anti-mouse-HRP (1:5000; Dako). Protein bands were visualised using 
ECL. Scale bar 50µm
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Figure 3.12: Examination of hyperglycaemia in AnxA2-/-endothelial cells..
AnxA2+/+ and AnxA2-/- endothelial cells were isolated and cultured for one week in the various 
conditions of glycaemia as shown. Cells were then fixed, stained and imaged using confocal
microscopy as detailed in the materials and methods. Anitbodies and reagents; Anti-VE-cadherin
(1:50), Anti-ZO-1 (1:300), phalloidin-633 (1:60), Anti-mouse-Alexafluor-488 (1:1000) and Anti-
rabbit-Alexafluor-568 (1:1000). Scale bar 50µm.
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various culture conditions, regardless of the presence or absence of annexin 2, or culture 
in hyperglycaemia. Examination of F-actin in AnxA2
+/+ endothelial cells similarly 
demonstrated consistency in the varying culture conditions. However, in AnxA2
-/- 
endothelial cells, there was a much more striking change in the localisation of F-actin, 
with the increased presence of actin stress fibers throughout the entire population of 
cells. Although striking this was not unexpected as it has previously been shown by 
Hayes et al that annexin 2 has a major role in the organisation and dynamics of the actin 
cytoskeleton
323. When this increase in stress fibre formation is taken into account it 
appears that culturing these cells in hyperglycaemia has no discernable effects on the 
localisation of F-actin. 
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Chapter 4 Results 
 
Having demonstrated subtle changes in annexin 2 in response to hyperglycaemia 
in vitro, investigations were continued in an in vivo setting. The streptozotocin induced 
model of diabetes is a well reported system described in many publications concerning 
diabetes research
390,391,392,393,394,395,396. Streptozotocin specifically targets the beta-islet 
cells of the pancreas destroying their capability to produce insulin and hence inducing a 
type-1 diabetes like state. To examine the role of annexin 2 and diabetes in vivo we first 
tested the hypothesis that loss of annexin 2 would influence the severity of diabetes in 
this established model. 
 
4.1 Blood glucose concentration in streptozotocin induced diabetes 
 
One of the major effects of uncontrolled diabetes is an increase in the 
concentration of blood glucose. To examine this in our system we induced diabetes in 
wild type c57bl/6 mice using streptozotocin. In this initial study blood glucose 
concentrations were recorded on a fortnightly basis for the initial 8 weeks, with 
subsequent measurements every 4 weeks. As expected, animals with diabetes 
immediately exhibited a significantly higher level of blood glucose than their control 
littermates (Figure 4.1; blue and yellow lines) (p<0.001). The specific effect of loss of 
annexin 2 was then considered, by comparing blood glucose concentration data for 
annexin 2 knockout animals, with and without diabetes, hereafter referred to as AnxA2
-
/- non-diabetic and AnxA2
-/- diabetic respectively (Figure 4.1; purple and cyan lines). 
The loss of annexin 2 did not significantly affect blood glucose concentration in either 
the non-diabetic or diabetic animals, since the degree of hyperglycaemia in the AnxA2
-/- 
animals closely followed that of AnxA2
+/+.  
 
4.2 Further examination of blood glucose concentration in streptozotocin induced 
diabetes 
 
Upon analysis of the data from the first study of blood glucose levels, it was 
noticed that at the final time points blood glucose levels often exceeded the maximum   87
Figure 4.1: Effect of diabetes on blood glucose in AnxA2+/+ and AnxA2-/- mice.
Annexin 2 wild type and null animals, both non-diabetic and diabetic, were tested for blood 
glucose levels at the various time points stated. Lines are mean values, from all animals available 
for the populations and time points, with error bars denoting ± SEM. Blue line: AnxA2+/+ non-
diabetic, purple line: AnxA2-/-non-diabetic, yellow line: AnxA2+/+ diabetic and teal line: AnxA2-/-
diabetic. n≥3
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Figure 4.1: Effect of diabetes on blood glucose in AnxA2+/+ and AnxA2-/- mice.
Annexin 2 wild type and null animals, both non-diabetic and diabetic, were tested for blood 
glucose levels at the various time points stated. Lines are mean values, from all animals available 
for the populations and time points, with error bars denoting ± SEM. Blue line: AnxA2+/+ non-
diabetic, purple line: AnxA2-/-non-diabetic, yellow line: AnxA2+/+ diabetic and teal line: AnxA2-/-
diabetic. n≥3
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detectable for the glucose sensor at 500 mg/dl. This produced a false ceiling at this 
maximal value, potentially masking some of the results. To resolve this problem in 
subsequent studies, blood samples exceeding the recording range of the sensor were 
diluted in an equal volume of water and re-recorded thereby extending the potential 
recording range to 1000 mg/dl. There were two further issues arising from the first 
study that were also subsequently corrected. The first was that initially only non-fasted 
blood glucose levels were collected, which would hinder comparisons with current 
literature, since the generally accepted method is to measure fasted blood glucose levels. 
The second issue was that no initial starting values for blood glucose levels were 
obtained, thus making it impossible to accurately assess any changes in blood glucose 
levels following streptozotocin treatment.   
With these considerations duly addressed, a new set of blood glucose levels 
were collected for AnxA2
+/+ and AnxA2
-/- non-diabetic and diabetic animals. In this 
study animals were first fasted for 4 hours before collection of blood glucose data in 
order to measure fasted blood glucose levels. In addition to this, at various time points, 
non-fasted blood glucose concentration data were also collected (not shown). In this 
second study both AnxA2
+/+ and AnxA2
-/- non-diabetic animals maintain a normal level 
of blood glucose, and both data sets follow each other closely. In contrast, diabetic 
AnxA2
+/+ and AnxA2
-/- animals exhibited a sharp rise in blood glucose from the point 
of streptozotocin administration, levelling off 4 weeks later at approximately 600 mg/dl 
(Figure 4.2). Data from the diabetic animals were significantly different from their non-
diabetic littermates at week 2 (p<0.001) as expected, but were broadly similar between 
each other with differences only apparent late in the data set at 16 weeks after onset of 
diabetes. Since the remaining data points were virtually identical, and because other 
factors commented on in the discussion may have given rise to the changes seen at week 
16, the data sets from AnxA2
+/+ and AnxA2
-/- diabetic animals were deemed to be 
similar.  
 
4.3 Examination of glucose homeostasis in AnxA2
+/+ and AnxA2
-/- non-diabetic and 
diabetic mice 
 
Although comparison of AnxA2
+/+ and AnxA2
-/- non-diabetic mice from both 
studies indicated that there were no substantial differences in blood glucose levels when 
examined over the length of the study, subtle differences were noted at some time points 
suggesting that annexin 2 may have a mild modulatory effect. To investigate this    89
Figure 4.2: Effect of diabetes on blood glucose in fasted AnxA2+/+ and AnxA2-/- mice.
Annexin 2 wild type and null animals, both non-diabetic and diabetic were fasted for 4 hours and 
tested for blood glucose levels at the various time points stated. Lines are mean values, from all 
animals available for the populations and time points, with error bars denoting ± SEM. Blue line: 
AnxA2+/+ non-diabetic, purple line: AnxA2-/- non-diabetic, yellow line: AnxA2+/+ diabetic and teal 
line: AnxA2-/- diabetic. n≥3
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Figure 4.2: Effect of diabetes on blood glucose in fasted AnxA2+/+ and AnxA2-/- mice.
Annexin 2 wild type and null animals, both non-diabetic and diabetic were fasted for 4 hours and 
tested for blood glucose levels at the various time points stated. Lines are mean values, from all 
animals available for the populations and time points, with error bars denoting ± SEM. Blue line: 
AnxA2+/+ non-diabetic, purple line: AnxA2-/- non-diabetic, yellow line: AnxA2+/+ diabetic and teal 
line: AnxA2-/- diabetic. n≥3
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further, blood glucose concentration data were collected from all available time points 
both from the first and second studies. The data were then further split into non-fasted 
and fasted states, reflecting the change in experimental design used in the second study. 
Hence fasted data were only collected from the second study, whilst both the first and 
second studies contributed to the non-fasted data. In both fasted and non-fasted states it 
can be seen that the mean blood glucose levels of the non-diabetic AnxA2
-/- animals 
were significantly lower than those of their AnxA2
+/+ counterparts (p<0.001 – non-
fasted, p<0.01 – fasted) (Figure 4.3A). In addition, it could also be seen that upon 
fasting both AnxA2
+/+ and AnxA2
-/- non-diabetic animals exhibited a significant 
increase in blood glucose concentration (p<0.001) (Figure 4.3B). Having observed that 
non-diabetic animals exhibit an increase in blood glucose concentration in response to 
fasting, data from diabetic animals were analysed in a similar way using results 
obtained from weeks 2-16 post streptozotocin injection. Like their non-diabetic 
littermates, AnxA2
+/+ diabetic animals exhibited a small increase in blood glucose 
concentration upon fasting from already elevated levels (Figure 4.3C), although this was 
not statistically significant. However, blood glucose levels from AnxA2
-/- diabetic 
animals were significantly reduced in response to fasting (p<0.001), with the additional 
observation that AnxA2
-/- animals had a significantly higher level of blood glucose 
when non-fasted (p<0.001) compared to their AnxA2
+/+ diabetic counterparts. Whether 
this reduction in blood glucose concentration in diabetic AnxA2
-/- mice is a result of an 
abnormal response to fasting, or the presence of higher blood glucose levels when un-
fasted is unclear. To further investigate and confirm this reduction in blood glucose 
levels in AnxA2
-/- animals when fasted, data from those animals in the second study 
subjected to blood glucose concentration sampling, both before and after fasting, were 
plotted as a function of change in blood glucose concentration in response to fasting. 
These data are shown in figure 4.3D, and although they are limited by a small sample 
size, it is nevertheless clear that AnxA2
-/- diabetic animals display a significant 
reduction in blood glucose concentration in response to fasting when compared to their 
AnxA2
+/+ diabetic counterparts (p<0.01). 
 
4.4 Examination of weight gain in the streptozotocin model of diabetes 
 
One of the other affects of uncontrolled type-1 diabetes is failure to gain weight 
(http://www.diabetes.org.uk). To examine this in our model system the weights of 
AnxA2
+/+ and AnxA2
-/-  non-diabetic and diabetic animals were recorded on a   91
Figure 4.3: AnxA2-/-animals show lower basal blood glucose levels and aberrant responses to 
fasting.
(A,B) Blood glucose data were collected from non-diabetic animals as detailed in the materials and 
methods and pooled for all available time points. Data from the 1st study and unfasted data from 
the 2nd study were combined to create the unfasted means, with only the 2nd study contributing to 
the fasted mean. All data are means of all available time points, with error bars denoting ± SEM. 
Statistical analysis was carried out using a 2-tailed Students t-test. (C) Blood glucose data were 
pooled for weeks 2-16. Only data from the 2nd study were used to calculate the means. All data are 
means from the selected time points, with error bars denoting ± SEM. Statistical analysis was 
carried out using a 2-tailed Students t-test. (D) Selected animals were subjected to blood glucose 
tests both pre and post fasting with the differences used to create the mean values shown. Error 
bars denote +/- SEM and statistical analysis was carried out using a 2-tailed students t-test. 
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Figure 4.3: AnxA2-/-animals show lower basal blood glucose levels and aberrant responses to 
fasting.
(A,B) Blood glucose data were collected from non-diabetic animals as detailed in the materials and 
methods and pooled for all available time points. Data from the 1st study and unfasted data from 
the 2nd study were combined to create the unfasted means, with only the 2nd study contributing to 
the fasted mean. All data are means of all available time points, with error bars denoting ± SEM. 
Statistical analysis was carried out using a 2-tailed Students t-test. (C) Blood glucose data were 
pooled for weeks 2-16. Only data from the 2nd study were used to calculate the means. All data are 
means from the selected time points, with error bars denoting ± SEM. Statistical analysis was 
carried out using a 2-tailed Students t-test. (D) Selected animals were subjected to blood glucose 
tests both pre and post fasting with the differences used to create the mean values shown. Error 
bars denote +/- SEM and statistical analysis was carried out using a 2-tailed students t-test. 
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fortnightly basis for the initial 8 weeks, with subsequent measurements every 4 weeks 
in both studies.  
Over the 40 week period AnxA2
+/+ and AnxA2
-/- non-diabetic animals gained 
weight in a similar manner (Figure 4.4A). Data from the AnxA2
+/+ and AnxA2
-/- 
diabetic mice confirmed that streptozotocin induced diabetes is sufficient to suppress 
weight gain, with the difference in weights becoming significantly different to the non-
diabetic counterparts at week 4 (p<0.05). The data also demonstrate that the loss of 
annexin 2 does not noticeably modulate the effect of diabetes on weight gain. Data from 
the second study can are shown in figure 4.4B, with non-diabetic animals gaining 
weight throughout the 16 week period, whereas diabetic animals failed to gain weight 
over that same period. The differences in weight gain were significantly different 
between non-diabetic and diabetic animals for both AnxA2
+/+ and AnxA2
-/- animals at 
week 2 (p<0.05), two weeks earlier than that of the first study. 
 
4.5 Fluorescein angiography and analysis of pericyte dropout 
 
Having shown that AnxA2
-/- diabetic animals have both differences and similarities to 
their AnxA2
+/+ counterparts it was decided to assess whether the loss of annexin 2 might 
influence the vascular pathology associated with diabetic retinopathy, either promoting 
or protecting against vascular leakage. The classical method whereby vascular changes 
are measured in the eye is fluorescein angiography, and therefore we set about 
examining our diabetic animals for signs of disease. Six mice from AnxA2
+/+ and 
AnxA2
-/- control and diabetic groups, 16 weeks post streptozotocin-induced diabetes, 
were anaesthetised, injected with fluorescein and the resultant fluorescent retinal image 
recorded at 2, 4, 6, 8 and 10 minutes post-injection. Representative images from both 
AnxA2
+/+ and AnxA2
-/- control and diabetic animals show that no vascular leakage was 
apparent at 16 weeks post diabetes (Figure 4.5A), since no radiating fluorescent signal, 
as illustrated in figure 4.5B, can be seen. The retinal vessels examined showed no signs 
of leakage in any of the animals, nor was there any evidence of microaneurysms or 
neovascularisation, indicating the absence of overt diabetic retinopathy in these animals 
at this age. The movies of the fluorescein angiograms are appended to the inside back 
cover of this thesis. However, it should be noted that a key aspect of diabetic 
retinopathy in the streptozotocin induced model of diabetes is that signs and symptoms 
can take well over one year to present; thus the animals examined may simply have not 
been old enough. However, to investigate the vasculature more closely   93
Figure 4.4: Effect of diabetes on weight gain in AnxA2+/+ and AnxA2 -/- mice.
Annexin 2 wild type and null animals, both non-diabetic and diabetic, were weighed at the various 
time points indicated. Lines are mean values, from all animals available for the populations and 
time points, with error bars denoting ± SEM. Blue line: AnxA2+/+ non-diabetic, purple line: AnxA2-
/- non-diabetic, yellow line: AnxA2+/+ diabetic and teal line: AnxA2-/-diabetic. n≥3
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Figure 4.4: Effect of diabetes on weight gain in AnxA2+/+ and AnxA2 -/- mice.
Annexin 2 wild type and null animals, both non-diabetic and diabetic, were weighed at the various 
time points indicated. Lines are mean values, from all animals available for the populations and 
time points, with error bars denoting ± SEM. Blue line: AnxA2+/+ non-diabetic, purple line: AnxA2-
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mice.
(A) Animals from all four groups were subjected to fluorescein angiography as described in the 
materials and methods. Images were taken at 2 minute time points up to 10 minutes, with the optic 
nerve head in the centre and vessels radiating outward. The movies from which these stills were 
taken is available on the DVD attached to the back cover of this thesis. (B) Image taken from 
Chen. Y. et al, (2009), Microvascular Research, 78(1), p119-127, to illustrate the appearance of 
vascular leakage from retinal vessels (arrows).
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and with better resolution, retinas from AnxA2
+/+ and AnxA2
-/- non-diabetic and 
diabetic animals were subjected to a trypsin digest protocol and stained with periodic 
acid Schiff (PAS) stain, counterstained with haematoxylin. Figure 4.6 shows a 
representative image from the n=3 samples examined for each group, with the graphical 
representation of the endothelial cell: pericyte ratio below. In each image endothelial 
and pericyte nuclei were counted, identified by their different 
morphology
397,398,399,400,401, and a ratio calculated of the number of pericytes per 
endothelial cell. Averages from the analysis demonstrate that whilst diabetic animals 
have significantly fewer pericytes per endothelial cell than their non-diabetic littermates 
(p<0.05), there were no significant differences between AnxA2
+/+ and AnxA2
-/- mice, in 
both the non-diabetic and diabetic states. This would indicate that whilst the action of 
diabetes is sufficient to reduce the number of pericytes, the loss of annexin 2 does not 
exacerbate or attenuate this effect.    
 
4.6 Retinal stress in diabetic AnxA2
+/+ and AnxA2
-/- animals 
 
Since no microaneurysms were detected, and the pericyte to endothelial ratios in 
retinas from AnxA2
-/- diabetic animals were essentially identical to those of their 
AnxA2
+/+ counterparts, an additional symptom of diabetic retinopathy was assessed. 
When the retina becomes stressed through diabetes one of the initial events to occur is 
the up-regulation of glial fibrillary acidic protein (GFAP) in Müller cells. GFAP is 
normally only expressed, and at low levels, by retinal astrocytes, but can be 
dramatically up-regulated in Müller cells in a stressed or diabetic retina. AnxA2
+/+ and 
AnxA2
-/- non-diabetic and diabetic eyes were thus isolated from animals 16 weeks post 
streptozotocin or sham injection, cryosectioned, stained for GFAP protein, and 
examined by confocal microscopy. Retinas from both AnxA2
+/+ and AnxA2
-/- non-
diabetic animals displayed nuclei and F-actin staining indicative of normal retinal 
architecture, with GFAP positive cells in the ganglion cell layer (Figure 4.7, arrows). 
The level and area of the ganglion cell layer positive for GFAP appears a little more 
extensive in the non-diabetic AnxA2
-/-, but not so high as to suggest a significant glial 
cell activation. Diabetic animals also showed nuclei and F-actin staining indicative of 
normal retinal architecture but in both cases exhibited slightly higher levels of GFAP 
staining in the ganglion cell layer in comparison to their control littermates, suggesting 
modest up-regulation of GFAP protein in this region of the retina. However, since 
GFAP Figure 4.6: Trypsin digests of retinas from non-diabetic and diabetic AnxA2+/+ and AnxA2-/-
mice.
Eyes were taken from animals subjected to 16 weeks diabetes and their non-diabetic littermate 
controls, retinas were isolated followed by digestion with trypsin to remove the non-vascular cells. 
Retinal preparations were then stained with PAS and counterstained with H&E to reveal pericyte
(Red arrow) and endothelial cell nuclei (Black arrows). Nuclei were then counted per field of view 
for n=3 samples, and pericyte to endothelial cell ratios calculated, averages ± SD  of which can be 
seen in the graph. *=p<0.05
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96Figure 4.7: GFAP staining of retins from non-diabetic and diabetic AnxA2+/+ and AnxA2-/-
mice.
Eyes (n=3) from all four groups were isolated, enucleated and cryosectioned as detailed in the 
materials and methods. 10µM sections were fixed in 4% PFA and stained for DNA (Blue) GFAP 
(Red) and F-actin using Anti-GFAP (1:100), DAPI (1:500), Phalloidin-633 (1:60), Anti-Goat-
Alexafluor-568 (1:1000). Arrow head indicate GFAP positive cells. Scale bar 20µm, labels of 
retinal layers, PL-Photoreceptor layer, ONL-Outer nuclear layer, OPL-Outer plexiform layer, INL-
Inner nuclear layer, IPL-Inner plexiform layer, GCL-Ganglion cell layer.
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up-regulation in Müller cells as a consequence of diabetes is usually detected in the 
outer plexiform layer, and none of the data showed staining in that area of the retina, it 
was deemed that GFAP was not significantly up regulated in these cells. 
 
4.7 Histological examination of AnxA2
+/+ and AnxA2
-/- non-diabetic and diabetic 
retinas 
 
Having detected only modest changes of GFAP expression in the AnxA2
-/- 
diabetic retina in comparison to control, although not at the level of Müller cells, other 
early changes that are thought to occur in the progression of diabetic retinopathy, such 
as the death of photoreceptors
402, were examined using histological methods. First, 10 
µm cryosections taken from the same eyes examined for GFAP staining, were also 
stained using haematoxylin and eosin (H&E) and periodic-acid Shiff (PAS). However, 
the quality of the tissue was such that no reasonable interpretation of the results could 
be made, due to the nature of the cryogenically-embedded sections, and the samples 
were discarded. Due to this an improved method of sample preparation was employed, 
in which fresh eyes were isolated from AnxA2
+/+ and AnxA2
-/- non-diabetic and 
diabetic animals 16 weeks post streptozotocin or sham injections. Eyes were then fixed 
in 2% glutaraldehyde / 2% paraformaldehyde, embedded in araldite resin, sectioned to 
0.7 µm and stained with toluidine blue. The various layers of the retina are clearly 
distinguishable, allowing for more detailed interpretation than would have been possible 
using cryosections (Figure 4.8). Histological changes examined at this level would 
manifest as either changes in retinal thickness, or the appearance of anatomical 
anomalies. Within the different groups, the thickness of the retina varied to some extent, 
most likely due to irregularities in the orientation of the optic cup during sectioning. The 
apparent differences in total retinal thickness should therefore be deemed insignificant. 
Comparison of retinas between AnxA2
+/+ and AnxA2
-/- non-diabetic and diabetic 
samples yielded no overt changes in the relative thicknesses of each of the individual 
layers of the retina. Since there were also no cellular anomalies detected, the absence of 
annexin 2 or presence of diabetes was judged to have no major influence on retinal 
histology. 
 Figure 4.8: Toluidine Blue staining of retinas from AnxA2+/+ and AnxA2-/- non-diabetic and 
diabetic animals.
Eyes from AnxA2+/+ and AnxA2-/-non-diabetic and diabetic animals (n=3 each) were enucleated, 
fixed in 2% paraformaldhyde / 2% glutaraldehyde and embedded in araldite resin as detailed in the 
materials and methods. Blocks were then sectioned at 0.7µm and stained with toluidine blue, also as 
detailed in the materials and methods. Sections are taken from points nearest the optic nerve head, 
with the internal limiting membrane at the top of the image and RPE at the bottom. Scale bar 10µm, 
labels of retinal layers, RPE-Retinal pigment epithelium, PL-Photoreceptor layer, ELM-External 
limiting membrane, ONL-Outer nuclear layer, OPL-Outer plexiform layer, INL-Inner nuclear layer, 
IPL-Inner plexiform layer, GCL-Ganglion cell layer, NFL-Nerve fiber layer, ILM-Inner limiting 
membrane.
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4.8 Annexin 2 and the endothelial response to VEGF 
 
Physical changes that occur in the retina as a consequence of diabetic 
retinopathy may be induced by factors other than hyperglycaemia. One of the signalling 
molecules most strongly implicated in the progression of diabetic retinopathy is 
vascular endothelial growth factor (VEGF)
196,197,198. With the physical manifestations of 
diabetic retinopathy examined, and no significant changes found at 16 weeks post 
diabetes onset, we next investigated whether the loss of annexin 2 alters, or modulates, 
the signalling pathways downstream of VEGF. VEGF can stimulate various responses 
in endothelial cells, one of which is an increase in permeability, through the re-
distribution of VE-cadherin
104. To assess whether this was true of endothelial cells 
lacking annexin 2 we conducted a series of studies using freshly isolated primary 
microvascular endothelial cells from the brains of AnxA2
+/+ and AnxA2
-/- non-diabetic 
mice, and examined potential changes in junctional protein localisation in response to 
VEGF. The results of the first study are shown in figures 4.9-4.11. In these experiments 
cells were serum-starved overnight before stimulation with VEGF (50ng/ml) in fresh 
media. The distributions of three proteins were examined in each of the cell cultures, 
namely VE-cadherin (Figure 4.9), β-catenin (Figure 4.10) and F-actin (Figure 4.11). 
AnxA2
+/+ endothelial cells treated with vehicle alone maintained the localisation of VE-
cadherin at the cell junctions with no change of signal (Figure 4.9). In contrast, 
AnxA2
+/+ endothelial cells treated with 50ng/ml VEGF showed a loss of VE-cadherin 
from the junctions at 30 minutes, still evident at 1 hour, with localisation to the 
junctions restored at 6 hours. Examination of the action of VEGF on VE-cadherin in 
AnxA2
-/- endothelial cells yielded a contrasting result, since these cells treated with 
vehicle alone lost their VE-cadherin localisation at the junctions at 30 minutes, with 
restoration of junctional VE-cadherin at 3-6 hours, much like the AnxA2
+/+ cells treated 
with VEGF. AnxA2
-/- endothelial cells treated with VEGF showed a different pattern, in 
that VE-cadherin localisation was disrupted at 30 minutes and 3 hours, which was more 
pronounced than observed in cells treated with vehicle alone at 1 hour, with junctional 
localisation restored by 6 hours. Localisation of the two other proteins investigated in 
this experiment, namely β-catenin and F-actin was also examined. β-catenin (Figure 
4.10) was used as a control marker for adherens junction localisation and exhibited the 
distributional changes seen in VE-cadherin throughout all the different samples in this 
experiment. F-Actin (Figure 4.11) distribution also changed, with less cortical F-actin Figure 4.9: Effect of VEGF on VE-cadherin localisation in AnxA2+/+ and AnxA2-/-
endothelial cells.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for VE-cadherin using Anti-VE-
cadherin (1:50) and Anti-goat-Alexafluor-488 (1:1000). Scale bar 50 µm
T= 0
T= 5 min T= 30 min T= 1 h T= 3 h T= 6 h
T= 0
0ng/ml VEGF >>
50ng/ml VEGF >>
0ng/ml VEGF >>
50ng/ml VEGF >>
T= 5 min T= 30 min T= 1 h T= 3 h T= 6 h
A
n
x
A
2
+
/
+
A
n
x
A
2
-
/
-
101T= 0
T= 5 min T= 30 min T= 1 h T= 3 h T= 6 h
T= 0
0ng/ml VEGF >>
50ng/ml VEGF >>
0ng/ml VEGF >>
50ng/ml VEGF >>
T= 5 min T= 30 min T= 1 h T= 3 h T= 6 h
Figure 4.10: Effect of VEGF on β-catenin localisation in AnxA2+/+ and AnxA2-/- endothelial 
cells.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for β-catenin using Anti-β-catenin
(1:100) and Anti-rabbit-Alexafluor-568 (1:1000). Scale bar 50 µm
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Figure 4.11: Effect of VEGF on F-actin localisation in AnxA2+/+ and AnxA2-/- endothelial 
cells.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for F-actin using Phalloidin-633 (1:60). 
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evident when VE-cadherin had been mobilised from the cell junctions by VEGF, 
returning to a normal distribution by 6 hours post VEGF or vehicle addition in all 
samples. Although the observations of VE-cadherin re-distribution suggest that     
AnxA2
-/- endothelial cells have an alternative response to the action of VEGF, the loss 
of VE-cadherin from the junctions of AnxA2
-/- endothelial cells treated with vehicle 
alone suggests an unusual sensitivity of junctional proteins in the AnxA2
-/- endothelial 
cells to environmental changes.  
  With these considerations in mind, we altered the protocol to eliminate the 
problem of loss of junctional VE-cadherin in cells treated with vehicle alone. To do this 
50% of the media left on cells overnight was removed, mixed with VEGF to yield a 
final concentration of 50ng/ml, and then gently added back to minimise the shock to the 
cells. The results are shown in Figure 4.12-4.14, and unlike the initial experiment in 
which AnxA2
+/+ and AnxA2
-/- endothelial cells were treated with vehicle alone, VE-
cadherin (Figure 4.12), β-catenin (Figure 4.13) and F-actin (Figure 4.14) distributions 
were all unchanged at all time points with vehicle alone. However, the actions of VEGF 
on both AnxA2
+/+ and AnxA2
-/- cells under these conditions were also markedly 
reduced compared to the first experiment, with only the 5 minute time point showing 
any difference, and only with regard to VE-cadherin localisation. In all the experiments 
β-catenin was maintained at the junctions and hence can be used as a marker for 
junctional integrity. F-Actin structures were also constant in this experiment, indicating 
that the action of VEGF was not sufficient to change its distribution regardless of the 
presence or absence of annexin 2. However, comparison of VE-cadherin and β-catenin 
localisation at 5 minutes post VEGF treatment demonstrated that whilst AnxA2
+/+ cells 
maintained the enrichment of VE-cadherin at the junctions of the cell, AnxA2
-/- cells did 
not (black arrow heads; Figure 4.15), suggesting that VE-cadherin is more readily 
mobilised away from junctions by VEGF in cells lacking annexin 2. 
 
4.9 AnxA2
-/- endothelial cells isolated from diabetic mice display disorganised VE-
cadherin 
 
Since the progression of diabetic retinopathy and the actions of VEGF are 
mediated in part through alterations in VE-cadherin localisation, we examined whether 
diabetes in vivo would have any effects on VE-cadherin that could be visualised in 
cultured endothelium. In the previous chapter endothelial cells isolated from cell lines 
and primary brain endothelium were exposed to hyperglycaemia for 1 week in vitro T= 0
T= 5 min T= 30 min T= 1 h T= 3 h T= 6 h
T= 0
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Figure 4.12: Enhanced sensitivity of VE-cadherin to VEGF in endothelial cells lacking 
annexin 2.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for VE-cadherin using Anti-VE-
cadherin (1:50) and Anti-goat-Alexafluor-488 (1:1000). Scale bar 50 µm
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Figure 4.13: Effect of VEGF on β-catenin localisation in AnxA2+/+ and AnxA2-/- endothelial 
cells.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for β-catenin using Anti-β-catenin
(1:100) and Anti-rabbit-Alexafluor-568 (1:1000). Scale bar 50 µm
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Figure 4.14: Effect of VEGF on F-actin localisation in AnxA2+/+ and AnxA2-/- endothelial 
cells.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for F-actin using Phalloidin-633 (1:60). 
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107Figure 4.15: AnxA2-/-primary endothelial cells exposed to VEGF display changes in VE-
cadherin localisation at 5 minutes.
AnxA2+/+ and AnxA2-/-primary endothelial cells were isolated and exposed to 50 ng/ml VEGF or 
vehicle (0.1% BSA, PBS) protocol as detailed in the materials and methods. Cells were then fixed 
in 4% PFA at the various time points indicated and stained for VE-cadherin using Anti-VE-
cadherin (1:50) and Anti-goat-Alexafluor-488 (1:1000). and B-catinin using Anti-β-catenin (1:100) 
and Anti-rabbit-Alexafluor-568 (1:1000).
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with no significant differences detected. Having demonstrated that both AnxA2
+/+ and 
AnxA2
-/- animals treated with streptozotocin have elevated blood glucose levels, it was 
decided to see what effect 16 weeks of in vivo hyperglycaemia would have on brain 
endothelial cell cultures. Consistent with the data in chapter 3, in non-diabetic animals 
the loss of annexin 2 was insufficient to disrupt the localisation of VE-cadherin, but 
cells contained more prominent actin stress fibres (Figure 4.16). Endothelial cells from 
diabetic mice differed in various respects. First, exposure to in vivo diabetic conditions 
resulted in substantially reduced yields from both AnxA2
+/+ and AnxA2
-/- mice, since 
only small isolated patches of cells could be detected, rather than sheets of confluent 
endothelium. Nevertheless, there appeared to be no change in the distribution of F-actin 
attributable to diabetes, although any potential changes are more indicative of, or 
masked by the effect of, culture in sub-confluent conditions. Upon examination of 
AnxA2
-/- endothelial cells extracted from diabetic mice the increase in actin stress fibre 
phenotype is still evident, however, in comparison to AnxA2
+/+ diabetic endothelial 
cells the distribution of VE-cadherin at some cell to cell contacts is discontinuous, 
suggesting a defect in junctional targeting (Figure 4.17, red arrows). These data would 
therefore suggest that the loss of annexin 2 in diabetic conditions may disrupt the 
localisation of VE-cadherin, however, further sampling of diabetic animals would be 
needed to provide statistical significance. Figure 4.16: Assessment of VE-cadherin localisation in endothelial cells isolated from 
AnxA2+/+ and AnxA2-/- non-diabetic and diabetic animals.
Endothelial cells were isolated from AnxA2+/+ and AnxA2-/-non-diabetic and diabetic animals, 16 
weeks post streptozotocin or sham treatment, as detailed in the materials and methods. Cells were 
then cultured for 1 week in either hyperglycaemic (25mM glucose) or euglycaemic (5mM glucose) 
conditions. Samples were then fixed in 4% paraformaldehyde and stained for DNA, VE-cadherin, 
F-actin and annexin 2 using DAPI (1:500), Anti-VE-cadherin (1:50), Annexin 2 (1:100; from Dr 
Jesus Ayala-Sanmartin) and Phalloidin-633 (1:60), Anti-Goat-Alexafluor-488 (1:1000), Anti-
Rabbit-Alexafluor-568 (1:1000). Scale bar: 50 µm
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Figure 4.17: Assessment of VE-cadherin localisation in endothelial cells isolated from 
AnxA2+/+ and AnxA2-/- non-diabetic and diabetic animals.
Endothelial cells were isolated from AnxA2+/+ and AnxA2-/-non-diabetic and diabetic animals, 16 
weeks post streptozotocin or sham treatment, as detailed in the materials and methods. Cells were 
then cultured for 1 week in either hyperglycaemic (25mM glucose) or euglycaemic (5mM glucose) 
conditions. Samples were then fixed in 4% paraformaldehyde and stained for VE-cadherin Anti-
VE-cadherin (1:50) and Anti-Goat-Alexafluor-488 (1:1000). Areas of intact VE-cadherin staining 
are illustrated in green arrows whilst those in red depict areas where VE-cadherin is absent. Scale 
bar: outside panels = 50 µm , inside panels = 20µm.
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Chapter 5 Results 
 
Work in the previous chapter revealed that AnxA2
-/- diabetic animals exhibit 
early indicators of diabetic retinopathy, and that cells lacking annexin 2 may have 
altered responses to VEGF. During the collection of data for blood glucose levels and 
weight, it was noticed that cages housing diabetic mice lacking annexin 2 needed 
cleaning more often than those of their wild type counterparts. Although increased urine 
output is a recognised consequence of uncontrolled diabetes, excessive urine output 
beyond that expected can be indicative of more severe problems. Diabetic kidney 
disease (Diabetic nephropathy) is characteristic of uncontrolled diabetes, culminates in 
decreased kidney function and has links with the incidence of diabetic retinopathy
403,404, 
hence we decided to examine whether the lack of annexin 2 accelerated the progression 
of diabetic nephropathy. 
 
5.1 Assessment of polydipsia in diabetic mice 
 
One of the symptoms of uncontrolled diabetes is excessive urination and hence 
excessive drinking or polydipsia. Since we had neither the permission nor equipment to 
measure urine production accurately, we instead measured the amount of water 
consumed by the various groups of mice over a 24 hour period. To achieve this, mice 
were housed either alone or in phenotypic groups and their water bottles weighed before 
and after a given 24 hour period. Both AnxA2
+/+ and AnxA2
-/- mice without diabetes 
had a similar intake of water at approximately 6 ml in a 24 hour period (Figure 5.1). 
Diabetic mice had a 4-6 fold increase in their water intake over their control littermates 
(AnxA2
+/+ 26.7 ± 1.49 ml) (AnxA2
-/- 33.7 ± 1.00 ml), with AnxA2
-/- diabetic mice 
exhibiting a significant increase in the amount of water consumed, compared to their 
diabetic AnxA2
+/+ counterparts (p<0.01).  
 
5.2 Assessment of microalbuminuria in diabetic mice 
 
Having shown that AnxA2
-/- diabetic mice display polydipsia, the presence of 
increased albumin in the urine, or microalbuminuria, was examined. Early in the day 
mice were handled over material that would collect any urine excreted as a normal 
consequence of their handling. Urine samples, 16 weeks post streptozotocin or sham   114
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Fig 5.1: Assessment of water consumption in diabetic mice.
All mice examined for polydipsia had their water reservoirs weighed before and after a given 24 
hour period to measure water intake as detailed in the materials and methods. Mean water volume 
consumed was then plotted on the graph shown. Error bars denote ±SEM, *=p<0.01.
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treatment, were then tested for levels of albumin and creatinin by ELISA (Figure 5.2). 
The data show that the levels of albumin excreted by the AnxA2
+/+ control mice are 
within those expected for the c57bl/6 strain (77.6 ± 26.2 µg albumin / mg creatinin)
405. 
Comparing this then to their diabetic counterparts a trend towards higher albumin 
excretion levels can be observed, although the differences are not statistically 
significant. Comparison of AnxA2
+/+ non-diabetic mice to AnxA2
-/- non-diabetic mice 
reveals a similar trend, whereby albumin levels are increased in mice lacking annexin 2 
to around twice the level of their wild-type counterparts (161.9 ± 74.8 µg albumin / mg 
creatinin), in contrast, the differences in this case are close to being significant 
(p<0.077). Interestingly, AnxA2
-/- diabetic mice had the highest albumin excretion rate 
of all the mice (399.1 ± 195.1), which is significantly higher than the AnxA2
+/+ diabetic 
mice (p<0.05), indicating that mice lacking annexin 2 have increased albumin excretion 
than wild type mice, potentially exacerbated by some inherent kidney dysfunction 
induced by the loss of annexin 2.  
 
5.3 Kidney weights of diabetic mice are increased 
 
Having demonstrated potential kidney problems in the AnxA2
-/- mice, at least at the 
level of albumin and urine excretion, and that the presence of diabetes exacerbates these 
changes, it was decided to examine the kidneys of these mice in more detail. Kidney 
weights of the mice were assessed, with comparisons to their final body weight to give a 
percentage of body weight (Figure 5.3). Both AnxA2
+/+ and AnxA2
-/- non-diabetic mice 
yielded similar results, 1 ± 0.16% and 0.8 ± 0.11% respectively, indicating that the loss 
of annexin 2 does not influence kidney weight. When compared to diabetic mice, it was 
observed that AnxA2
-/- diabetic mice had a significantly higher mean kidney weight 
than their non-diabetic littermates (1.39 ± 0.28%) (p<0.05) as did AnxA2
+/+ diabetic 
mice (1.36 ± 0.17%) (p=0.05). Interestingly there was no significant difference between 
AnxA2
+/+ and AnxA2
-/- diabetic mice, indicating that although the presence of diabetes 
was sufficient to induce changes in kidney weight the loss of annexin 2 did not 
exacerbate or attenuate this effect.    116
Fig 5.2: Assessment of microalbuminuria in diabetic mice.
Urine samples were collected from AnxA2+/+ and AnxA2-/-non-diabetic and diabetic mice 16 weeks 
post streptozotocin treatment and subjected to albumin and creatinin ELISAs as detailed in the 
materials and methods. Data were then plotted from n=4 (AnxA2+/+ and AnxA2-/-non-diabetic) or 
n=5 (AnxA2+/+ and AnxA2-/- diabetic) mice as mean µg albumin / mg creatinin ± SD. *=p<0.06 
**=p<0.05.
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Fig 5.3: Assessment of kidney weights in diabetic mice.
Kidneys from mice were weighed and compared to the final weight recording of the mouse to give 
a percentage weight value. Error bars denote ± SD, 3 ≤n≤8. *=p=0.05, **=p<0.05
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5.4 Haematoxylin and eosin (H&E) staining of kidney reveals AnxA2
-/- diabetic 
animals have aggravated diabetic nephropathy  
 
To obtain an overall view of the various anatomical regions of the kidney 6µm 
sections were taken from paraffin embedded tissue and stained with H&E (Figure 5.4). 
Each set of images consists of a gross low magnification view from a midline coronal 
section, with higher magnification images from different areas of the kidney: cortex, 
medulla, calyces / renal pelvis and glomeruli. Both AnxA2
+/+ and AnxA2
-/- non-diabetic 
mice display a normal anatomical structure of the kidney, with the various regions 
clearly defined and no malformations detectable. This indicates that the absence of 
annexin 2 is not sufficient to cause any obvious problems in the general structure of the 
kidney. However, if images of kidney sections obtained from AnxA2
+/+ non-diabetic 
mice are compared with those of the AnxA2
+/+ diabetic mice some minor differences 
become apparent. Tubules in the cortex region appear mildly dilated, the tubules of the 
medulla also seem less uniform in their distribution, potentially indicating that some 
have been lost, and tubules of the calyces also appear less organised and uniform. These 
differences however are minor compared to those observed in the AnxA2
-/- diabetic 
kidney, where there is substantial dilation of the tubules in all the various regions, with 
the different regions harder to identify since the general organisation of the kidney is 
severely compromised. With these indications of increased diabetic nephropathy noted a 
further staining regimen was employed to visualise more clearly the apparent changes.   
 
5.5 Periodic acid Schiff staining in AnxA2
-/- diabetic animals 
 
In addition to general morphological changes observed by H&E staining, 
changes evident in diabetic kidney tissue can be observed more clearly using periodic 
acid Schiff (PAS) stain. Hence similar kidney sections to those that were stained with 
H&E were also stained with PAS to highlight these changes (Figure 5.5). PAS staining 
confirms that AnxA2
-/- diabetic mice have an accentuated response to diabetes, whilst 
AnxA2
-/- control mice appear to have normal kidney architecture. The advantage with 
the PAS stain is that the basement membranes of the tubules and glomeruli are more 
readily visible as red lines on the images. Some distinction was also possible between 
the epithelial cells and their microvillar extensions that project into the lumen. 
Qualitative evaluation of these images reveals that AnxA2
-/- diabetic animals have 
reduced tubular cell thickness in comparison to their control littermates and Fig 5.4: H&E staining of kidneys reveals indications of accentuated diabetic nephropathy in 
AnxA2-/- diabetic mice. Kidneys were isolated, fixed, embedded and sectioned as detailed in the 
materials and methods. H&E staining was applied also as detailed in the material and methods 
with, representative images of 3 separate samples shown above. Panel A shows an overall image of 
the kidney, B shows the cortex region, D the medulla and C the calyx / renal pelvis, with panel E 
showing a single glomerulus. Different regions are illustrated in AnxA2+/+ Non-diabetic C=Cortex, 
M=Medulla, R=Calyx/Renal pelvis, yellow outline in panel E indicates glomerulus . Scale bar in all 
images = 100 µm.
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119Fig 5.5: PAS staining of kidneys reveals indications of accentuated diabetic nephropathy in 
AnxA2-/-diabetic mice. Kidneys were isolated, fixed, embedded and sectioned as detailed in the 
materials and methods. PAS staining was applied also as detailed in the material and methods with 
representative images of 3 separate samples shown above. Panel A shows an overall image of the 
kidney, B shows the cortex region, D the medulla and C the calyx / renal pelvis, with panel E 
showing a single glomerulus. Scale bar in all images represents 100 µm 
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AnxA2
+/+ mice. To attempt to assess the degree of cellular thinning 300 cells from three 
individual animals were quantified and lengths measured. In comparison to the 
AnxA2
+/+ non-diabetic mice the data show that AnxA2
-/- non-diabetic mice have a 
slightly reduced tubular cell thickness, and that diabetic AnxA2
+/+ and AnxA2
-/- tubular 
cell thickness is significantly less than the non-diabetic controls (p<0.05) (Figure 5.6). 
In addition, AnxA2
-/- diabetic mice display a slightly reduced cell thickness in 
comparison to the AnxA2
+/+ diabetic counterparts, though the difference is not 
significant. A further advantage of staining kidney sections with PAS is that any 
potential mesangial matrix expansion can be detected. Assessment of mesangial matrix 
content was made by measurement of the percentage area of intensely PAS positive 
extravascular region in each glomerulus, not including Bowman’s space. Both AnxA2
+/+ 
and AnxA2
-/- non-diabetic animals display a similar level of mesangial matrix with 
approximately 5% of the total extravascular area intensely PAS positive (Figure 5.7). In 
addition, both AnxA2
+/+ and AnxA2
-/- diabetic animals show significantly more PAS 
positive regions than their non-diabetic littermates (p<0.05), demonstrating that diabetes 
induces an increase in mesangial matrix. Furthermore AnxA2
-/- diabetic mice have 
significantly more mesangial matrix than AnxA2
+/+ diabetic mice (p<0.01), 
demonstrating that the absence of annexin 2 exacerbates the accumulation of this matrix 
in diabetes. 
 
5.6 Electron microscopy reveals basement membrane thickening in diabetic mice 
 
Although PAS staining illustrates the basement membrane and mesangial matrix 
in the kidney better than H&E staining, to get an accurate measurement of the thickness 
of the basement membrane higher magnification are resolution are required, and hence 
electron microscopy was employed. Kidney cortex samples from AnxA2
+/+ and   
AnxA2
-/- control and diabetic mice were processed for electron microscopy, and 
examined on a JEOL 1010 transmission electron microscope.  
Inspection of the general architecture of the tubular cell reveals that the loss of 
annexin 2 is insufficient to cause any gross ultrastructural changes, in particular the 
apical villi of the tubular epithelial cells are apparently normal (Figure 5.8). Normal 
cellular ultrastructure was also observed in the majority of both the AnxA2
+/+ and 
AnxA2
-/- diabetic samples (Figure 5.9). However, in these samples there were instances 
where the consequences of diabetes were evident in reduced cell thickness, and reduced 
villi length (Figure 5.10). In addition to examination of general architecture, basement   122
Fig 5.6: AnxA2-/- diabetic mice show reduced epithelial cell thickness.
Images of kidneys stained with PAS were taken from both AnxA2+/+ and AnxA2-/- non-diabetic 
and diabetic mice and subjected to cell thickness analysis as demonstrated above using Image-J 
software. Mean thickness was then plotted on the graph shown with error bars denoting ±SEM. 
Scale bar represents 100µm. *=p<0.05. n=300 (100 cells quantified from 3 individual mice)
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Fig 5.7: Analysis of mesangial matrix expansion in diabetic mice.
Images of kidneys stained with PAS were taken from both AnxA2+/+ and AnxA2-/-non-diabetic and 
diabetic mice and analysed for amount of mesangial matrix, seen as an intense PAS stain. 
Representative images are shown of AnxA2+/+ and AnxA2-/-non-diabetic and diabetic above with 
yellow dotted lines denoting the glomerulus and red dotted lines the mesangial matrix. Red areas 
were then collated and expressed as a percentage of total glomerula area. The graph shows the 
mean area of mesangial matrix of each animal group ± SD. *= p<0.01.
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123Fig 5.8 Examination of kidney tubular cells by electron microscopy.
Kidney samples were prepared for imaging by electron microscopy, as detailed in the materials and 
methods. Samples were prepared from AnxA2+/+ and AnxA2-/- non-diabetic. In each group of 
images A is an overview of the tubule cell whilst B and C give views of the apical villi and 
basement membrane respectively. N=nucleus, BM= Basement membrane, AV=apical villi. Scale 
bar = 2µm.
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124Fig 5.9 Examination of kidney tubular cells by electron microscopy.
Kidney samples were prepared for imaging by electron microscopy, as detailed in the materials and 
methods. Samples were prepared from AnxA2+/+ and AnxA2-/- Diabetic. In each group of images A 
is an overview of the tubule cell whilst B and C give views of the apical villi and basement 
membrane respectively. N=nucleus, BM= Basement membrane, AV=apical villi. Scale bar = 2µm.
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Fig 5.10 Examination of kidney tubular cells by electron microscopy.
Kidney samples were prepared for imaging by electron microscopy, as detailed in the materials and 
methods. Samples were prepared from AnxA2+/+ and AnxA2-/- Diabetic. In each group of images A 
is an overview of the tubule cell whilst B and C give views of the apical villi and basement 
membrane respectively. N=nucleus, BM= Basement membrane, AV=apical villi. Scale bar = 2µm.
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membrane thicknesses were measured from all the groups of mice. This analysis reveals 
the presence of some degree of basement membrane thickening in both the AnxA2
+/+ 
and AnxA2
-/- diabetic animals compared to their non-diabetic littermates (Figure 5.11). 
However, the extent of this change was not statistically significant, and the degree of 
thickening in AnxA2
+/+ and AnxA2
-/- diabetic mice was broadly similar. The tubular 
basement membrane is not however the principle site of thickening and hence capillary 
basement membranes of the glomeruli were also examined. Figure 5.12 shows a 
representative example from each of the groups of mice that were used for the 
quantification, with the lumen of the capillary evident in the centre of the image 
surrounded by fenestrated endothelium, basement membrane, and podocyte foot 
processes. In addition to measuring basement membrane thickness, it was also possible 
to detect potential changes in the endothelial and podocyte cell layers. Examining first 
the endothelium, in all the images from the four groups the endothelium appears 
fenestrated, suggesting that the absence of annexin 2 or the presence of diabetes does 
not alter this defining characteristic. The endothelium also appears continuous around 
the entire capillary, again suggesting that no significant loss of endothelial cells occurs 
as a result of diabetes or loss of annexin 2.  
Examination of podocytes revealed a slightly different result. Firstly, podocytes 
in AnxA2
+/+ and AnxA2
-/- non-diabetic mice appeared similar with even spacing 
between podocyte feet, and normal effacement of those feet to the basement membrane. 
Changes between the AnxA2
+/+ non-diabetic and AnxA2
+/+ diabetic images are apparent 
however, with fewer podocyte feet and increased levels of effacement (Figure 5.12, red 
arrows), suggesting changes consistent with diabetic nephropathy. Examining next the 
AnxA2
-/- non-diabetic and diabetic images, similar changes in the podocyte feet are 
apparent, suggesting that these cells have undergone comparable disease-induced 
modifications, although whether the extent of change between the AnxA2
+/+ and 
AnxA2
-/- diabetic animals is different is not easily assessed via electron microscopy 
alone, and would require further studies. Returning to the issue of basement membrane 
changes, the average thickness was quantified for a number of different capillary images 
for all four groups of mice. Both AnxA2
+/+ and AnxA2
-/- non-diabetic mice exhibited 
similar thickness of the basement membrane (Figure 5.10). However, more substantial 
differences were observed in mice exposed to diabetes, both AnxA2
+/+ and AnxA2
-/-, 
with similar levels of thickening apparent, demonstrating that although diabetes is 
sufficient to drive an increase in basement membrane thickness, loss of annexin 2 does 
not compound that effect.    128
Fig 5.11: Diabetic mice show increased tubular basement membrane thickness.
Electron microscopy images were taken of kidney samples, and tubular basement 
membrane thickness quantified using Image-J. The graph shows mean value of all the 
measurements taken for each group ± SD, n=60 (30 measurements from 2 mice). 
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Fig 5.12: AnxA2-/-and AnxA2+/+ diabetic mice show increased glomerular capillary basement 
membrane thickness.
EM images were taken from the various groups of mice and basement membrane thickness 
quantified using Image-J. The graph shows mean value of all the measurements taken for each 
group ± SD, n=60 (30 measurements taken from 2 mice). CL=Capillary lumen, BM=Basement 
membrane, PF=Podocyte feet, Red arrows=Podocyte foot effacement. Scale bar = 1 µm
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5.7 Diabetic mice show intact endothelial junctions in vivo 
 
Since most of the data in this chapter indicate problems with the glomeruli of 
mice exposed to diabetes that may be exacerbated by the loss of annexin 2, confocal 
microscopy was used to ascertain whether vascular endothelial cell junctional markers 
were affected in these mice. Kidneys from each group of mice were cryosectioned and 
stained for VE-cadherin, ZO-1 and F-actin, and projection images of glomeruli 
generated. Examining initially the staining for AnxA2
+/+ control mice (Figure 5.13), 
VE-cadherin staining was observed throughout the glomerulus, with particular areas of 
enrichment evident, presumably at endothelial cell junctions. Some staining of the 
surrounding tissue was also observed, including the nuclei, which was not expected, and 
since VE-cadherin has not been localised to the nucleus, this staining was considered 
likely to be artefactual. ZO-1 staining was also observed throughout the glomerulus, 
again with specific sites of enrichment, also presumably at the interfaces between cells. 
Interestingly, the sites of ZO-1 enrichment do not overlap with those of VE-cadherin, 
suggesting that the cells staining strongest for ZO-1 may be interstitial cells such as 
podocytes and mesangial cells. F-actin staining was observed throughout the glomerulus 
with no specific enrichments. Examining the differences between the other groups of 
mice, in all cases glomeruli were positive for VE-cadherin, ZO-1 and F-actin, with 
distributions similar to that of AnxA2
+/+ non-diabetic mice, indicating that either the 
actions of diabetes or loss of annexin 2 were not sufficient to cause any changes in the 
localisation of these proteins. While images were being collected for the examination of 
glomeruli, it was noted that areas of vasculature were easily identifiable. Figure 5.14 
shows that VE-cadherin staining is clearly evident in all images across the full range of 
mice, with no change in its distribution as a consequence of loss of annexin 2 or the 
actions of diabetes. ZO-1 staining was also evident in all images, but a much lesser 
extent that VE-cadherin. F-actin staining was evident in all samples and illustrates the 
supporting cells that are wrapped around the vessel.  
5.8 Annexin 2 is upregulated in response to diabetes 
 
Because the antibodies available to stain annexin 2 were raised in mice, imaging 
of annexin 2 in murine kidney and eye produced unconvincing results. Other antibodies 
were therefore also tested on kidney sections, but similarly failed to yield images of 
sufficient quality for analysis (data not shown). To assess the effect of diabetes onD
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Fig 5.13: Assessment of glomerular junctional protein localisation.
Kidney tissue was sectioned, fixed and stained for analysis by confocal microscopy as detailed in 
the materials and methods. Glomeruli were then imaged, with a representative from each group of 
mice shown here, sections were stained using antibodies and reagents: DAPI (1:500), Anti-VE-
cadherin (1:50), Anti-ZO-1 (1:300), Phalloidin-633 (1:60), Anti-Goat-Alexafluor-488 (1:1000), 
Anti-Rabbit-Alexafluor-568 (1:1000). Scale bar = 20µm
131Fig 5.14: Assessment of kidney vessel junctional protein localisation.
Kidney tissue was sectioned, fixed and stained for analysis by confocal microscopy as detailed in 
the materials and methods. Vessels were then imaged, identified by the intense F-actin stain, with a 
representative from each group of mice shown here, sections were stained using antibodies and 
reagents: DAPI (1:500), Anti-VE-cadherin (1:50), Anti-ZO-1 (1:300), Phalloidin-633 (1:60), Anti-
Goat-Alexafluor-488 (1:1000), Anti-Rabbit-Alexafluor-568 (1:1000). Scale bar = 20µm
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annexin 2 expression levels western blotting was performed on samples from eye, brain 
microvasculature and kidney of AnxA2
+/+ non-diabetic and diabetic mice. Levels of 
annexin 2 were quantified by densitometry and normalised to tubulin. Annexin 2 up-
regulation was evident in most tissues, particularly the brain microvasculature, 
increasing three fold over control (Figure 5.15). Levels of annexin 2 in the eye were 
approximately double those of the control, whereas kidney annexin 2 was elevated 1.7 
fold. Due to the preliminary nature of the experiment and hence low sample numbers, 
significant differences could only be assigned to the kidney (p<0.05), however it can be 
seen from both the brain vasculature and eye data that greater sample numbers may 
have yielded similarly significant results.   134
Annexin 2
Tubulin
Non-diabetic Diabetic Non-diabetic Diabetic Non-diabetic Diabetic
Eye Brain vasculature Kidney
Fig 5.15: Annexin 2 is up-regulated in the diabetic eye, brain vasculature and kidney.
Protein samples were isolated from the eye (n=1, graph A), brain vasculature (n=2, graph B) and 
kidney (n=3, graph C) of AnxA2+/+ non-diabetic and diabetic animals as described in the materials 
and methods. Lysates were then western blotted for annexin 2 and tubulin as shown above and 
densitometry conducted using Image-J to give levels of annexin 2 normalised to tubulin. Error bars 
denote ±sd. Antibodies: Anti-annexin-2 (1:1000; BD Biosciences), Anti-tubulin (1:10) and Anti-
mouse-HRP (1:5000). Bands resolved using ECL. *=p<0.05
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Chapter 6 Discussion 
 
Annexin 2 has been shown to be involved in many different cellular processes, 
some of which are implicated in the endothelial dysfunction that occurs in diabetes. To 
assess whether annexin 2 was involved in the endothelial cell response to 
hyperglycaemia, cells were cultured in a range of conditions, namely euglycaemia, 
15mM glucose, 25mM glucose and +20mM mannitol for one week, in order to permit 
comparision with other studies that examined endothelial cell function in this 
context
406,407,408. Levels and distribution of annexin 2 were then examined, followed by 
assessment of cells lacking annexin 2, in order to explore a hypothetical role for annexin 
2 in the endothelial dysfunction seen in diabetes.  
 
6.1 Assessment of levels of annexin 2 using in vitro hyperglycaemia 
 
Annexin 2 levels have been reported to fluctuate in various cellular processes, as 
has been illustrated in studies of annexin 2 during the cell cycle
409. It has been 
previously demonstrated by Lei et al that the levels of annexin 2 found on the surface of 
endothelial cells increase in response to hyperglycaemic conditions
378. This could not be 
confirmed in our study, since persistent tubulin contamination of the extracellular 
samples was indicative of intracellular contamination. Although the assessment of 
extracellular annexin 2 was problematic, its elution from the surface of the endothelial 
cells did allow for the accurate assessment of intracellular annexin 2 levels in response 
to in vitro hyperglycaemia. In both HUVEC and hCMEC/D3 endothelial cells, culture 
in hyperglycaemia for 1 week failed to alter the intracellular levels of annexin 2, with 
GPNT cells cultured for up to 9 weeks demonstrating this effect was also consistent at 
later time points. Since hyperglycaemia has been shown to increase the levels of 
annexin 2 on the surface of the endothelium through increased binding to heat shock 
protein 90α
378, one might postulate that although the protein levels of annexin 2 do not 
change in response to hyperglycaemia, there may nevertheless be effects on the 
transcriptional regulation of the annexin 2 gene. 
 
6.2 Examination of the alterations in distribution of annexin 2 in response to 
hyperglycaemia 
   137
Since the levels of annexin 2 remained stable in response to hyperglycaemia, 
changes in it’s distribution were examined using confocal microscopy. Proteins known 
to be involved in the progression of diabetes in endothelial cells, namely GLUT-1
410, 
ZO-1
411, VE-cadherin
412 and F-actin
413 were also examined, such that any change in 
their distribution might be linked to changes in annexin 2. 
In this study we identified subtle changes in the perinuclear levels of GLUT-1 
when HUVEC were exposed to in vitro hyperglycaemia, with a slightly increased signal 
in cells treated with 25mM glucose, whilst those treated with 15mM glucose appeared 
to exhibit a decrease in perinuclear GLUT-1. The possibility of changes in the 
perinuclear distribution of GLUT-1 in response to hyperglycaemia add to an already 
controversial subject since there is still some debate as to whether GLUT-1 levels are 
increased or decreased in response to hyperglycaemia
388,389, and similarly whether there 
is an increased or decreased level of glucose transport
414,415, the controversy arising at 
least in part due to a lack of similarity between studies. Since GLUT-1 is known to 
shuttle to membrane compartments to adjust the glucose permeability of the cell
416,417 it 
may not be unreasonable to assume changes in its distribution could explain some of the 
disparities in results, especially since diabetes is sufficient to alter elements of the 
endocytosis pathway
418, and the extent of those changes is dependent upon length of 
hyperglycaemic insult and endothelial cell type examined.  
The results of this study also showed that the distribution and organisation of F-
actin was altered in response to hyperglycaemia. Actin is a highly dynamic protein 
altering in response to various stimuli
419. In times of cellular stress actin ‘stress fibers’ 
are formed
420 and hence it is not unsurprising to see them formed here in a 
hyperglycaemic dose-dependent manner. Whether in this case they formed as a direct 
consequence of hyperglycaemia alone is questionable, since stress fibers also formed in 
cells treated with increased mannitol, and hence may be due to increased osmotic stress. 
Changes in the distribution of actin are of potential interest regarding annexin 2, since 
the two proteins are closely linked as detailed in the Introduction. As annexin 2 is 
known to function as an actin capping protein
323, the loss of annexin 2 leads to the 
formation of stress fibers
323, and annexin 2 is one of the first proteins to become 
glycated
375 it would be interesting to determine whether glycation interferes with 
annexin 2 function in a manner that leads to the formation of stress fibers.   
The other proteins examined, namely VE-cadherin, ZO-1 and annexin 2, 
remained constant, in that in vitro culture in hyperglycaemia was insufficient to cause 
any loss of junctional protein localisation, or alter their distribution. Whilst the   138
maintenance of ZO-1 at the cell junctions in response to hyperglycaemia is consistent 
with other studies
421, data from the literature indicate that significant changes in VE-
cadherin distribution may have been more readily seen at an earlier time point, since 
although discontinuous staining of VE-cadherin was evident after 2 hours in HUVEC 
treated with 25mM glucose, the significance of this result was lost after 4 days of 
culture
422. No comparison of the result obtained for annexin 2 can be made, since the 
response of annexin 2 to hyperglycaemia has not previously been examined in this way. 
However, the interpretation of annexin 2 distribution should be undertaken with care 
since the antibody used is directed against the N-terminal region of the protein, near the 
site of its interaction with S100A10. Thus, staining of annexin 2 in these figures is 
probably indicative of monomeric annexin 2 only, since the tetrameric annexin 2-
S100A10 complex is inaccessible to the antibody. It is also the case that most of the 
annexin 2 stained is in the cytosol, which may mask subtle enrichments to cellular 
organelles. For this reason, changes in the distribution of annexin 2 were next examined 
using biochemical techniques that would allow the examination of the total pool of 
annexin 2, and hence may reveal changes not detectable by confocal microscopy. 
In these experiments, we utilised one of the key properties of annexin 2 in its 
ability to bind membranes. A crude method of isolating membrane fractions is to use 
detergent to obtain detergent-soluble and insoluble fractions
423. Although this method 
has been shown to be effective in other studies, in our hands annexin 2 could not be 
efficiently fractionated. An alternative protocol utilising Percoll™ similarly failed to 
provide results that could be accurately interpreted, but did provide better fractionation 
than the detergent-based method. The most satisfactory result were obtained using a 
sucrose density gradient approach, which has been shown to be effective in other work 
examining the effects of diabetes, more specifically oxidative stress and its role in 
translocating annexin 2 to the endoplasmic reticulum in Hela cells
424. Using this method 
it was observed that the actions of hyperglycaemia were sufficient to move the peak of 
annexin 2 to a denser fraction, in a dose-dependent manner. This result was confirmed 
by reference to the distribution of transferrin receptor, a marker of early endosomes, 
which remained in the same fractions regardless of the culture conditions, illustrating 
that the effect on annexin 2 was not due to variations in the sucrose gradient.  
The question arising from this experiment concerns to which membranous 
compartment of the cell is annexin 2 moving, and what is inducing this effect. Although 
the stimulus for this effect is undoubtedly incubation in hyperglycaemia, the actions of 
hyperglycaemia can have various effects on the endothelial cell, as outlined in the   139
Introduction. Pertaining to annexin 2, in the literature the actions of diabetes have been 
reported to potentially alter the structure or function of annexin 2 through 
glutathionylation and glycation. More specifically, in vitro oxidative stress has been 
shown to induce the glutathionylation of both the monomeric and tetrameric forms of 
annexin 2 at cysteines 8 and 132
425,426. The glycation of annexin 2 was demonstrated in 
vivo using streptozotocin induced diabetic rats, whereby after one month of diabetes, 
membranous compartments of the lung vasculature were shown to contain glycated 
annexin 2, along with glycated forms of components of the the actin cytoskeleton 
including the p34 subunit of the Arp2/3 complex, Ras suppressor protein-1 and actin
375. 
Since these events are described as early events in diabetes it is possible that either, or 
both of these processes may have provided stimulus for the effect seen in the sucrose 
gradient. Deliberating next upon how these modifications may have caused the 
movement of annexin 2 to other compartments of the cell, glutathionylation has been 
shown to alter the function of annexin 2, reducing its capacity to bind membranes by up 
to around 70%
425, whilst glycation has been shown in vitro to reduce the functionality of 
other proteins such as collagen, delaying wound healing
427. If it is then further 
considered that work in this thesis has demonstrated that the levels of annexin 2 protein 
are not increased by 1 week culture in hyperglycaemia, with potentially more actin 
stress fibers formed in HUVEC exposed to 25mM glucose, it could be postulated that 
the movement of annexin 2 to alterative compartments of the cell could be indicative of 
inactivation of the protein and possibly degredation, especially since lysosomes are 
more dense than that of early endosomes
428. Alternatively, since annexin 2 translocation 
to alternative membrane structures has been demonstrated
429 in reaction to stress 
responses, such as hyperosmolarity, phorbol ester or pervanadate and high density 
compartments of the cell, with as of yet unknown function, containing caveolin have 
been identified
430, it is not unreasonable to hypothesise that annexin 2 may be 
translocating to serve a functional requirement.  
 
6.3 In vitro hyperglycaemia in AnxA2
-/- endothelial cells 
 
Roles for annexin 2 in the progression of diabetes have been postulated both by 
our group and others, potentially identifying diabetes as an annexinopathy, and are 
described in detail in the Introduction. Briefly, the hypotheses focus around the 
increased presence of annexin 2 on the surface of endothelial cells in response to 
hyperglycaemia due to its increased binding to heat shock protein 90α
378. Interestingly,   140
whether this translocation serves to induce more or less plasmin formation, for which 
annexin 2 has an established role
359,64, is disputed
376,378. The major difference between 
the two studies was the addition of insulin to the experimental procedure
431, and since 
annexin 2 has been shown to be phosphorylated by the insulin receptor
379,380, this 
suggests that phosphorylation may decrease the potential for annexin 2 to aid plasmin 
formation, especially since other modifications close to the site where annexin 2 is 
phosphorylated can reduce its capacity to bind t-PA
359,383,382. In both hypotheses the 
contribution of annexin 2 to the progression of diabetes is centred around its ability to 
aid plasmin formation, altering the fibrinolytic balance of the endothelium.  
Since earlier work in this thesis had suggested that the actions of 
hyperglycaemia may reduce the availability or change the function of annexin 2, we 
next investigated the consequences of diabetes on endothelial cells lacking annexin 2. 
For this purpose we used the annexin 2 knockout mouse
361, in which two exons have 
been replaced with a neomycin resistance gene. The annexin 2 knockout mouse 
(AnxA2
-/-) has been used previously to demonstrate the role of annexin 2 in fibrin 
generation, neoangiogenesis, haematopoietic stem cell homing and stabilisation of its 
binding partner S100A10. More specifically, mice lacking annexin 2 have been shown 
to accumulate fibrin in the microvasculature, demonstrate incomplete clearance of 
arterial thrombi induced by injury and have reduced t-PA induced plasmin formation
361. 
In addition, isolated endothelial cells or aortic ring explants show reduced migration 
through Matrigel, demonstrating that the reduction in plasmin formation has functional 
consequences in vitro
361. Further to this, the authors also utilised two in vivo models of 
neovascularisation, namely FGF-stimulated cornea and oxygen induced retinopathy, 
showing that AnxA2
-/- mice exhibit less neoangiogenesis, supporting the idea of a role 
for annexin 2 in the degradation of the extracellular matrix to permit neovascularisation 
in vivo. The same mice have also been used in three other studies, in a publication by 
Jung et al it was demonstrated that the AnxA2
-/- mice have fewer haematopoietic stem 
cells in their bone marrow, which in addition to various treatments of wild-type mice 
and cell cultures with blocking peptides, RNA interference and antibody treatments 
directed against annexin 2, implicates annexin 2 in the homing of haematopoietic stem 
cells to the bone marrow
432. Second, loss of annexin 2 in mice has been shown to reduce 
the levels of its binding partner S100A10, since in the absence of annexin 2 the 
ubiquitination site of S100A10 is unprotected leading to its constitutive degradation 
363. 
Finaly, annexin 2 has been shown to have a role in the activation of Src and FAK in the   141
circadian phagocytosis of photoreceptor outer segments by retinal pigment epithelial 
cells
342. 
As part of our investigations using the AnxA2
-/- mouse, isolation of endothelial 
cells from the brain microvasculature demonstrated that the loss of functional annexin 2 
protein was insufficient to disrupt VE-cadherin localisation from the membrane of the 
cells, either in the presence or absence of hyperglycaemia. This may seem surprising 
since annexin 2 has been implicated in the stabilisation and formation of cell junctions 
of both vascular and non-vascular cells through interactions with proteins such as Rac1 
in epithelial cells
343, in addition to targeting of E-cadherin to the junction of epithelial 
cells as a result of calcium depletion and subsequent restoration
344. Indeed, annexin 2 
has also been shown to be important for VE-cadherin stabilisation since the loss of 
annexin 2 from HUVEC cells has been shown to be sufficient to cause mis-localisation 
of the protein and hence de-stabilisation of the adherens junction
349. With the added 
parameter of hyperglycaemic insult that has been shown to be detrimental to junctional 
stability
433, the results obtained herein are unexpected given the current literature. There 
are potential reasons for this discrepancy, not least that the cells isolated as part of this 
study are derived from the microvascular brain endothelium, and the vascular cells used 
in the study of annexin 2 function on VE-cadherin stabilisation were conducted in 
HUVECs. As outlined in the Introduction, endothelial cells are adjusted to the 
environment in which they find themselves
28,29. Since the junctional integrity of the 
endothelial cells that comprise the blood brain barrier is particularly strong, mechanisms 
may be in place to protect these junctions from changes in either glycaemia or protein 
composition. Indeed, studies have demonstrated both in diabetic patients
434 and animal 
models of diabetes
435 that the integrity of the blood brain barrier is preserved, and no 
indication of vascular leakage, examined by the presence of albumin, sucrose or IgG in 
the brain tissue, can be found after extended periods of diabetes. However, contrary 
evidence has also been published similarly both in diabetic patients
436, and animal 
models of diabetes
437, illustrating that the blood brain barrier is susceptible to 
permeability changes as a consequence of diabetes. Thus, the actions of diabetes on the 
blood brain barrier are still under debate.  
Another potential reason for the apparent inconsistency of the results with the 
published literature is that although genetic knockout mouse models are a versatile and 
powerful tool for scientific research, they do have their own distinct disadvantages
438, 
amoung which is the potential for adaptation to the loss of the given protein of   142
interest
439,440, in this case annexin 2. Hence, it may well be possible that other annexins 
are up-regulated or their activity increased to compensate for the loss of annexin 2.  
In summary, through in vitro studies we have demonstrated that the levels of 
annexin 2 protein are not altered in response to hyperglycaemia, but it’s distribution 
may be altered, with regard to subcellular compartmentalisation. In addition to this, it 
was found that the loss of annexin 2 was not sufficient to accentuate any effect 
hyperglycaemia may have on junctional integrity, but that this may have been a 
consequence of the type of endothelial cell used.   
Although in vitro studies of diseases such as diabetes provide a valuable insight 
into the mechanics of disease progression, many of these conditions are multifactoral in 
nature. Since diabetes is no exception, and the resulting hyperglycaemia affects many 
different cell types changing multiple cellular processes, as outlined in the Introduction, 
a true representation of the contribution of annexin 2 to the actions of diabetes can only 
be assessed using in vivo model of disease. Thus, using both AnxA2
+/+ and AnxA2
-/- 
mice a chemically induced models of diabetes was instigated, allowing the contribution 
of annexin 2 function to be addressed in the setting of hyperglycaemia, and the plethora 
of other factors involved in diabetic endothelial dysfunction.  
 
6.4 Streptozotocin induced diabetes in AnxA2
-/- mice 
 
In vivo models of diabetes have been used for many investigations employing 
both genetic and chemical induction, as outlined in a review by Rees & Alcolado
441. 
Streptozotocin is a drug widely used to induce diabetes in rodents, with more studies in 
rats, than mice. Since the streptozotocin model of diabetes is well established, more 
recent papers have examined the effects, both in vivo and in vitro, of exogenous 
reagents, genetic alteration or protein changes
390,391,392,393,394,395,396,442.  
Weight loss, or reduced weight gain, is a symptom of uncontrolled diabetes. In 
our study both AnxA2
+/+ and AnxA2
-/- mice treated with streptozotocin displayed 
reduced weight gain and hyperglycaemia which were significantly different than their 
control littermates. The observation of reduced weight gain is consistent with other 
studies that have utilised streptozotocin, demonstrating that diabetic mice either have a 
reduced weight to that of their controls at the point of sampling
443,444, or that diabetic 
mice fail to gain weight over the period of time they were examined
445. Hence, our 
observations confirm that diabetes has been successfully induced in these animals. In 
addition since no detectable difference in weight gain / loss was observed between the   143
AnxA2
-/- and AnxA2
+/+ mice regardless of diabetes, it can therefore be concluded that 
the loss of annexin 2 is not sufficient to change either weight gain as part of normal 
physiology, or exacerbate the lack of weight gain / weight loss incurred by the actions 
of diabetes. 
Diabetic mice were observed to have blood glucose levels significantly higher 
than their control littermates at two weeks post streptozotocin treatment. The levels of 
hyperglycaemia achieved in this study for both AnxA2
+/+  and AnxA2
-/- mice were 
somewhat higher than those quoted in the literature for c57bl/6 mice treated with the 
low-dose streptozotocin protocol at approximately 300mg/dl
446,447,448, potentially due to 
an inadequate response to fasting; as will be elaborated upon later. An alternative 
explanation acknowledges that differences in the strain of mouse used can produce 
varying levels of hyperglycaemia
449,450, with slight differences even detected between 
very closely related c57bl/6J and c57bl/6KsJ
451. A more recent study examining the 
differences in strain regarding the progression of diabetic nephropathy in response to 
streptozotocin demonstrated this phenomenon effect in five different strains of mice 
namely, MRL/Mp, BALB/c, 129/EvSv, c57bl/6 and Dba/2
452. 
However, since the level of hyperglycaemia achieved as part of this study was 
higher than that quoted in the literature for the strain used, and the data regarding 
reduced weight gain were consistent with the model, it was concluded that we had 
successfully induced diabetes in these mice. Interestingly the time course of glucose 
increase was similar between AnxA2
+/+ and AnxA2
-/- diabetic mice, indicating that the 
loss of annexin 2 does not affect the onset of chemically induced diabetes.  
Upon analysis of the data in non-diabetic animals it was observed that fasting for 
4 hours increased blood glucose relative to the non-fasted state. This is both the 
opposite of the expected result and not in accordance with the literature, since studies 
have shown fasting of non-diabetic mice to yield an approximately 50mg/dl reduction in 
their blood glucose level
453,454,455. However, since mice were placed into fresh cages at 
the point of fasting, and this was a consistent result across the 16 week study, it brings 
into question the murine response to food withdrawal and blood glucose sampling. In 
the process of obtaining blood glucose levels mice were restrained, such that the tail 
vein could be accessed easily. However, restraint has been shown to increase the levels 
of blood glucose in mice
456,457; with c57bl/6 mice particularly prone to hyperglycaemic 
responses to restraint induced stress
458. Other studies have also shown that the levels of 
blood glucose increase in mice when active
459, and since mice post restraint were active   144
for extended periods of time, this could have contributed to the observed 
hyperglycaemic response to fasting.  
Interestingly, regardless of fasting, non-diabetic AnxA2
-/- mice had a 
significantly lower level of blood glucose than their wild-type counterparts, indicating 
that the loss of annexin 2 results in abnormal glucose handling. Many different 
knockout mouse models have reported similar results by alteration of various aspects of 
the glucose homeostasis system. Alteration to the insulin signalling pathway, either 
through increased insulin transcription by reduction of Smad3 levels
460, enhancement of 
insulin signalling through depletion of SOCS7
461, or increased sensitivity to insulin 
through deletion of the p85α regulatory subunit of PI3K
462, have been shown to induce 
hypoglycaemia in mice. In addition, disruption of the thioredoxin pathway
463, or 
reduction of the ability of the pancreas to release insulin or glucagon
462 can also induce 
hypoglycaemia. As well as these alterations to established constituents of the glucose 
homeostasis pathways, another annexin, namely annexin 7 has been implicated in these 
processes. In a study by Srivastava et al the β-islet cells of the pancreas were observed 
to express different levels of proteins in the fed or fasted state, however, upon loss of 
annexin 7 these cells were no longer able to adapt to the change in environment and 
gene expression remained the same regardless of whether they were fed or fasted
464. 
The mice were also shown to have increased glucose clearance after glucose tolerance 
testing, with their peripheral tissues hyper-responsive to insulin. However, no 
significant hypoglycaemia was seen when control mice were compared to the annexin 7 
knockouts.  
Since the AnxA2
-/- mouse has not been used previously to investigate glucose 
homeostasis, this is the first report of hypoglycaemia in these mice. Potential 
explanations for this observation can be inferred from the literature, focusing on the 
known responses of annexin 2 to insulin signalling. Annexin 2 has been shown to be 
phosphorylated by the actions of the insulin receptor, and to mediate cellular alterations 
to the actin cytoskeleton dependent upon phosphorylation, that can be inhibited upon 
knockdown or neutralisation of the protein
379,380. Signalling events mediated by the 
insulin receptor occur both when the insulin receptor is in the membrane, and upon 
endocytosis
465. If either the endocytosis of the receptor is inhibited, or the signalling of 
the endocytosed receptor is enhanced, hypoglycaemia can ensue via increased glucose 
uptake, increased glycogen synthesis and an increase in its downstream signalling 
pathways
466,467,468. Since annexin 2 has been shown to be involved in endocytosis
332, 
particularly in response to phosphorylation
336, it would not be unreasonable to   145
hypothesise that loss of annexin 2 would be sufficient to alter the endocytic pathway, 
such that the correct sorting of the insulin receptor is affected, and abnormal signalling 
events occur. Another potential explanation for the apparent hypoglycaemia of AnxA2
-/- 
mice is closely linked to the insulin signalling pathway, and centres around GLUT-4. 
When stimulated by insulin GLUT-4 moves to the plasma membrane, where it mediates 
the uptake of glucose into the cell for its utilisation
469. Recently a pool of insulin-
unresponsive GLUT-4 was identified in muscle, in which annexin 2 was enriched
470. 
The authors of the paper hypothesised that this new pool of GLUT-4 was continuously 
circulating between the plasma membrane and the new intracellular pool, the rate of 
which might be influenced by insulin signalling. Since, as outlined above, annexin 2 can 
mediate the effects of the insulin signalling pathway, and has established roles in 
endocytosis, it could be hypothesised that the presence of annexin 2 is critical for the 
correct functioning of this insulin-insensitive pool of GLUT-4. If ablation or reduction 
of annexin 2 protein resulted in more of this insulin-insensitive pool of GLUT-4 in the 
plasma membrane, the peripheral utilisation of glucose would be increased, and hence 
hypoglycaemia would ensue.  
Upon the initiation of diabetes in these animals, fasted diabetic AnxA2
+/+ and 
AnxA2
-/- mice exhibited similar levels of hyperglycaemia ranging from 500-600mg/dl. 
Interestingly, when the same mice are not fasted prior to their blood glucose 
measurement a different trend becomes apparent, with AnxA2
-/- diabetic mice having a 
significantly higher blood glucose level than AnxA2
+/+ counterparts. Both of these 
observations conflict with the previous observation that non-diabetic AnxA2
-/- mice 
have a lower basal blood glucose level. However, if it is considered that in non-diabetic 
mice the increase in the insulin signalling pathway may be a compensatory mechanism 
to an increase in endogenous glucose production, through increased gluconeogensis, the 
subsequent hyperglycaemia of these AnxA2
-/- mice upon the actions of diabetes, and 
hence ablation or reduction of insulin signalling, could be explained. Although an 
increase in the rate of gluconeogenesis in various knockout animal models has been 
reported
471,472,473, no such association of annexin 2, or any other annexin, could be 
attributable to the mechanisms that influence the rate of gluconeogenesis, reviewed 
in
474, and hence this rationalisation for the effect seen in diabetic AnxA2
-/- mice shall 
remain a postulation. 
More relevant to the previous data, other knockout mouse models have also 
reported that higher levels of hyperglycaemia can be induced upon initiation of 
streptozotocin induced diabetes, due to a dysfunction in the insulin signalling pathway   146
prior to the onset of diabetes utilising mice with a liver-specific knockout of IGF-1
475, 
and alterations to the ability of the pancreatic islets to secrete insulin in mice lacking 
Group VIA phospholipase A(2)
476. As outlined above AnxA2
-/- non-diabetic mice show 
hypoglycaemia indicative of a dysfunctional regulation of the insulin signalling 
pathway, and hence this may explain the differences observed in AnxA2
-/- mice upon 
the initiation of diabetes. 
A further interesting observation that can be drawn from the diabetic blood 
glucose data, is the exaggerated reduction of blood glucose levels in the AnxA2
-/- 
diabetic mice in response to fasting. As stated previously non-diabetic mice examined 
as part of this study increased their blood glucose levels in response to fasting, and 
although this is not consistent with published literature regarding fasting of mice, it may 
have been produced by a stress response. However, upon examination of the diabetic 
mice, whereas AnxA2
+/+ mice maintained their blood glucose concentration in response 
to fasting, AnxA2
-/- diabetic mice exhibited a significant reduction. Potential 
explanations for this effect once more return to the insulin signalling pathway, and the 
defects the absence of annexin 2 may cause. In models of disruption of the insulin 
signalling pathway, previously outlined above, in addition to the effects on insulin 
signalling, an increase in peripheral glucose uptake was observed
112,460,461,462, examined 
through glucose tolerance testing. In these experiments, animals with increased 
peripheral glucose uptake reduced their glucose levels quicker in response to a bolus 
injection of glucose than that of their control littermates, an effect that is analogous to 
the increased reduction of blood glucose levels in AnxA2
-/- diabetic mice post fasting. 
Since in the absence of annexin 2 non-diabetic mice exhibit hypoglycaemia, potentially 
through increased peripheral glucose uptake, it would not be unreasonable to 
hypothesise that the same would be true when these animals were diabetic, and 
therefore the data presented here in these mice upon the action of diabetes may provide 
further evidence in support of the hypothesis.
 
In summary, although the loss of annexin 2 does not affect the onset of diabetes 
in the streptozotocin model, differences can be found in glucose handling. AnxA2
-/- 
non-diabetic mice exhibit hypoglycaemia potentially either due to dysregulation of the 
insulin signalling pathway, mislocalisation of GLUT-4, increased glucose uptake in the 
peripheral tissues or a combination of two or more of these. An increase in the rate of 
glucose uptake in the peripheral tissues is likely since in the AnxA2
-/- diabetic animals 
glucose levels reduced more drastically in response to fasting.  
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6.5 Diabetic retinopathy and AnxA2
-/- diabetic mice 
 
Having successfully established a model of diabetes in the AnxA2
-/- mice we set 
about examining whether the loss of annexin 2 could have any detrimental effects on the 
microvascular disease evident in diabetes, starting with diabetic retinopathy. 
Fluorescein angiograms taken at 16 weeks post diabetes induction demonstrated that 
there were no differences between AnxA2
-/- and AnxA2
+/+ diabetic animals, and that 
diabetic animals had normal retinal vasculature. Other studies that have examined 
diabetic retinopathy by fluroescein angiography typically examine later time points
205 
since it can take up to a year for vascular leakage as a result of diabetic retinopathy to 
present. A much earlier time point was taken in this study since diabetes in our animals 
proved lethal post 16-18 weeks of diabetes in the majority of cases. This level of 
mortality is in contrast to other studies that have utilised the streptozotocin induced 
diabetes model to examine mice over a long period of time
477,478. However, in these 
studies streptozotocin treated animals underwent routine insulin treatment linked to 
their weight gain / loss to proling survival, so it is not surprising that differences are 
apparent.   
Since our study was not long enough to examine diabetic retinopathy by 
fluorescein angiography, earlier symptoms of the disease were examined. One of the 
initial events to occur in the retina in response to hyperglycaemia is the loss of 
pericytes
479. In the absence of specific antibodies for pericyte cells, the retina could not 
be efficiently examined using fluorescence microscopy, and hence pericyte dropout was 
examined using a conventional histological method. To achieve this PAS staining with a 
haematoxylin counterstain of trypin digested retina revealed the nuclei present in the 
vasculature, which could then be identified as either endothelial cells or pericytes. 
Various publications have used this method to study pericyte dropout in the diabetic 
retina in both rats
397,400,401 and dogs
398,399. In our study, whilst significant differences in 
the pericyte to endothelial cell ratio were detected between the control and diabetic mice 
of either genotype, indicating changes indicative of retinopathy had occurred in these 
animals, differences were not apparent between AnxA2
+/+ or AnxA2
-/- mice.  
Since the investigation of pericyte dropout did not reveal any significant 
differences between that of AnxA2
+/+ and AnxA2
-/- mice, an earlier manifestation of 
diabetic retinopathy was assessed. As detailed in the introduction, the metabolically 
stressed retina up-regulates GFAP in Müller cells, hence we examined GFAP in the 
retinas of the AnxA2
-/- diabetic mice. No significant up-regulation of GFAP in the inner   148
plexiform layer was detected in either the AnxA2
+/+ and AnxA2
-/- non-diabetic or 
diabetic mice. Although these data are contrary to those published for rat, in which a 
substantial up-regulation of GFAP can be seen after streptozotocin treatment for 10
480 
and 24
481 weeks, or incubation of retinal explants to glycated-BSA for 4 days
482, it is 
consistent with publications in mice that demonstrate no GFAP up-regulation can be 
detected in mice at various time points ranging from 2 weeks to 22 months
483,478. 
In the absence of significant differences between AnxA2
+/+ and AnxA2
-/- 
diabetic animals upon examination of the retina, both by pan-retinal examination for 
pericyte dropout, and specific examination of metabolic stress and hence GFAP up-
regulation, cross-sections of retina were examined using conventional histology to see if 
any abnormalities could be detected. Upon analysis of the data no abnormalities in any 
of the retinas were detected. Similar studies have also used this technique to quantify 
retinal cell death in streptozotocin induced diabetic rats, observed as a reduction in 
retinal thickness
402. The data obtained as part of this study did show some changes in 
retinal thickness, but these were evenly distributed across all the different mice, 
indicating that the changes were due to variations in sectioning and not the result of cell 
death.  
Finally, since diabetic retinopathy is thought to affect the vessel junctions 
leading to leakage either through the actions of VEGF
224,484,485, MMPs
486 or 
inflammatory factors
487,488, as detailed in the Introduction, we next investigated whether 
in vivo diabetes could influence the distribution of cell junction proteins in the 
endothelium. To achieve this, endothelial cells were isolated in a similar manner to the 
previous data examining the short term effects on AnxA2
-/- endothelial cells exposed to 
hyperglycaemia in vitro. In contrast to the previous data, endothelial cells from diabetic 
mice had been exposed to in vivo hyperglycaemia, and hence were more physiologically 
relevant than normal endothelial cells exposed to in vitro hyperglycaemia for one week. 
Upon examination of these cells it was seen that the yield from diabetic animals was 
much lower than from non-diabetic animals, suggesting that exposure to diabetes for 16 
weeks had altered the cells’ ability to survive the isolation procedure or attach to the 
surface of the culture dish. Similar to the previous experiment, staining of VE-cadherin 
was then conducted, revealing areas of discontinuous staining in AnxA2
-/- diabetic 
endothelial cells which were not evident in either the control animals or their diabetic 
AnxA2
+/+ counterparts. This would indicate that exposure of cells lacking annexin 2 to 
in vivo hyperglycaemia for 16 weeks is sufficient to alter their ability to form and 
maintain VE-cadherin adherens junctions. Reasons for this effect are difficult to dissect   149
from these data alone, but would likely involve hyperglycaemic memory; the process by 
which cells exposed to hyperglycaemia are irreversibly damaged, leading to an 
accumulative effect even during periods of euglycaemia
489,490,491. If it is assumed that 
the cells would have incurred a relatively large insult over the period of time exposed to 
diabetes in vivo it could be hypothesised that upon loss of annexin 2, endothelial cells 
are less able to cope with the cellular changes incurred when placed into an in vitro 
system where support from smooth muscle cells and systemic survival factors is absent 
or diminished.   
When all the above examinations of diabetic retinopathy are combined it can be 
concluded that our study has shown that the loss of annexin 2 in diabetic mice is not 
sufficient to give differential disease presentation at 16 weeks post diabetes. However, 
what can be seen is that subtle changes may be taking place in endothelial cells, making 
them less conducive to isolation, and disrupting endothelial junctions when annexin 2 is 
absent. As mentioned previously other studies have utilised later time points to examine 
this disease, and any further studies would certainly need to examine later time points, 
in conjunction with insulin treatment to ensure that diabetic animals survive beyond 16-
18 weeks post-induction.  
Having demonstrated that the loss of annexin 2 has mild effects on the 
localisation of VE-cadherin, but no significant effects on the progression of diabetic 
retinopathy at 16 weeks, the effects one of the major cytokines implicated in diabetic 
retinopathy, namely VEGF
492, present at high levels in diabetic patients
224 was 
investigated using isolated AnxA2
-/- endothelial cells. One of the effects of VEGF on 
endothelial cells in culture is the loss of VE-cadherin from cell junctions
493,494,495, hence 
we examined in our system whether the loss of annexin 2 influences the stability of 
VEGF induced VE-cadherin junction disruption. Through two independent studies we 
showed that VE-cadherin in AnxA2
-/- endothelial cells was more sensitive to both the 
actions of VEGF, and non-specific shock through changing their media, illustrating that 
the loss of annexin 2 may alter the stability of VE-cadherin. Although this contrasts 
with our previous data showing that loss of annexin 2 was insufficient to alter the 
distribution of VE-cadherin in euglycaemia or hyperglycaemia in vitro, it is in 
agreement with the published literature regarding annexin 2 and VE-cadherin
349, and 
our data regarding the stability of VE-cadherin in endothelial cells isolated from 
AnxA2
-/- diabetic mice. As outlined in the Introduction, in the work by Heyraud et al 
annexin 2 was observed to translocate to the membranes of endothelial cells upon 
confluence where it bound a complex containing VE-cadherin, the interaction of which   150
was independent of actin. Further to this, they demonstrated that disturbance of VE-
cadherin localisation at cell junctions could be elicited using siRNA directed against 
annexin 2. The authors then went on to hypothesise that interactions of annexin 2 with 
SHP-2, illustrated in other work
347, and the potential for annexin 2 to act as a link 
between VE-cadherin and the actin cytoskeleton, may provide the mechanism by which 
annexin 2 stabilises VE-cadherin at junctions. Using this information, it could be 
hypothesised that the hyper-responsiveness of AnxA2
-/- endothelial cells to VEGF is as 
a result of incomplete stabilisation of the VE-cadherin adherans junction, resulting in 
increased sensitivity to VEGF.  
During the investigation of diabetic retinopathy in the AnxA2
-/- mice, once it 
became evident that only mild alterations to the retina were apparent, the mice were 
examined for other potential symptoms of diabetic microvascular disease. One key 
observation was that the cages containing diabetic AnxA2
-/- mice required cleaning 
more often than those containing AnxA2
+/+ diabetic mice. This indicated that there were 
some potential differences in the levels of urine excretion, and since the kidneys can be 
severely effected in diabetes, we next investigated whether AnxA2
-/- diabetic mice 
displayed increased progression of diabetic nephropathy in comparison to their 
AnxA2
+/+ counterparts. 
The initial observation of increased urine output was confirmed, indirectly, by 
examination of their water intake. AnxA2
-/- diabetic animals were seen to consume 
significantly more water than AnxA2
+/+ mice. Since non-diabetic animals displayed 
similar levels of water consumption, this suggests that loss of annexin 2 alone is 
insufficient to change kidney function, and a physiological insult, in this case diabetes, 
is required for differences to become apparent. Other studies have also examined the 
level of water consumed by rats exhibiting diabetic nephropathy
496 and report similar 
increases. However, more commonly the effect of diabetes on polydipsia is examined 
by measurement of urine excreted rather than water consumed, an approach that also 
shows large increases in urine output in rats or mice using both genetic and 
streptozotocin based models of diabetes
497,498,499.  
 
6.6 Diabetic nephropathy and AnxA2
-/- diabetic mice 
 
Having provided indirect evidence for changes in the kidney function of   
AnxA2
-/- diabetic mice, a further symptom of diabetic nephropathy was assessed, 
namely microalbuminuria. The presence of increased albumin in the urine is indicative   151
of decreased kidney function, and a potential risk factor for the development of diabetic 
nephropathy
500. In our study AnxA2
-/- diabetic mice displayed a statistically significant 
increased presence of albumin in the urine in comparison to their AnxA2
+/+ diabetic 
counterparts, which in turn exhibited a negligible increase in albumin excretion relative 
to their to their non-diabetic littermates, and consistent with data reporting that the 
c57bl/6 strain of mice is particularly resistant to diabetic nephropathy
501,452. 
Interestingly non-diabetic mice also showed differences in the excretion of albumin, 
with AnxA2
-/- non-diabetic mice having slightly higher urinary albumin levels than non-
diabetic AnxA2
+/+ mice. This would indicate, contrary to the data examining polydipsia, 
that loss of annexin 2 is sufficient to induce some small changes in kidney function, and 
that the actions of diabetes exacerbate these changes.  
Combined, the previous two data sets illustrate that loss of annexin 2 is 
sufficient to accelerate the progression of the early symptoms of diabetic nephropathy, 
both through increased urine output; measured by water intake, and by albumin 
excretion. One question that cannot be addressed from these data alone is whether the 
increased urine output and albumin excretion are due to changes in the selectively 
permeable barrier of the glomerulus, or due to reduced re-absorption of water in the 
nephron. A large body of work examining annexin 2 function in junction formation and 
regulation of apical transport has been conducted in kidney epithelial cells. Thus, 
annexin 2 has been shown to be important for the formation and maintenance of cell 
junctions in MDCK cells through Rac1
343 and AHNAK
502 induced cell polarisation, and 
cholesterol dependent recruitment of E-cadherin to the periphery of the cell
344. In 
addition annexin 2, as part of the heterotetrameric complex containing S100A10 on the 
surface of MDCK cells, has been proposed to bring opposing membranes together, and 
hence have a role in tight junction formation
355, whilst annexin 2 has been reported to 
determine cell confluence through orchestration of the cPLA2/S100A10 interaction
503. 
A role for annexin 2 in apical transport in these cells has also been shown, since MDCK 
cells lacking annexin 2 have reduced delivery of vesicles containing sucrase isomaltase 
to the apical membrane. Additionally, the correct localisation and functioning of the 
TRPV5 and TRPV6 channels involved in calcium re-absorption, has been shown to 
involve annexin 2
504,505,506. These data might suggest that the most likely source of 
dysfunction would be the re-absorptive capacity of the nephron, rather than the 
selectively permeable barrier of the glomerulus. Of particular interest are data indicating 
that annexin 2 is found in complex with the channel protein aquaporin-2
371, and is 
important in its translocation to the membrane
507, as well as its responses to stimuli such   152
as vasopressin
508. Aquaporin-2 is critical in the regulation of body water homeostasis, 
and since functional changes in its ability to localise to the plasma membrane, 
illustrated by two point mutations, can lead to polydipsia
509, it may be hypothesised that 
loss of annexin 2 in diabetes is sufficient to increase water intake and excretion above 
that of wild type animals due to the mis-localisation of aquaporin-2.  
Having shown that the loss of annexin 2 has the potential to alter kidney 
function during diabetes, and potentially during normal physiology, the gross 
morphology and detailed histology of the kidney were examined to see if any changes 
could be detected. Consistent with published literature in the rat, both AnxA2
+/+ and 
AnxA2
-/- diabetic mice had significantly increased kidney weights
510,511, although no 
differences in kidney weight between AnxA2
+/+ and AnxA2
-/- diabetic mice were 
detected. Upon histological examination of the kidneys AnxA2
+/+ diabetic animals 
showed changes consistent with the progression of diabetic nephropathy, such as 
increased tubule dilation, and loss of nephrons
512. AnxA2
-/- diabetic animals displayed 
similar changes, but on a much greater scale, which were readily observed in the H&E 
and PAS stained sections. Interestingly, AnxA2
-/- non-diabetic animals displayed no 
detectable changes in comparison to AnxA2
+/+ non-diabetic animals, suggesting that 
although there may be subtle differences in kidney function due to the loss of annexin 2, 
these are not sufficient to induce any gross histological changes, and are more likely to 
reflect changes at the subcellular level.  
As mentioned previously, depletion of annexin 2 in MDCK cells has been 
shown to reduce the localisation of AHNAK to the plasma membrane, known to be 
important not only for cell polarisation, but also the maintenance of cell thickness in 
vitro
502. Analysis of epithelial cell thickness in vivo in our AnxA2
+/+ and AnxA2
-/- 
diabetic mice revealed that although diabetic animals displayed reduced tubule cell 
thickness when compared to their non-diabetic control, no significant differences were 
detectable between the AnxA2
+/+ and AnxA2
-/- diabetic animals. Although no 
significant differences were detected, the small changes in cell thickness suggest that 
the loss of annexin 2 may have the potential to reduce cell tubule thickness, in vivo, 
since in both non-diabetic and diabetic AnxA2
-/- mice the mean values were slightly 
lower than in the AnxA2
+/+ mice, consistent with observations in vitro in other 
studies
502.  
A further symptom of diabetic nephropathy examinable by histology is the 
degree of mesangial matrix expansion. In agreement with the literature diabetic mice 
had increased levels of mesangial matrix in the glomeruli
513, equivalent to published   153
data regarding diabetic nephropathy in c57bl/6 mice
501,452. AnxA2
-/- diabetic animals 
also showed a significantly higher level of mesangial matrix expansionthan their 
AnxA2
+/+ counterparts, with AnxA2
+/+ and AnxA2
-/- non-diabetic animals having 
similar levels of mesangial matrix. This result shows that whilst the absence of annexin 
2 is not sufficient to increase the level of mesangial matrix, in the presence of diabetes, 
those animals without annexin 2 show more expansion than the wild type mice. The role 
for annexin 2 in this context is more likely to centre on its established role in plasmin 
formation
64. Since annexin 2 is present in the mesangial cells and phosphorylated by the 
actions of PKC
514, which is activated in diabetes (reviewed in
515), it would not be 
unreasonable to assume that it may have some role in plasmin generation on the surface 
of these cells
331. In addition, since the suppression of plasmin activity is one of the 
defining steps in the accumulation of extracellular matrix
516, further reduction in the 
potential of these cells to produce plasmin, through removal of annexin 2, would 
therefore lead to a higher production of extracellular matrix, which concurs with our 
data here.  
Having demonstrated that the loss of annexin 2 has potential effects upon the 
development of diabetic nephropathy through the use of light microscopy, further 
detailed examination of kidney histology was conducted in a preliminary study using 
electron microscopy. Overall examination of the kidney tubule cells revealed that while 
there were no major ultrastructural differences between the AnxA2
+/+ and AnxA2
-/- 
mice in either non-diabetic or diabetic samples, the actions of diabetes were sufficient to 
perturb tubular cell structure, reducing villi length and cellular thickness consistent with 
the results obtained using light microscopy. In addition to examination of the tubular 
cells of the kidney the general structure of the glomerulus was examined. As outlined in 
the Introduction, a large part of the early manifestations of diabetic nephropathy can be 
attributed to changes in podocytes
517, such as increased apoptosis and foot effacement. 
In the images taken of glomeruli from diabetic mice it was noted that AnxA2
-/- diabetic 
mice appeared to have increased effacement of the podocytic foot processes in 
comparison to the AnxA2
+/+ diabetic mice, which may also suggest increased apoptosis 
of these cells. Quantification of basement membrane thickness was also examined both 
for tubule and glomerular capillary basement membranes. AnxA2
+/+ and AnxA2
-/- 
diabetic animals displayed an increase in basement membrane thickness, consistent with 
published literature utilising streptozotocin-induced diabetes in rats
512 and mice
518, 
however no differences were detected between AnxA2
+/+ and AnxA2
-/- diabetic animals. 
These data suggest that although the loss of annexin 2 is not sufficient to increase   154
basement membrane thickness, a potential role for the disruption of the interactions 
between podocytes and the basement membrane of the glomerular capillary may be 
evident. Although a role for annexin 2 in podocytes has not been reported, the fact that 
annexin 2 has an established role in actin dynamics
323, known to be important for the 
correct functioning of the podocyte
519,520, suggests that loss of annexin 2 may affect the 
function of these cells or their ability to adapt to a diabetic environment.   
To further address the question of the contribution of annexin 2 to diabetic 
microvascular disease in the kidney, the junctional proteins VE-cadherin and ZO-1 were 
assessed in the glomeruli of diabetic mice using confocal microscopy. Previous 
publications regarding the expression of ZO-1 in diabetic glomeruli have indicated a 
reduced level of the protein, with removal from the junction and therefore increased 
cytosolic staining
273. In both the diabetic AnxA2
+/+ and AnxA2
-/- glomeruli no such 
changes in ZO-1 localisation were observed, although since the publication stated used 
electron microscopy, the level of detail obtained here may be insufficient. Examination 
of VE-cadherin in these glomeruli showed staining indicative of intact junctions in both 
AnxA2
+/+ and AnxA2
-/- non-diabetic and diabetic mice, with F-actin staining similarly 
unaffected, also suggesting that these cell junctions had not been disrupted. Taken 
together there results indicate that changes to the epithelial cells of the nephron as a 
result of the loss of annexin 2 may be the primary cause of the differences detected 
between AnxA2
+/+ and AnxA2
-/- diabetic mice.  
Finally, at the beginning of this thesis we set about examining whether in vitro 
hyperglycaemia up-regulates the amount of annexin 2 found intracellularly, and 
concluded that it was not. In cases of renal failure or renal damage, up-regulation of 
annexin 2 has been reported
370,521, and since differences between in vitro and in vivo 
hyperglycaemia have been illustrated as part of the work in this thesis, we set about 
examining whether changes could be detected in the level of annexin 2 in response to in 
vivo hyperglycaemia. Western blots of isolated brain microvasculature, retina and 
kidney were performed, although only preliminary samples of brain microvasculature 
and eye could be obtained. Nevertheless, in all three cases an up-regulation of annexin 2 
was detected, with significant differences detected in the kidney, indicating that chronic 
in vivo hyperglycaemia causes effects on annexin 2 expression that differ from in vitro 
hyperglycaemia. Some of the effects seen here could be a function of increased surface 
expression of annexin 2 since it is known that its levels on the surface of the 
endothelium increase in response to hyperglycaemia
378. It is unlikely however that the 
levels of increase seen, particularly in the brain microvasculature, would be accountable   155
to increased surface expression alone, hence it is more likely that intracellular levels 
also increase. Speculations into the reasons why annexin 2 levels increase in diabetes, 
would focus both on the enhancement of plasmin activity in order to maintain normal 
haemostasis, potentially compensating for annexin 2 that may have been functionally 
inactivated by the consequences of diabetes
522, and stabilisation of the junctions 
between cells that can be affected by the progression of diabetes
349,344.  
 
6.7 Conclusions 
 
The aim of work in this thesis was to examine a hypothetical role for annexin 2 
in diabetes, and more specifically diabetic retinopathy and diabetic nephropathy. To 
achieve this we examined annexin 2 using both in vitro hyperglycaemia and in vivo 
models of diabetes, the latter achieved using streptozotocin in the annexin 2 knockout 
mouse. The preface for such an investigation was taken from the previous observations 
in the literature that annexin 2 is altered by the consequences of hyperglycaemia both 
via glycation
375 and oxidative stress
383, and shows responses distinct to those exhibited 
in normal physiology, such as increased translocation to the surface of endothelial 
cells
378, were it may compensate for damage incurred as a consequence of diabetes. In 
addition exogenous annexin 2 has been shown to be effective at preventing diabetic 
nephropathy, through enhancement of plasmin formation
374; and hence annexin 2 was 
identified as potentially crucial in preventing the progression of diabetic microvascular 
disease.  
Since pharmacological inhibition of annexin 2 is not possible, we set about 
examining a role for annexin 2 in diabetic microvascular disease using the annexin 2 
knockout mouse. Using this system, changes were detected in various aspects of in vitro 
endothelial cell biology, diabetic retinopathy and diabetic nephropathy, as discussed 
above. Three major differences emerged: changes in glucose homeostasis, VE-cadherin 
localisation and re-absorption of solutes and water, which collectively serve to highlight 
a common element in this thesis, namely the role of annexin 2 in the targeting and 
trafficking of proteins in response to stimulus. In all three data sets, loss of annexin 2 
resulted in reduced or exaggerated responses of the key proteins involved with the 
trafficking and targeting roles of annexin 2 as likely causes of the effects seen. 
Interestingly, subtle differences were additionally detected in AnxA2
-/- non diabetic 
animals, both in the context of glucose homeostasis and albumin excretion. This serves 
to illustrate another key element of annexin 2 function, that although the annexin 2   156
knockout mouse is viable with few differences detected between it and its wild-type 
counterpart, differences may only become detectable in situations in which the body is 
stressed. This could reflect redundancy within the annexin family, a concept that has 
been noted in the literature for other annexins
523,524,525, but also shows that at least some 
of the functions of annexin 2 cannot be fulfilled by other proteins. 
These studies have revealed potential roles of annexin 2 in diabetic 
microvascular disease both in the eye and kidney, and therefore have created areas of 
annexin research that have not yet explored. The work in this thesis is the first reported 
use of streptozotocin to induce diabetes in any annexin knockout mouse, and the first to 
reveal physiological differences in glucose homeostasis in the AnxA2
-/- mice in both the 
presence and absence of diabetes. Further work into the role of annexin 2 in diabetes 
should focus on the roles of protein targeting and trafficking, utilising the kidney 
epithelium as a useful model, both in the context of diabetes and normal physiology. In 
addition, the involvement of annexin 2 in glucose homeostasis opens an exciting new 
are of annexin research, and studies designed to examine this process would provide 
new insight into the role of annexin 2 in an area of outstanding biomedical importance.  
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